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ABSTRACT 
 
One of the primary contributing factors to the escalating costs of health care is the high cost of 
innovator pharmaceutical products. As a consequence, health authorities in various countries and in 
particular in the developing world have identified generic prescribing and generic substitution as 
possible strategies to contain the escalating costs of health care provision. There is therefore a need 
for formulation scientists in developing countries to invest more time in the research and 
development of generic formulations. 
 
Clobetasol 17-propionate (CP) generic cream formulations containing 0.05% w/w of the drug were 
manufactured and characterized using in vitro testing. Formulation development studies were 
preceded by the development and validation of an RP-HPLC with UV detection for the quantitation 
and characterization of CP in innovator and generic cream formulations during formulation 
development and assessment studies. Furthermore the in vitro release rates of CP release from 
innovator and generic cream formulations were monitored using a validated in vitro release test 
method developed in these studies.  
 
The formulation of CP cream products was accomplished using a variety of commercially available 
mixed primary emulsifiers, such as Estol® 1474, Ritapro® 200, Emulcire® 61 WL and Gelot® 64. 
Successful formulations were selected based on their ability to remain physically stable 
immediately after manufacture and for 24 hours after storage at room temperature (22˚C). Estol® 
1474 was found to produce an unstable cream and was therefore not investigated further.  
 
 iii
The other three emulgents produced stable creams, but only the in vitro release profile of CP from a 
cream manufactured to contain Gelot® 64 was found to be statistically similar to that of the 
innovator formulation. Therefore the cream containing Gelot® 64 was selected as the most 
appropriate prototype generic cream formulation and was characterized in vitro in terms of CP 
content, viscosity, pH and in vitro release rate. Data generated from these studies were compared to 
those of the innovator product, Dermovate® cream, using statistical methods.  
 
The CP content, pH and in vitro release rate data of the CP formulation were similar to those of the 
innovator product, however the intrinsic viscosity of Dermovate® cream was almost three (3) times 
greater than the intrinsic viscosity of the test formulation developed using Gelot® 64. 
 
The CP cream formulation developed in these studies was stored for 4 weeks at 40 ± 2˚C and 25 ± 
5% RH in an incubator and the formulation was found to be stable. A formulation has been 
developed and assessed and found to be suitable for use as a topical semi-solid dosage form for CP. 
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STUDY OBJECTIVES 
 
Eczema or dermatitis is a common dermatological disorder affecting approximately one-third of a 
given population and is the most common skin condition in the Republic of South Africa (RSA). 
Topical corticosteroid formulations such as creams or ointments applied three (3) times daily are 
considered the most appropriate therapy for the treatment of eczema. Topical corticosteroids are 
however considered costly for the majority of patients and as a consequence the use of white 
petrolatum and hydrogenated vegetable oil as supplemental therapy is usually required. The high 
cost of therapy is a result of the use of innovator products of the super-potent topical corticosteroids 
such as clobetasol 17-propionate (CP) that are required for the treatment of severe or chronic 
eczema, especially of the hands and feet. The availability of generic formulations of innovator 
products will make medicinal products more affordable and accessible to a wider population.  
 
The objectives of this study were: 
 
1. To develop, optimize and validate a simple, selective, sensitive, precise, accurate and linear 
reversed phase high performance liquid chromatographic method that is suitable for the 
quantitative analysis of CP in cream formulations and for the assessment of CP release from 
topical formulations during in vitro testing.  
2. To develop and validate a reliable, reproducible and discriminatory in vitro release test method 
for use in formulation development studies to assess product quality and ensure batch-to-batch 
consistency of topical formulations manufactured to contain 0.05% w/w CP. 
3. To design and develop a generic version of Dermovate® cream and to evaluate the product in 
terms of several in vitro performance characteristics. 
4. To determine the stability of the CP cream formulation developed in these studies at elevated 
temperatures.   
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CHAPTER ONE 
 
CLOBETASOL 17-PROPIONATE  
 
1.1. INTRODUCTION 
 
It is generally believed that the introduction of hydrocortisone in the early 1950s, for the 
treatment of patients with inflammatory conditions such as atopic dermatitis and other 
eczematous eruptions was a milestone in topical therapy of dermatological conditions [1, 2]. 
Subsequently, various topical corticosteroids of increasing potency have been synthesised and 
made available to dermatologists, whilst research has led toward the concomitant development of 
vehicles that enhance the activity of the glucocorticoid class of drugs [3-5].  
 
The potency levels of the corticosteroids can be measured by use of the human vasoconstrictor 
[6] or skin blanching [7] assay, in which blanching is assessed in healthy volunteers after topical 
application of a corticosteroid formulation [6-8]. The blanching assay has been a reliable 
technique for the determination of the relative potency of topical corticosteroids, and has been 
shown to be effective for the correlation of potency and clinical effectiveness [8]. Based on the 
vasoconstrictor assay, topical corticosteroids are ranked according to their potency level, with the 
weakest class, including hydrocortisone, labelled as class VII compounds and the most potent 
steroids, including  clobetasol 17-propionate, labelled as class I compounds [1, 2]. 
 
The chemical structure of clobetasol 17-propionate (CP) is depicted in Figure 1.1.  CP is a class I 
or super-potent synthetic di-halogenated analogue of prednisolone [1, 9-11]. CP is  1800 times 
more potent than hydrocortisone when potency is measured using the human skin blanching 
assay [1, 7] and it is currently the most potent topical corticosteroid available on the market [2, 3, 
9, 10, 12-14]. Since 1973, CP has been used for the short-term treatment of patients with 
inflammatory and pruritic manifestations of moderate-to-severe glucocorticoid-responsive 
dermatoses [1, 10, 11]. CP is currently available as a 0.05% w/w CP formulation in a variety of 
vehicles, including cream, ointment, gel, lotion and more recently foams [15-17]. 
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1.2. DESCRIPTION 
  
CP is 21-chloro-9α-fluoro-11β,17α-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-
propionate[18-21].   
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Figure 1.1. Chemical structure of clobetasol 17-propionate (C25H32ClFO5, MW = 467.0) 
 
CP occurs as a white, almost white or cream-coloured, crystalline powder [15, 18, 22] and is 
odourless [10, 14]. CP contains not less than 97.0 percent and not more than 102.0 percent 
C25H32ClFO5, calculated with reference to a dry reference standard substance [22, 23]. 
 
1.3. PHYSICOCHEMICAL PROPERTIES  
 
1.3.1. Solubility 
 
1.3.1.1. Overview 
 
The solubility data of CP in water, ethanol and other organic solvents at room temperature 
(22○C) are summarized in Table 1.1 [10, 14, 18, 20-22]. These data reveal that CP is practically 
insoluble in water, is sparingly soluble in ether, but is soluble in ethanol and is freely soluble in 
acetone, chloroform and dichloromethane [18, 20, 21, 23].  
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Table 1.1. Solubility of CP  
Solvent Solubility 
Water 2 µg/ml 
Ethanol 10 mg/ml 
Ether 1 in 1000 
Acetone 1 in 10 
Chloroform 1 in 10 
Dichloromethane 1 in 10 
 
1.3.1.2. Solubility studies 
 
1.3.1.2.1. Overview 
 
The solubility of CP in propylene glycol (PG) and acetonitrile (ACN) has not yet been reported. 
Consequently solubility studies of CP in PG and ACN were undertaken. Since PG and ACN 
were used in the preparation of the receptor medium for use in in vitro release test studies 
(Section 3.2.6.4., Chapter 3) and in the preparation of the mobile phase for use in RP-HPLC 
studies (Section 2.3.2.8., Chapter 2) respectively, it was considered essential to evaluate the 
solubility of CP in these two solvents.  
 
1.3.1.2.2. Propylene glycol (PG) 
 
The solubility of CP in PG was determined experimentally as described and reported in Section 
3.2.6.3., and was found to be 8.55 ± 2.51 mg/ml (n = 3) (Table 3.1, Section 3.2.6.3, Chapter 3). 
  
1.3.1.2.3. Acetonitrile (ACN) 
 
The solubility of CP in ACN was also determined experimentally following a similar procedure 
with minor modifications as described in Section 3.2.6.3. The procedure used when determining 
solubility was conducted at room temperature (22˚C) rather than at 32˚C, and samples were 
shaken at 120 rpm using a Model-3521 Junior Orbit Shaker (Lab-Line Instruments, Inc., Melrose 
Park, IL, USA). The solubility of CP in ACN was found to be 491.12 ± 0.15 mg/ml (n = 3).  
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1.3.2. Dissociation constant (pKa) 
 
CP does not have any ionisable functional groups and thus does not dissociate and therefore 
there is no reported dissociation constant [20].  
 
1.3.3. Partition coefficient  
 
The octanol/water partition coefficient (log Po/w) of CP has been reported as 3.50 [21, 24]. The 
log Po/w is defined as the logarithm of the partitioning ratio of a substance between octanol and 
water, and is commonly used to quantitatively characterize the lipophilic nature of organic 
compounds [25, 26]. Similarly lipophilicity has been described as a molecular parameter, which 
may be used to describe the distribution equilibrium of a drug molecule between water and 
various water immiscible, lipid-like organic solvents or other solubilising media such as, for 
example, biological membranes [25, 27, 28].  
 
Roberts et al., [29] argued that the lipophilicity of a solute is the main determinant for solute 
partitioning into the stratum corneum from aqueous systems. Based on the log Po/w parameters, 
CP can therefore be considered more lipophilic than hydrocortisone, which has a log Po/w of 1.61 
[25, 29], and will more than likely partition into the stratum corneum from aqueous based semi-
solid formulations such as gels and creams faster than hydrocortisone would.  
 
1.3.4. Melting range 
 
CP has a melting range of approximately 195.5-197.0○C, at which temperature CP also 
decomposes [21-23]. 
 
1.3.5. Optical rotation 
 
The specific optical rotation of CP in a 1% w/v solution in 1,4-dioxan is +96º to +104º, 
calculated with reference to a dry reference standard [22]. 
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1.3.6. Stability 
 
CP is unstable in the solid state and must be protected from light [22]. A solution or lotion of CP 
should be stored at temperatures of between 4-25○C, and should not be used near an open flame 
[14]. CP creams or ointments should be stored at a temperatures of between 5-30○C and the 
cream should not be refrigerated [14, 15].  
 
CP gel formulations should be stored at temperatures of between 2-30○C [14, 16] and CP foams 
should be stored at controlled room temperatures of between 20-25○C and should not be exposed 
to heat or stored at temperatures exceeding 49○C [14, 17]. Since the contents of a foam product 
are usually under pressure, the container should also not be punctured, used or stored near heat or 
an open flame, or placed into a fire or incinerator for disposal [14].  
 
1.3.7. Ultraviolet absorption spectrum 
 
The ultraviolet (UV) absorption spectrum of CP, determined experimentally in a binary mixture 
of ACN:water (50:50) is depicted in Figure 1.2. The UV absorption spectrum was generated 
using a Model-GBC 916 UV-VIS Double Beam Spectrophotometer (GBC Scientific Equipment 
Pty. Ltd, Melbourne, Victoria, Australia), with the scanning range and speed set at between 200-
800 nm and 600 nm/min, respectively.  
 
The data revealed that CP has a wavelength of maximum absorption (λ-max) of 240 nm. Despite 
the use of different solvent systems, the absorption spectrum of CP obtained in these studies 
using ACN:water (50:50) as a vehicle was similar to that previously reported in the literature 
using methanol as the solvent or vehicle [21].  
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Figure 1.2. UV absorption spectrum of CP in ACN:water (50:50) 
 
1.3.8. Infra-red Absorption Spectrum  
 
The infra-red (IR) absorption spectrum of CP was determined using potassium bromide (KBr) 
pressed disks and the resultant spectrum is shown in Figure 1.3 [22]. The IR absorption spectrum 
of CP shows principal peaks at wave-numbers 1666, 1612, 1724, 1063 and 1010 cm-1 [20] and 
the relevant band assignments determined using theoretical concepts [30] are summarized in 
Table 1.2. 
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Figure 1.3. IR absorption spectrum of CP (adapted from 22) 
 
 
Table 1.2. Major infra-red band assignment for CP 
Band position (cm-1) Assignment 
1666 C=C stretching of the aliphatic non-conjugated alkene 
1612 C=O stretching of the ketone 
1724 C-Cl stretching of chlorine 
1063 COO stretching of the ether 
1010 O-H bending of the alcohol 
 
1.3.9. Crystal Structure  
 
Haramura et al., [11] determined the crystal structure of CP using x-ray analysis and single 
crystals of CP, purified by recrystallization from a methanol-acetonitrile solution. They reported 
that the CP crystals belong to the group P21 and that the cell dimensions are a = 7.6961(3) Ǻ, b = 
14.6036(5) Ǻ, c = 10.4355(5) Ǻ, β = 95.739(2) Ǻ and that the final discrepancy factor, R, is 
0.038. Furthermore Harumara et al., [11] postulated that in the pregna-1,4-diene-3-one skeleton, 
rings A, B, C (Figure 1.1) adopt planar, chair and chair conformations, respectively, whereas ring 
D takes on an envelope shape at C14. 
 
Haramura et al., [11] also argued that the stereochemistry of the methyl group at C16 is in the 
alpha (α) configuration, which may result in steric hindrance between this methyl group and the 
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methyl group at C13. Nevertheless, they also postulated that the non-bonded C18 to C23 distance 
of 4.103 Ǻ is indicative of the fact that such steric hindrance may be relieved.  
 
According to Haramura et al., [11] the distance between the C20, carbonyl carbon and the O25 
carbonyl oxygen is 2.742 Ǻ. The torsion angle, C17-O24-C25-O25 of -7.2º reveals that this part 
of the molecule deviates significantly from the plane. The non-polarity of the CP is presumably 
due to the C20-O25 interaction [11].   
 
Haramura et al., [11] also reported that there are seven intermolecular interactions within the CP 
molecule for which the geometrical parameters indicate that the interactions are due to hydrogen 
bonds. Moreover Haramura et al., [11] argued that there is a single intermolecular oxygen bond 
between the hydroxyl group and the carbonyl group attached to ring A.   
  
1.4. STEREOCHEMISTRY AND STRUCTURE ACTIVITY RELATIONSHIP 
 
All topical corticosteroids have a basic skeletal structure consisting of a fully reduced 
phenanthrene ring system fused to a five-membered ring, giving rise to a 
cyclopentanoperhydrophenanthrene nucleus, which is comprised of three six-membered and one 
five-membered rings [31]. A further common attribute of the corticosteroid class of drugs is the 
presence of methyl functional groups attached at positions 10, 13, 18 and 19 respectively (Figure 
1.1).    
 
The four rings of the corticosteroid skeleton do not exist in a flat place and the structure has no 
elements of symmetry with each of the 19 positions being chemically distinct from each of the 
other positions in the structure [31]. Furthermore, the corticosteroid skeleton is a rigid structure, 
and it has been suggested that small changes in the position of a substituent usually results in a 
significant change in the biological activity of the molecule [31].  
 
Over the years, research has focused on strategies to optimise the potency and, in particular, the 
anti-inflammatory and immunosuppressive capacity of the corticosteroids, while minimizing 
adverse events and unwanted side effects associated with their use [9]. Although modifications to 
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the basic structure have led to the synthesis of topical corticosteroids with greater potency, these 
new highly potent molecules are often associated with a greater potential to precipitate adverse 
reactions to the molecule on administration [9].  
 
As with all corticosteroids, CP consists of the basic four-ring 21-carbon structure. The 4,5 double 
bond in ring A in addition to the 3-ketone group are essential for anti-inflammatory activity, 
while the presence of a 1,2 double bond increases the glucocorticoid activity relative to 
mineralocorticoid effects [9, 18, 31, 32]. The 9α-fluoro group in ring B enhances both 
glucocorticoid and mineralocorticoid activity whereas the 11-hydroxy group in ring C is essential 
for anti-inflammatory and glucocorticoid activity but not for mineralocorticoid effects [9, 18, 
32].  
 
The addition of a methyl functional group at position C16 in ring D eliminates mineralocortucoid 
activity, while the presence of a propionate ester at position C17 and a chlorine atom at position 
C21 increases topical activity due to a considerable increase in the lipophilicity of the molecule 
[9, 18, 32] 
 
1.5. CLINICAL PHARMACOLOGY 
 
1.5.1. Mode of action 
 
1.5.1.1. Overview 
 
The physiological activity of corticosteroids can be divided into two broad categories, viz., 
mineralocorticoid effects that control electrolyte and fluid balance in the body and glucocorticoid 
effects that influence carbohydrate, fat and protein metabolism [18, 33]. Although compounds 
that lack the unwanted mineralocorticoid activity have been produced, to date it has proved 
impossible to dissociate the glucocorticoid properties of synthetic topical corticosteroids from 
their anti-inflammatory activity [33].  
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Topical corticosteroids are generally believed to have anti-inflammatory, antiproliferative, 
antipuritic, and vasoconstrive properties [34]. However, it is through their anti-inflammatory 
action that these agents are thought to exert their main therapeutic effects in a wide range of 
acute and chronic inflammatory diseases, including most steroid-responsive dermatoses, 
irrespective of aetiology [35].   
 
1.5.1.2. Anti-inflammatory action  
 
The precise mechanism by which CP and other topical corticosteroids exert their anti-
inflammatory effect in the treatment of steroid-responsive dermatoses is still uncertain [11, 15, 
36]. However it is generally believed that at a cellular level, corticosteroids bind to specific 
glucocorticoid receptors (GR) that are 777 amino acid protein members of the superfamily of 
ligand-regulated nuclear receptors [9]. The GR have a modular structure and their principle 
functions of transactivation, DNA binding and ligand binding are localised to specific domains in 
that structure [36]. The GR are located and maintained in the cytoplasm as inactive multi-protein 
complexes of two heat shock proteins (hsp90), which promote glucocorticoid binding but 
prevent binding of the GR to DNA [9, 36].  
 
The binding of a steroid to the GR is followed by dissociation of the hsp90 after which the 
glucocorticoid-GR complex migrates into the nucleus of the cell and binds to DNA at specific 
regions known as the glucocorticoid response elements on certain genes [34]. Successful binding 
results in an increase in the production of lipocortin-1 [36]. Lipocortin-1 is a protein that has 
been reported to belong to the annexin superfamily [9, 36], and its main function is to inhibit the 
activity of phospholipase A2 directly, thereby decreasing the production of pro-inflammatory 
prostaglandins, leucotrines, thromboxanes and leucocyte migration [36].  
 
Apart from the direct regulatory effect on gene transcription, it has also been reported that topical 
corticosteroids can regulate transcription of other transcription factors indirectly [34]. In 
particular, corticosteroids have been shown to increase cellular levels of an inhibitory nuclear 
factor (IκBα) by stimulating the expression of the IκBα gene [37].  IκBα then diffuses into the 
cytosol and binds to the nuclear factor-κ B (NF-κB) thereby preventing translocation of NF-κB 
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to the nucleus and suppression of various gene products regulated by NF-κB, such as the 
cytokines and adhesion molecules [37, 38]. Since NF-κB activates various immuno-regulatory 
genes in response to pro-inflammatory stimuli, the inhibition of its activity can be a major 
contributing factor in the anti-inflammatory activity of the glucocorticoids [38]. In this way, 
corticosteroids may affect the transcription of genes that do not contain a glucocorticoid-
responsive receptor [34]. 
 
Topical corticosteroids have also been shown to inhibit the transcription of various pro-
inflammatory cytokine genes involved in skin disease such as interleukin (IL)-1, IL-2, IL-6, 
interferon gamma (IFN-γ), and tumour necrosis factor-alpha [34]. Furthermore, corticosteroids 
appear to stimulate lymphocyte expression of genes for anti-inflammatory cytokines such as 
transforming growth factor-β and IL-10 [34]. Through regulation of cytokine production, it has 
been suggested that corticosteroids probably play a role in rebalancing the T-helper cell type 1 
(TH1) to TH2 lymphocyte ratio in skin lesions [34]. The anti-inflammatory effects that have been 
associated with corticosteroid treatment include inhibition of capillary dilation and dermal 
oedema and the suppression of endothelial cell and lymphocyte function [34].  
 
1.5.1.3. Immuno-suppressive effects 
 
Corticosteroids have also been reported to inhibit the proliferation of various cell types, such as 
the T-lymphocytes [34].  However the anti-proliferative effects have not yet been clearly 
defined, although it has been suggested that the effects are more than likely a consequence of the 
blockade of cytokine expression and the suppression of cytokine effects [34]. Furthermore it has 
been reported that some of the anti-proliferative effects of the corticosteroids may be mediated 
through lipocortins which act as secondary messengers for corticosteroid compounds [34]. IL-10 
and transforming growth factor-β1 have been shown to potentiate the inhibitory effects of the 
corticosteroids on T-lymphocyte proliferation [34].  
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1.5.1.4. Anti-mitotic and vasoconstrictive effects 
 
 It has also been reported that topical corticosteroids have anti-mitotic and vasoconstrictive 
activities in addition to their anti-inflammatory and immuno-suppressive actions [9]. The anti-
mitotic effects of the corticosteroids are secondary to the general reduction of protein synthesis 
and may explain the therapeutic action of the corticosteroids in scaling dermatoses such as 
psoriasis [9]. Similarly, the vasoconstrictive activity of the corticosteroids as demonstrated in 
vascular beds may contribute to the anti-inflammatory activity of topical corticosteroids. 
Although the mechanism by which vasoconstriction is induced is not yet completely elucidated, 
it is thought to be related to the inhibition of natural vasodilators such as histamine, bradykinins 
and prostaglandins [9].  
  
1.5.2. Indications 
 
CP is usually indicated in the management of significant inflammation of the skin that is 
naturally thick or thickens as a result of disease, to such an extent that penetration of a less potent 
topical corticosteroid would be poor, thereby making treatment difficult or ineffective [39]. 
Typical indications for CP use include the treatment of psoriasis of the body, palmoplanter 
psoriasis, lichen planus, lichen simplex chronicus, lupus erythematosus, and acute exacerbations 
of atopic dermatitis in adults [39].  
 
CP is also indicated in the management of severe and acute attacks of any type of eczema and 
chronic eczema, especially of the hands and feet where hyperkeratosis becomes an issue, chronic 
hyperkeratotic sporiasis of the hands and feet, localised bullous disorders, keloids, pretibial 
myoedema, vitiligo and also in the suppression of reaction after cryotherapy [20]. CP is 
occasionally used for the management of light or photo-sensitivity reactions [20].  
 
1.5.3. Contra-indications 
 
CP preparations are contraindicated in patients with a known history of hypersensitivity to CP 
and other related compounds or any excipients that may be used in the respective formulations 
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[15-17].  The use of CP in neonates and paediatric patients under the age of 12 is contraindicated 
due to the potent local and more importantly systemic effects should they be absorbed [1, 10, 15, 
20]. CP formulations should not be used in the treatment of acne vulgaris, rosacea or perioral 
dermatitis or as monotherapy in the treatment of widespread plaque psoriasis [10, 14, 20]. 
 
CP should also not be used for the treatment of cutaneous infections caused by viruses, bacteria 
or fungi [20]. If concomitant skin infections develop during CP therapy, appropriate antifungal 
or antibacterial therapy must be initiated [14] and should the infection not respond to therapy, CP 
should be discontinued until the infection is adequately controlled [14]. Skin infestations such as 
scabies must not be managed with CP as exacerbations of the disease may occur or the disease 
may be disguised [20]. The use of CP on the face, groin, or axillae is also contraindicated [20]. 
 
1.5.4. Adverse Effects 
 
1.5.4.1. Overview 
 
Since the commercial introduction of CP in 1973, primarily for the treatment of specific 
dermatoses (Section 1.5.2), indications for the prescription of this potent corticosteroid have 
been modified due to potential deleterious side effects that have been reported [40]. Serious side 
effects nearly always follow the dispensing of uncontrolled repeat prescriptions [41] and have 
been reported more frequently for the treatment of psoriasis than in eczema, probably due to the 
fact that the parakeratotic keratin of psoriatic skin is more permeable than normal keratin [20]. 
The adverse effects are noticeable as localised skin reactions occurring at the site of application 
and generalised adverse effects arising from systemic absorption of the compound [2, 9].  
 
1.5.4.2. Local side effects 
 
Burning, stinging, irritation and itching sensations have been reported as the most frequent local 
cutaneous reactions in 1% of patients treated with CP creams in controlled clinical trials [15]. 
Less frequent local side effects include, cracking of the skin, erythema, folliculitis, numbness of 
fingers, skin atrophy and telangiectasia [15]. The use of CP may exacerbate pre-existing or 
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coexistent dermatoses, such as rosacea, perioral dermatitis, tinea infections and resistant psoriatic 
lesions [15]. 
 
1.5.4.3. Systemic side effects 
 
Systemic side effects are usually not common but can arise when locally applied CP preparations 
are absorbed through the skin and enter the general circulatory system [2]. The occurrence of 
systemic absorption is rare and side effects are often clinically insignificant, particularly if the 
formulation is used on an ad hoc basis [2]. The greatest risk of systemic side effects occurs when 
large amounts of CP formulations are used over very large areas of the body for prolonged 
periods of time [2, 20].  
 
CP has the potential to cause suppression of the hypothalamic-pituitary (HPA) axis, Cushing’s 
syndrome, diabetes and hypertension [20]. Suppression of the HPA-axis has occurred following 
administration of topical dosages of as low as 2 g of the 0.05% w/w cream, ointment and gel or 7 
g of the 0.05% w/w foam on a daily basis [15-17]. Cushing’s syndrome has been reported in 
infants and adults following the prolonged use of topical CP formulations [15].   
 
HPA-axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain and 
inter-cranial hypertension have also been reported in children being treated with topical 
corticosteroids [15]. Manifestations of adrenal suppression in children include low plasma levels 
and an absence of response to adrenocorticotropic hormone (ACTH) stimulation, whereas those 
of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema 
[15-17].  
 
1.5.5. High risk groups 
 
1.5.5.1. Pregnancy 
 
The teratogenic potential of CP in humans is still unknown [14], however reproductive studies in 
mice and rabbits using subcutaneous dosages of CP of up to 1 mg/kg and 10 µg/kg, respectively 
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revealed substantial harm, including cleft palate, skeletal immaturity, increased rates of still birth 
and fetal resorption [14]. The administered doses were approximately 1.4 and 0.05 times those 
that would be typical of topical doses in humans of either the CP cream or ointment formulations 
[15-17].  
 
Since CP can undergo percutaneous absorption [14] the data obtained from reproductive studies 
suggest that the use of CP in pregnancy should be avoided [14]. It is also worth noting that 
although no study has shown the absolute teratogenicity of CP, other potent corticosteroids have 
been shown to be teratogenic in animals following topical application [14]. Therefore the use of 
CP in pregnancy is contraindicated. 
 
1.5.5.2. Lactation 
 
Corticosteroids that are administered systemically are reportedly secreted in human milk and 
could, therefore, suppress growth and interfere with endogenous corticosteroid production in 
breast feeding infants [15]. It is unknown whether topical application of corticosteroids may 
result in sufficiently high systemic levels following absorption to produce detectable quantities in 
human milk. However since many drugs are excreted in breast milk, caution should be exercised 
when CP cream, ointment, gel or foam formulations are administered to nursing mothers [15-17]. 
 
1.5.5.3. Paediatric use  
 
The safety and effectiveness of CP cream, ointment, gel and foam formulations in paediatric 
patients has not yet been established [15]. Consequently the use of CP in patients under the age 
of 12 years of age is not recommended. Paediatric patients are at a greater risk of HPA-axis 
suppression and Cushing’s syndrome than adults when they are treated with topical 
corticosteroids [15]. This is a result of the fact that paediatric patients have a higher skin surface 
area to body mass ratio than adults [15-17].   
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1.5.5.4. Geriatric use 
 
In clinical studies in which CP cream, ointment, gel and foam formulations were used, a 
sufficient number of patients over the age of 65 years were not included in the study to 
categorically conclude whether geriatric patients respond differently to topical steroid therapy 
than younger patients [15-17].  
 
While other clinical experience has not revealed age-related differences in response, dosages 
should generally be titrated carefully in geriatric patients by initiating therapy at the low end of 
the dose range [15]. The greater frequency of decreased hepatic, renal or cardiac function and 
concomitant disease drug therapy suggest that care must observed when treating elderly patients 
with topical corticosteroid products [14]   
 
1.6. PHARMACOKINETICS 
 
1.6.1. Dosage and Administration 
 
CP cream, ointment and gel should be applied sparingly as thin films and should be rubbed 
gently into the affected area twice daily, preferably in the morning and evening [14, 15]. CP 
foams and solutions should be applied to the affected areas of the scalp twice daily, in the 
morning and evening [14, 17]. Some patients may respond initially to once daily or intermittent 
therapy, for example, twice daily for three days per week [14].  
 
The use of CP should be discontinued and a less potent topical corticosteroid preparation 
substituted as soon as it is clinically feasible to alter therapy [10].  CP dosage should not exceed 
50g of a CP 0.05% w/w cream, ointment, gel and foam or 50 ml of CP 0.05% w/v lotion per 
week and the extended duration of a course of CP therapy should not exceed 14 days [10]. It has 
been reported that many clinicians have indicated that prolonged CP therapy may be necessary in 
rare cases in patients with resistant dermatological conditions, and careful monitoring of their use 
in these patients is essential [10, 14].  
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1.6.2. Absorption  
 
Percutaneous penetration and absorption of CP varies between individuals and can be altered by 
using a variety of vehicles [14] and/or percutaneous penetration enhancers [42]. Absorption can 
be increased by use of occlusive dressings [14, 41, 43] and use of percutaneous penetration 
enhancers such as for example surface active agents, cyclodextrins or pyrrolidones [44, 45].   
Following topical application of normal doses of CP to most areas of healthy skin, only small 
amounts of the drug reach the dermis and subsequently the systemic circulation [10]. 
Nevertheless, systemic absorption may be increased when the usual dosage is exceeded or when 
the skin is inflamed or diseased [10]. 
 
Mean peak plasma concentrations of CP of 0.63 ng/mL have been reported in one study, eight 
(8) hours following a second dose of 30 g of CP that was applied thirteen (13) hours after an 
initial dose of the 0.05% w/w CP ointment in healthy individuals with healthy skin. [14].  Mean 
peak plasma concentrations of CP were slightly higher and occurred ten (10) hours after a second 
dose of CP when a 0.05% w/w CP cream was administered to subjects [14]. Mean peak plasma 
concentrations of approximately 2.3 and 4.6 ng/mL respectively have been reported to occur 
approximately three (3) hours after a single application of a 25 g dose of a 0.05% w/w ointment 
in patients with psoriasis or eczema, respectively [14].  
 
1.6.3. Distribution  
 
Advances in vehicle technology have enhanced the distribution of topical corticosteroids within 
the skin structure [39] as illustrated by the results of an in vitro trial comparing the amount of 
drug recovered after the application of 0.05% w/w CP lotion, cream or emollient cream [39]. 
Human skin samples sectioned by surgical excision were treated with different formulations and 
the levels of CP in the skin were measured after centrifugation and extraction of the skin sample 
[39]. It was found that significantly more CP was recovered in the epidermis, including the 
stratum corneum, following administration of the lotion formulation as compared to that 
following administration of a cream [39]. Similarly significantly more drug was recovered from 
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the epidermis and dermis following administration of the lotion as compared to that following 
administration of an emollient cream [39].  
 
1.6.4. Elimination 
 
The absorption of CP into the systemic circulation seldom occurs (Section 1.6.2). Nevertheless 
when percutaneous penetration and subsequent absorption of CP occurs, it has been reported that 
the same metabolic pathways that are active when clearing systemically administered 
corticosteroids are involved in the removal of the topically administered corticosteroid [14]. 
Although the systemic metabolism of CP has not been fully characterized or quantified [14], it 
has been reported that the small amount of CP that may be absorbed following topical 
application is metabolized in the liver [21] and excreted in the bile [14]  and in the urine [14, 21]. 
 
1.7. CONCLUSIONS 
 
The description, physicochemical characteristics, structural activity relationships, clinical 
pharmacology and pharmacokinetics aspects of clobetasol 17-propionate (CP) have been 
presented. CP is chemically known as 21-chloro-9α-fluoro-11β, 17α-dihydroxy-16β-
methylpregna-1,4-diene-3,20-dione 17-propionate. The empirical formula of CP is C25H32ClFO5, 
and its molecular weight is 467.0 g/mole. CP is a synthetic di-halogenated analogue of 
prednisolone and occurs as a white or almost white or cream-coloured crystalline powder which 
is odourless.  
 
Based on the human skin blanching assay CP has been labelled as a super-potent or class I 
topical corticosteroid and is one of the most potent topical corticosteroids currently available on 
the market. CP is marketed in a variety of vehicles such as creams, ointments, gels, lotions and 
foams each containing 0.05% w/w of the corticosteroid. 
 
CP does not have any ionisable functional groups and thus does not dissociate. The lack of such 
functional groups results in CP having a relatively high octanol/water partition coefficient or log 
Po/w of 3.5, making it relatively more hydrophobic than other corticosteroids such as for example 
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hydrocortisone. CP is therefore practically insoluble in water, but soluble in water-miscible 
solvents such as acetonitrile or ethanol and freely soluble in some water-immiscible solvents 
such as acetone, chloroform, and dichloromethane. The hydrophobic nature of CP suggests that 
CP will partition into the stratum corneum from aqueous based topical formulations such as 
creams and gels at a much faster rate than hydrocortisone.  
 
The melting range of CP is reported to be approximately 195.5-197.0○C at which temperature it 
also decomposes, while its specific optical rotation in a 1% w/v solution in 1,4-dioxan is between 
+96º to +104º. The ultraviolet (UV) absorption spectrum of CP reveals that CP has a wavelength 
of maximum absorption (λ-max) of 240 nm.  
 
CP is unstable in the solid state and must be protected from light. Solutions and semi-solid 
formulations containing CP should be stored at suitable temperatures of between 4-25○C for 
solutions, 5-30○C for cream and ointments, 2-30○C for gels and 20-25○C for foams.  
 
CP has structural features that are common to all topical corticortisteroids including 3-keto and 
11-hydroxy groups, which are essential for anti-inflammatory activity, a 1,2 double bond and a 
16-methyl group, which increases its glucocorticoid activity relative to the unwanted 
mineralocorticoid effects. Functional groups that are unique to CP include a 9α-fluoro group that 
enhances glucocorticoid and mineralocorticoid activity and a 17-propionate ester and a 21-
chlorine group, which increases the lipophilicity of the drug and hence its topical activity.  
 
The mechanism of action of CP may involve anti-inflammatory, immuno-suppressive, anti-
mitotic and vasoconstrictive effects. The anti-inflammatory action of CP may be due to its 
binding to specific glucocorticoid receptors (GR), which through a cascade of events decreases 
the production of pro-inflammatory prostaglandins, leucotrines and thromboxanes and leucocyte 
migration. The immunosuppressive effects of CP more than likely involve the blockade of 
cytokine expression and the suppression of cytokine effects. Whereas the anti-mitotic effects of 
CP may be secondary to a general reduction of protein synthesis the vasoconstrictive effects may 
be due to the inhibition of natural vasodilators such as histamine, bradykinins and/or 
prostaglandins.  
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CP is indicated for the treatment of significant inflammation of skin that is naturally thick or 
thickens as a result of disease and where penetration of a less potent topical corticosteroid would 
likely be poor. Some of the classical skin diseases that may require treatment with semi-solid 
formulations of CP include psoriasis of the body, palmoplanter psoriasis, lichen planus, lichen 
simplex chronicus, lupus erythematosus, and acute exacerbations of atopic dermatitis in adults.  
 
Preparations containing CP are contraindicated in neonates and paediatric patients under the age 
of 12 and in pregnant women, and caution should be exercised when CP formulations are 
administered in nursing mothers as well as geriatric patients.  As with most potent topical 
corticosteroids CP may be associated with local and very seldom systemic side effects. The most 
frequent local cutaneous reactions include burning, stinging, irritation and itching sensations and 
although systemic side effects are very rare, they may include the suppression of the 
hypothalamic-pituitary (HPA) axis, Cushing’s syndrome, diabetes and hypertension.  
 
CP semi-solid formulations should normally be applied sparingly as a thin film and rubbed 
gently into the affected area twice daily preferably in the morning and evening. CP dosage 
should not exceed 50g of CP 0.05% w/w cream, ointment, gel and foam or 50ml of CP 0.05% 
w/v lotion per week and the extended duration of a course of CP therapy should not exceed 14 
days. Percutaneous penetration of CP is very rare when CP formulations are used appropriately 
as described above. However in the unlikely event of CP absorption into the circulatory system 
CP is likely metabolised in the liver and excreted in the bile and urine.  
 
It is therefore, evident that CP has physicochemical and pharmacological properties, such as a 
relative high lipophilicty and local anti-inflammatory activity, respectively, which make the drug 
suitable for incorporation into semi-solid formulations, such as creams, ointments, gels and 
foams for topical administration. Consequently, CP was selected as an ideal candidate for 
inclusion into a generic cream formulation developed and assessed in these studies.  
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CHAPTER TWO 
 
DEVELOPMENT, OPTIMIZATION AND VALIDATION OF AN HPLC METHOD FOR 
THE ANALYSIS OF CLOBETASOL 17-PROPIONATE IN SEMI-SOLID DOSAGE 
FORMS 
 
2.1. INTRODUCTION 
 
The quantitative analysis of clobetasol 17-propionate (CP) in semi-solid formulations has 
primarily been accomplished using reversed-phase high performance liquid chromatography 
(RP-HPLC) with ultraviolet detection [3, 10, 46-48]. Several other analytical techniques that 
have been used for the quantitation of CP in dosage forms include normal-phase HPLC, 
ultraviolet spectroscopy, liquid chromatography-mass spectrometry (LC-MS) and liquid 
chromatography-mass spectrometry-mass spectrometry (LC-MS-MS or LC-MSn) [47].  
 
The Food and Drug Administration (FDA) has published a guidance document [49] in which it 
recommends that an appropriate, specific and sensitive analytical procedure be used to analyse 
and determine drug concentrations and the amount of drug released from dosage forms during in 
vitro release studies [49]. It has been reported that a major difficulty encountered in the analysis 
of semi-solid dosage forms is the potential interference due to formulation adjuvants and 
preservatives that are usually present in what are relatively complex formulations [50]. 
Generally, only one or two components are required to be quantitated and these components 
must be adequately separated from formulation exicipients, which may interfere with the assay 
procedure [50]. 
 
RP-HPLC is a commonly used, powerful and reliable analytical tool that can be used for the in 
vitro analysis of formulations such as creams, ointments and gels that are of a complex nature, 
since HPLC not only provides separation and quantitative data but also has the ability to 
eliminate almost all interference problems [51]. The objective of these studies was therefore to 
develop, optimize and validate a simple, selective, sensitive, precise, accurate and linear RP-
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HPLC method that is suitable for the quantitative analysis of CP in cream formulations and CP 
release during in vitro release studies.  
 
2.2. PRINCIPLES OF RP-HPLC 
 
Liquid chromatography (LC) is a method of chromatographic separation based on the difference 
in distribution of an analyte between two immiscible phases, in which the mobile phase is a 
liquid and percolates through a stationary phase, usually contained in a column [52]. Although 
various terms, including high-speed LC, high-efficiency LC and high-pressure LC, have been 
used to describe LC, high-performance liquid chromatography (HPLC) is now the generally 
accepted terminology [52]. 
 
In HPLC, a stationary phase is either coated onto a finely divided inert support or chemically 
bonded to a support material, contained within a stainless steel tube over which the mobile phase 
flows, thereby affecting the separation of individual components of a mixture [52, 53]. Coated 
phase LC uses a bulk liquid stationary phase, which is mechanically held to the support by 
adsorption [54], whereas in bonded phase chromatography (BPC), an organic stationary phase is 
chemically bonded to a support material rather than being held in place by mechanical means 
[55].  
 
BPC packing materials have been reported to be more stable than coated phase materials due to 
the fact that a stationary phase that is chemically bound to a support cannot be easily removed or 
lost during normal use of the column [56]. However, the poor reproducibility of some packing 
materials that are commercially available has been mentioned as being one of the major 
disadvantages of using BPC [56]. Nevertheless, the success of BPC has virtually eliminated the 
use of coated stationary phases in chromatography [52]. 
 
In HPLC, the sample to be analysed is dispersed into a mobile phase and the analyte(s) of 
interest pass through the stationary phase by pumping the mobile phase through the stationary 
phase using a solvent delivery module [53, 55]. As the analyte molecules pass through the 
column, there is constant interaction between the solute molecules, the stationary phase and the 
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mobile phase [53, 55]. Separation of the various components of a mixture is reported to occur as 
a result of differences in equilibrium of distribution of different solute molecules in the sample 
undergoing analysis [53, 55].  
 
Two principle modes of HPLC, viz., normal-phase HLPC (NP-HPLC) and reversed-phase HPLC 
(RP-HPLC) can be distinguished by the relative differences in the nature of the stationary phases 
used to effect a separation in addition to the corresponding  mobile phase composition and 
differences in the nature of the interaction of functional groups present in solute molecules with 
these phases [52, 53]. The nature of the functional groups of a molecule dictate the selectivity 
and specificity of an interaction between an analyte and the column support material or mobile 
phase, leading to the selectivity and specificity of a separation [53].   
 
NP-HPLC requires the use of a polar stationary phase and a non-polar mobile phase in order to 
separate analyte(s) of interest [53, 57]. In NP-HPLC the stationary phase may be either an 
adsorbent, such as silica, or a liquid phase that is bonded to a solid support. The mobile phase 
may consist of either a single non-polar solvent, such as hexane, or a mixture of non-polar 
solvents or a non-polar solvent mixed with a small amount of a polar non-aqueous solvent, such 
as methanol [57].  
 
NP-HPLC is most useful for the separation of compounds of moderate to strong polarity since 
non-polar solutes elute near the mobile phase front [53]. NP-HPLC is normally restricted to the 
separation of stereochemical isomers, diastereomers, low molecular weight aromatic compounds 
and long chain aliphatic compounds [53].  
 
In contrast, RP-HPLC entails the use of a hydrophobic bonded stationary phase with a mobile 
phase that consists of polar solvents such as water, with or without buffers or mixtures of water 
and water-miscible organic solvents such as methanol and acetonitrile [53, 57, 58]. RP-HPLC is 
usually the first choice of method for use in most pharmaceutical applications and especially for 
the analysis of neutral or non-polar compounds that dissolve in water-organic solvent mixtures 
[59]. Since the majority of pharmaceutical compounds of interest are relatively non-polar, most 
HPLC analyses in pharmaceutical research are carried out using RP-HPLC techniques [57].  
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BPC columns for both NP-HPLC and RP-HPLC may be categorized according to the length and 
functionality of the organic side chain used to manufacture the column [53]. Typically carbon 
chains ranging in length from three (3) to eighteen (18) carbon atoms, viz., C3, C4, C8 and C18, 
are chemically bonded to a silica support surface [53]. If the organic side chain is only alkyl in 
functionality, the resulting phase is hydrophobic and thus useful for the reversed -phase mode of 
analysis [53]. Consequently, stationary phases for RP-HPLC are prepared by reaction of residual 
silanol functional groups in a silica backbone with n-alkylchlorosilanes [58].   
 
RP-HPLC is used extensively in various scientific fields viz., pharmaceutical, agricultural and 
medical sciences, in addition to fundamental studies in the separation sciences [60]. However, 
despite its extensive application, the retention mechanism of molecules in RP chromatographic 
process has not yet been fully elucidated [56, 60]. This is more than likely due to the complexity 
of RP-HPLC systems, the properties of which have been reported to change dynamically with 
the composition of the mobile phase and type(s) of the stationary phase used in separations [61]. 
Nevertheless, some investigators have alluded to the fact that separation in RP-HPLC may be 
due to either adsorption effects or partitioning of a solute between a stationary phase and a 
mobile phase, or combinations thereof [53, 56]. 
 
2.3. METHOD DEVELOPMENT  
 
2.3.1. Overview 
 
A summary of RP-HPLC with UV detection methods that have been developed and used for the 
quantitative determination of CP in semisolid dosage forms is listed in Table 2.1. The data 
contained in these reports were used to set preliminary RP-HPLC conditions for the development 
of a suitable in vitro analytical method for the quantitation of CP in cream formulations and for 
the characterisation of release of CP from topical formulations developed in these studies. 
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Table 2.1. RP-HPLC methods used for the analysis of CP in semi-solid dosage forms 
Column Mobile phase Flow rate (ml/min) Detection method Reference 
µBondapak® C18 300 mm x 3.9 i.d methanol:water (75:25% v/v) 1.5 UV-240 nm 46 
Nova-Pak® C18 5-µm 150 mm x 3.9 mm i.d. methanol:water (70:30% v/v) 1.0 UV-254 nm 10 
Lichrospher® C18 125 mm x 4.0 mm i.d. methanol:aqueous phase pH 3.5 
adjusted with 0.05% citric acid 
(65:35% v/v) 
1.1 UV-240 nm 3 
Nova-Pak® C18 4-µm 150 mm x 3.9 mm i.d.  acetonitrile:water (50:50% v/v) 
 
1.0 UV-240 nm 47 
Purospher-Lichrocart® 5-µm C18 250 mm x 4.0 
mm i.d. 
acetonitrile:water (40:60% v/v) 1.0 UV-237 nm 48 
Phenomenex® Luna C18 150 mm x 4.6 mm i.d. methanol: 0.1M KH2PO4 pH 3: 
acetonitrile (10:40:50% v/v) 
1.0 UV-239 nm 62 
L1® 150 mm x 4.6 mm i.d. acetonitrile:0.05M NaH2PO4 pH 
2.5: methanol (95:85:20% v/v) 
1.0 UV-240 nm 23 
Spherisorb ODS® 2, 5µm, 50 mm x 4.6 mm i.d. methanol:0.05M NaH2PO4 pH 2.5: 
acetonitrile (10:42.5:47.5% v/v) 
1.0 UV-240 nm 22 
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2.3.2. Experimental  
 
2.3.2.1. Chemicals 
 
All chemicals used in these studies were at least of analytical reagent grade. HPLC-grade 
solvents, viz., methanol (UV cutoff of 215 nm) and acetonitrile (UV cutoff of 200 nm) were 
purchased from Romil Ltd. (Waterbeach, Cambridge, UK). HPLC-grade water was prepared 
using a Milli-RO® 15 water purification system (Millipore Co., Bedford, MA, USA) that 
consisted of a Super-C® carbon cartridge, two Ion-X® ion-exchange cartridges and an Organex-
Q® cartridge. The water was filtered through a 0.22 μm Millipak® 40 stack filter (Millipore Co., 
Bedford, MA, USA) prior to use.  
 
Clobetasol 17-propionate (CP) was purchased from Symbiotec Pharmalab P.V.T. Ltd 
(Pigdamber, Maharastra, India). Betamethasone 17-valerate (BV) was purchased from Sigma-
Aldrich SA (Pty) Ltd (Brackenfell, Western Cape, RSA) and Dermovate® cream (Glaxo 
Wellcome SA (Pty) Ltd, Midrand, Gauteng, RSA) was purchased from Wallaces Pharmacy 
(Grahamstown, Eastern Cape, RSA). 
 
2.3.2.2. Instrumentation  
 
Two modular HLPC-UV chromatographic systems, i.e., System 1 and System 2, were used in 
these studies. System 1 was used for the development, optimization and validation of the 
analytical method and System 2 for the characterisation of CP content and release in topical 
formulations during product development and assessment studies. A mini-revalidation of the 
analytical method was undertaken prior to using System 2 for quantitative purposes.   
  
System 1 
 
The modular HPLC-UV system consisted of a Beckman Model 112 Solvent Delivery Module 
(Beckman Instruments, Inc., San Ramon, CA, USA), a WISP™ Model 712 Autosampler 
(Millipore® Waters Associates, Milford, MA, USA) and a linear UV-100 detector 
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(Spectrachrom, NV, USA) set at λ = 240 nm. Data acquisition was performed using a dual-pen 
Model 561 strip chart recorder (Perkin-Elmer, Maywood, IL, USA) and separation was achieved 
on a Nova-Pak® 60 Å C18 4-µm (3.9 i.d. x 150 mm) cartridge column (Millipore® Waters 
Associates, Milford, MA, USA).  
 
System 2 
 
The modular HPLC-UV differed from System 1 in that it consisted of an Isochrom LC dual 
piston solvent delivery module (Spectra-Physics, San Jose, CA, USA) and data acquisition was 
performed using an SP-4600 Integrator (Spectra-Physics, San Jose, CA, USA). All the other 
system components were the same as those used for System 1.  
 
2.3.2.3. UV detection of CP and internal standard 
 
The ideal detector for HPLC should be sensitive, respond to all solutes universally or have 
predictable specificity, have a linear response over several orders of concentration, possess a low 
dead volume, be non-destructive, be insensitive to changes in temperature and mobile phase 
velocity changes, operate continuously and be reliable and convenient to use [52]. Unfortunately, 
no single detector is able to satisfy all these criteria and consequently analytical methods have to 
be optimized for specific pieces of equipment. 
 
In most cases, analytical method development for HPLC commences by use of ultraviolet (UV) 
detection with either a variable-wavelength spectrophotometric or diode-array detector [63].  UV 
detector technology has developed over the years and is associated with good sensitivity and 
linearity and can provide an adequate response for most samples, except when samples have 
little or no UV absorbance, analyte concentrations are too low for UV detection, sample 
interference is important, and/or qualitative structural information about a molecule is required 
[63]. 
 
It has been suggested that the manner in which a UV detector is used may affect the relative 
response of sample components and could potentially interfere with the selectivity, sensitivity 
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and baseline noise of an analytical method [63]. The achievement of adequate sensitivity is 
primarily dependent on the selection of an appropriate wavelength for analysis, which is chosen 
from knowledge of the UV absorption spectrum of the individual sample components to be 
evaluated [63]. The UV absorption spectrum of an analyte should therefore be evaluated prior to 
the development of a comprehensive HPLC method for analysis of that compound [63].  
 
The analysis of CP by RP-HPLC has been accomplished using UV detection at 237 nm [64], 239 
nm [62], 240 nm [3, 46, 47] and 254 nm [10]. An evaluation of the UV absorption spectrum of 
CP (Figure 1.2, Section 1.3.7.) reveals that the wavelength of maximum absorption (λmax) is 240 
nm. Consequently, the eluent in these studies was monitored at 240 nm. The detection of the 
internal standard does not have to occur at the λmax of the compound in question, since enough 
material may be added to a sample to achieve an adequate response from the molecule, at the 
desired attenuation used for analysis of the compound of interest.  
 
2.3.2.4. Column selection 
 
It has been suggested that the column is the heart of any HPLC separation procedure [65, 66]. It 
follows therefore that the availability of a stable, high-performance column is vital for the 
development of a rugged, reproducible and reliable analytical method. The stability of a column 
is especially important in method development since once a desired separation is achieved the 
column characteristics should remain unchanged for as long as possible and excellent column 
stability minimizes the need for further adjustment of the separation conditions or replacement of 
a column during any specific application of the method [65].  
 
Commercially available columns may differ in their reproducibility when purchased from 
different suppliers and in many cases differences exist in columns supplied from a single supplier 
[66]. Such differences can have a serious impact on developing a reproducible and useful HPLC 
method of analysis for a particular compound [65]. The decision to use a particular HPLC 
stationary phase is based on physicochemical characteristics such as the solubility, molecular 
weight and ionic nature of the analyte of interest, in addition to the column packing material and 
dimensions of the column [66, 67].  
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The majority of column materials used for HPLC separations make use of a silica particle base or 
support, although there are a number of columns that are now available that are packed with 
porous-polymeric support materials [65, 66, 68]. However, the majority of RP-HPLC separation 
techniques use silica-based bonded-phase chromatographic (BPC) columns [58, 66]. Such 
columns are made by reacting mono-functional chorodimethylsilanes with available silanol 
functional groups of a stationary phase material [58, 65, 66]. 
 
A variety of different alkyl and substituted alkyl silica materials are formed as a consequence of 
these reactions. Some of the examples of the types of bonded phase materials that have been 
produced include n-octadecylsilane (ODS or C18), n-octylsilane (C8), phenyl, dimethylsilane and 
dimethylamino functionalities [65, 66]. Separation of compounds on BPC columns in RP-HPLC, 
primarily depend on molecular interactions that occur between a solute and the components of 
the mobile and stationary phases being used for that separation [69].   The underlying 
mechanisms of a separation include hydrophobic and solute-solvent interactions that result in 
increased retention of compounds with large C-H or hydrophobic surface areas and shorter 
retention times for compounds containing polar or hydrophilic functional groups such as 
hydroxyl groups (OH) [68].  
 
The retention process in RP-HPLC involves partitioning of solutes between a mobile phase and 
the bonded alkyl groups of a stationary phase that contain organic solvents extracted from the 
mobile phase in use [68]. The retention of an analyte may be affected by the composition of the 
mobile phase and the structure of the stationary phase. Consequently, the length and surface 
density of alkyl chains in a stationary phase have been reported to be the primary determinant of 
the phase ratio between the mobile and stationary phases of a column, the orderliness of alkyl 
chains in that column and the solvent content (or polarity) of the stationary phase [68] .  
 
The stability of silica-based BPC columns depends on the types of silica support and bonded 
phases used to manufacture the column, the mobile phase pH and the type of the buffer and 
organic modifier(s) used to prepare the mobile phase. The loss of silane-bonded phases can occur 
due to hydrolysis of the siloxane bonds (Si-O-Si) that bind the silane to the support backbone of 
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the column. Furthermore, degradation of supports is accentuated at high temperatures, low pH 
and in highly aqueous mobile phases [65].  
 
The most commonly used columns that have been reported for the analysis of CP in dosage 
forms are octadecylsilyl (C18) based stationary phases[3, 10, 46-48, 70], which  may be due to the 
fact that CP is a highly hydrophobic drug with an octanol-water partition coefficient of 3.5 [47]. 
Therefore, retention and separation of CP on such columns can be easily accomplished using a 
mixture of water and water-miscible solvents such as methanol and/or acetonitrile. Other 
common features of these columns are the average particle size of the packing materials, which 
are ≤ 5 µm, and the column dimensions, which are 150 mm (L) x 3.9-4.6 mm (i.d.) (Table 2.1, 
Section 2.3.1). It has been suggested that the retention of a compound on an RP-HLPC analytical 
column may be affected by the column packing materials as well as the column dimensions [65, 
66].  
 
It is generally believed that the efficiency of packed RP-HPLC columns is enhanced with a 
decrease in the particle diameter of the stationary phase, such that the smaller the particles the 
better the resolution and sensitivity that can be obtained with the column of interest [65, 66]. 
Most RP-HPLC columns are packed with particles with sizes ranging between 3-10 µm and 
although smaller particles will generally result in high theoretical plate numbers (Section 2.3.2.5) 
and better sensitivity, they more than likely lead to high column back-pressures than the packing 
materials with large sizes [65, 66]. Consequently, RP-HPLC columns packed with particles with 
an average diameter of 5 µm may represent a good compromise in terms of column efficiency, 
back-pressure and lifetime of use [65].  
 
As far as column dimensions are concerned, it has been suggested that columns of lengths of 
between 100-1500 mm may be used for HPLC analysis, although most of the newer equipment 
allows for the use of columns with maximum lengths of only 250 mm [66].  Kromidas [71] 
suggested that the use of a longer column may improve resolution at the expense of retention 
times and column back-pressures. Similarly, the efficiency of well-packed columns of small 
particles of ≤ 10 µm in size has been reported to increase with an increase in the column internal 
diameter (i.d.) [66]. However, HPLC columns with i.d. of between 4-5 mm have been reported to 
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represent a good compromise of performance, convenience, amount of mobile phase used and 
column packing required in analytical applications [66].  
 
A Nova-Pak® 4 µm (150 mm x 3.9 i.d.) cartridge column, packed with dimethyl octadecylsilyl 
(C18) bonded amorphous silica was therefore selected for testing and thereafter for the 
development of an analytical method for the determination of CP in dosage forms.  
 
2.3.2.5. Column efficiency 
 
The efficiency of a chromatographic column can be expressed quantitatively as the number of 
theoretical plates (N) for a test substance conducted under favorable conditions and may be 
calculated using equation 2.1 [72].  
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Where,  
tR = retention time of a test peak 
W1/2 = peak width at half peak height. 
 
The value obtained for N for a column increases as the mean diameter of the packing material 
decreases, due to an increase in the associated surface area of the stationary phase available for 
interaction with the mobile phase and the analyte of interest [57]. Particles with an average 
diameter of 10 µm are considered standard for RP-HPLC [57].  
 
Such material provides excellent efficiency with an estimated theoretical plate count of 
approximately 8000 plates per column in addition to the ability to use relatively high solvent 
flow rates without exceeding the pressure limits of a system [57]. Packing particles of 5 µm 
diameter yield an approximate doubling of the column efficiency as compared to 10 µm packing 
materials but yield substantial increases in system back pressures at given mobile phase flow 
rates [57].  
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The efficiency of a column as measured by N is best determined with an ideal test system, rather 
than with the analyte for which the method is being developed and the conditions used during 
method development [72]. Column test systems may be comprised of a small, neutral test 
compound such as toluene or naphthalene, a flow rate of 1 ml/min and a mobile phase with a 
viscosity (η) of less than 1 cP, such as compositions of  0 to 100% acetonitrile-water mixtures 
maintained at temperatures of less than 20˚C [72].  
 
The efficiency of the column selected for use in these studies, a Nova-Pak® C18 4 µm (150 mm x 
3.9 i.d.) was interrogated by injection (n = 6) of a test mixture containing uracil, acetophenone, 
benzene, toluene and naphthalene onto the column at room temperature (22˚C). The separation 
was achieved using a mobile phase composition of acetonitrile-water (65:35) at a flow rate of 1 
mL/min.  Detection of the compounds was conducted at 254 nm and a typical chromatogram of 
the separation of the test mixture under these conditions is depicted in Figure 2.1.   
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Figure 2.1. Typical chromatogram of a test mixture containing uracil (1), acetophenone (2), benzene (3), 
toluene (4) and naphthalene (5) after separation on a 4 µm Nova-Pak® C18 (150 mm x 3.9 i.d.) cartridge 
column.  
 
The calculation of the theoretical plate number gives an indication of the efficiency and 
performance of a column. The Nova-Pak® C18 4 µm (150 mm x 3.9 i.d.) cartridge column yielded 
an average efficiency of 6905 ± 777 theoretical plates (n = 6). Although ideally a column of such 
small particle diameter (4 µm) and length (150 mm) should give an N value of more than 10000 
[65], the column was considered efficient and suitable to provide reproducible separations of CP 
while minimizing solvent usage at low flow rates, and it was therefore selected for method 
development and validation studies. The low column efficiency may have been due to the fact 
that the column was not new as it had been used for other applications in our laboratory. 
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2.3.2.6. Internal standard selection 
 
An internal standard (IS) is a compound added in equal amounts to all standards and test samples 
to be analyzed  [73] and is used to improve the accuracy of an analytical method by 
compensating for varying injection volumes and day-to-day instrumental changes [74, 75]. The 
physicochemical and analytical properties of an ideal IS should be similar to those of the analyte 
of interest [73]. Clobetasol butyrate [10], p-phenylphenol [3] and uracil [46] are some of the 
compounds that have used as IS for the analysis of CP. 
 
Potential internal standards that were tested included uracil (UR), prednisone (PR), 
triamcinolone (TA), pregnenolone carbonitrile (PC), stilboestrol dipropionate (SD), 
hydrocortisone acetate (HA),  betamethasone 17-valerate (BV) and mometasone furoate (MF). 
Separation was achieved using a mobile phase composition of acetonitrile-water (50:50) at a 
flow rate of 1 mL/min. Detection of compounds was conducted at 254 nm and the data generated 
in these studies are depicted in Table 2.2.   
 
Table 2.2. Retention times of CP and potential internal standards 
Compound Retention time 
Clobetasol 17-propionate (CP) 8.2 
Uracil (UC) 1.0 
Prednisone (PR) 1.0 
Triamcinolone (TA) 1.2 
pregnenolone carbonitrile (PC) 2.0 
stilboestrol dipropionate (SD) 2.0 
hydrocortisone acetate (HA) 2.2 
betamethasone 17-valerate (BV) 5.4 
mometasone furoate (MF)  8.8 
 
 
The retention times of UR, PR, TA, PC, SD and HA were considered too short and therefore 
undesirable. Consequently, UR, PR, TA, PC, SD and HA were not considered as suitable for use 
as IS, since the short retention times could result in interference from the solvent front or any 
other peaks that elute close to the solvent front during HPLC analysis. Similarly, MF was not 
selected since it eluted close to the retention time of CP. Only BV was eluted at a suitable 
retention time and at a distance from the solvent front without interfering with the CP peak. 
Consequently BV was selected as the most suitable IS for the analysis of CP. 
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2.3.2.7. Mobile phase selection  
 
It is worth noting that the development of a successful RP-HPLC separation does not rely solely 
on the selection of a suitable column, but also on matching an appropriate mobile phase to a 
specific column, analyte and sample matrix [76]. The retention times of compounds in RP-HPLC 
are adjusted by changing the mobile phase composition or solvent strength, which in turn 
depends on the choice of organic solvent and the concentration of that solvent in the mobile 
phase [67].  
 
Conversely, the correct choice of organic solvent requires a knowledge of the physicochemical 
characteristics such as boiling point, viscosity and UV absorbance of that solvent [76, 77]. 
Furthermore, solvent purity, cost and the impact of the solvent on retention of the analyte, in 
addition to interactions with the analyte and the stationary phase, should be carefully considered 
when selecting an organic modifier for use in RP-HPLC analysis [76-78].  
 
Methanol (MeOH) and acetonitrile (ACN) are the most commonly used organic modifiers in RP-
HPLC [79]. Tan et al., [80] reported that in hydro-organic mixtures, ACN and MeOH may self-
associate or associate with water molecules to form clusters, albeit to different extents. As the 
polarity of methanol is greater than that of acetonitrile, the former forms hydrogen bonds by 
accepting or donating protons, whereas the latter being aprotic is unlikely to form hydrogen 
bonds [80]. Therefore the difference in hydrogen bonding ability may influence the adsorption of 
a modifier into a stationary phase as well as solute partitioning, thereby influencing a resultant 
separation [80].  
 
CP is a hydrophobic compound and is practically insoluble in aqueous solutions, whereas it is 
freely soluble in water-miscible solvents, such as acetone, chloroform and dichloromethane 
(Table 1.1, Section 1.3.1.1). HPLC analysis of CP has therefore been achieved using bonded 
phase columns (C18) and mobile phases containing either MeOH or ACN as the organic modifier 
of choice (Table 2.1). The use of MeOH and water as the mobile phase in this analytical method 
resulted in asymmetric peak shapes with a high degree of peak tailing and exceedingly high 
column back-pressures. In contrast, excellent peak symmetry, resolution, a reduction in peak 
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tailing and column back-pressure were observed when mobile phases of binary mixtures of ACN 
and water were used. Typical chromatograms generated using a binary mixture of MeOH and 
water and a binary mixture of ACN and water are shown in Figure 2.2.  
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Figure 2.2. Typical chromatograms generated using a binary mixture of MeOH and water (A) and a 
binary mixture of ACN and water (B) as mobile phase (chromatograms graphically redrawn).  
 
ACN-water mixtures have lower viscosities than the corresponding MeOH-water mobile phases, 
resulting in higher theoretical plate numbers and lower column back-pressures, which ultimately 
result in better peak shapes [67, 79]. Although MeOH is less expensive and apparently less 
damaging to the environment than ACN [79] the use of MeOH-water binary mixtures as mobile 
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phase for this analytical method was considered inappropriate. In order to prolong the lifespan of 
the column and develop an effective separation for the quantitation of CP in semi-solid dosage 
forms ACN was used as the organic modifier and was the only solvent evaluated in these studies.  
 
2.3.2.8. Preparation of mobile phase 
 
Mobile phases were prepared by adding equal parts by volume of HPLC-grade ACN and HPLC-
grade water that had been prepared using a Milli-RO® 15 water purification system (Millipore 
Co., Bedford, MA, USA) to a glass Duran® Schott solvent mixing bottle (Schott Duran GmbH, 
Hattenbergstrasse, Germany). The mixture was allowed to equilibrate to room temperature and 
the mobile phase was filtered through a 0.45 µm Millipore® HVLP filter (Millipore, Bedford, 
MA, USA) and degassed under vacuum with the aid of a Model A-2S Eyela Aspirator (Rikakikai 
Co., Ltd, Tokyo, Japan) prior to use. Degassing of mobile phases is necessary to remove 
dissolved oxygen, which could lead to the formation of air bubbles in the flow cell of a detector 
or in the connecting tubing, thereby affecting the reproducibility and sensitivity of the detection 
system and the flow rate [77]. The mobile phase was freshly prepared daily and was not recycled 
during use.  
 
2.3.2.9. Preparation of stock solutions and calibration standards  
 
Standard stock solutions of CP (0.1 mg/ml) and BV (0.5 mg/ml) were prepared by accurately 
weighing 10 mg of CP and BV using a Model AG-135 Mettler Toledo top-loading analytical 
balance (Mettler Instruments, Zurich, Switzerland) into 100 ml and 20 ml A-grade volumetric 
flasks, and dissolving in 20 ml and 5 ml ACN, respectively. The stock solutions were placed in a 
Model 8845-30 ultrasonic bath (Cole-Parmer Instrument Comp. Chicago, IL, USA) for 5 min, in 
order to ensure complete dissolution of the drug, after which samples were made up to volume 
with ACN. Stock solutions were protected from light using aluminium foil and were, stored in a 
refrigerator at 4˚C. Stock solutions were used within a maximum period of two weeks based on 
stability study data generated as described in Section 2.4.7.3. Calibration standards of CP were 
prepared by serial dilution of the stock standard solution on a daily basis to produce solutions of 
concentration of 0.10, 0.50, 1.0, 3.0, 6.0, 12 and 18 µg/ml, using mobile phase as the solvent.  
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2.3.2.10. Effect of ACN concentration 
 
The impact of ACN concentration on the retention times of CP and BV was evaluated using a 
variety of binary mixtures of ACN and water (ACN/water). The mixtures varied in composition 
from 40–65% ACN and the data generated in these studies are depicted in Figure 2.3.  
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Figure 2.3. Effect of ACN concentration on the retention times of BV and CP  
 
It is clearly evident that BV has a shorter retention time (Rt) than CP with any of the ACN/water 
binary mixtures tested. This is more than likely due to the fact that CP by virtue of its 
physicochemical characteristics is relatively more hydrophobic than BV and therefore interacts 
to a greater extent with the stationary phase than BV does. 
 
The data also show that the retention times of BV and CP were inversely proportional to the 
ACN concentration in the mobile phase. In other words an increase in the ACN content of the 
mobile phase composition led to shorter retention times for both CP and BV. For example, at a 
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low ACN concentration of 40% v/v, BV had an Rt of 9.00 min, whereas CP had an Rt of 11.20 
min. However, at a high ACN concentration of 60% v/v, BV had an Rt of 2.45, whereas CP had 
an Rt of 3.28 min. The decrease in Rt for both BV and CP with an increase in the ACN content is 
more than likely due to enhanced solute-solvent interactions and diminished solute-stationary 
phase interactions.  
 
The aim of conducting these studies was to determine an optimal ACN concentration for use in 
the mobile phase that would produce acceptable retention times for both CP and BV. In our 
laboratory, retention times are considered acceptable when the first peak of interest, which is 
either the IS or the API, elutes 4 min after the solvent front, with the second peak of either the IS 
or the API eluting 2-4 min later, resulting in a maximum run time of approximately 10 min. 
Based on these criteria and the data illustrated in Figure 2.3 a binary mixture consisting of 50% 
w/w ACN-water was selected as the most suitable mobile phase for the separation of CP and BV.  
 
2.3.2.11. Effect of flow rate 
 
The effects of mobile phase flow rate on the retention times of CP and BV are illustrated in 
Figure 2.4. The results of these studies indicate that, as expected, the retention time of both CP 
and BV decrease as mobile phase flow rate was increased. A rapid HPLC separation with respect 
to a run time of approximately 10 min for the analysis of CP in pharmaceutical formulations was 
desired. A flow rate of less than 0.8 ml/min resulted in a CP retention time of greater than 10 
min, which was considered unacceptable since the method would be time-consuming and result 
in long overnight analyses.  
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Figure 2.4. Effect of mobile phase (50 %v/v ACN) flow rate on the retention times of BV and CP  
 
Although increasing the flow rate to 1.4 ml/min resulted in relatively short retention times for 
both CP and BV, closer inspection of the chromatogram revealed some peak shouldering, 
especially in the case of BV peak, which was possibly due to poor column performance at high 
flow rates. However, when the flow rate was set at 1.0 ml/min, sharp well-resolved peaks with 
the desired retention times for both BV and CP were observed (Figure 2.5). Consequently the 
mobile phase flow rate was set to 1.0 ml/min and this rate was used for all subsequent analyses.  
 
2.3.2.12. Optimal mobile phase composition and flow rate 
 
The final mobile phase selected for the analysis of CP using BV as the IS was a binary mixture 
of ACN and water in a ratio of 50:50 or 50 %v/v ACN. The peak shape and retention times were 
found to be suitable when this mobile phase composition was used with excellent resolution 
between CP and the IS. The mobile phase flow rate was set at 1.0 ml/min with resultant retention 
times of 5.6 min and 8.2 min for BV and CP respectively. 
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The total run time for sample analysis was 10 min and the use of this flow rate and resultant run 
time ensured that comparatively low volumes of mobile phase and solvents were consumed by 
the analysis of CP in test samples. A typical chromatogram of the separation achieved using this 
mobile phase and the reported chromatographic conditions, is shown in Figure 2.5.  
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Figure 2.5. Typical chromatogram of a mixture of the internal standard, betamethasone 17-valerate (BV) 
and clobetasol 17-propionate (CP) using a mobile phase of 50% v/v ACN-water and a flow rate of 1.0 
ml/min 
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2.3.2.13. Chromatographic conditions  
 
The final chromatographic conditions established for the analysis of CP are summarized in Table 
2.3.  
 
Table 2.3. Chromatographic conditions for the analysis of CP  
Column Nova-Pak® C18 150 mm x 3.9 mm i.d., 4 µm 
Mobile phase Acetonitrile : water (50:50)  
Flow rate 1.0 ml/min 
Retention times 5.6 min (BV) and 8.2 min (CP) 
Column pressure 1300 psi 
Column temperature Ambient (22˚) 
Injection volume 15 µl 
Wavelength 240 nm  
Sensitivity 0.005 AUFS 
Integrator speed 0.5 mm/min 
Recorder input 10 mV full scale 
 
 
2.4. METHOD VALIDATION 
 
2.4.1. Overview 
 
One of the most critical factors in developing pharmaceutical drug substances and products is 
ensuring that the analytical test methods used to analyze fine chemicals and products generate 
valid and meaningful data in terms of reliability, accuracy and precision, regardless of whether it 
is intended for acceptance, release, stability or pharmacokinetic studies [81, 82].  Validation of 
an analytical method is a process that provides documented evidence that an analytical test 
method performs in an appropriate manner for the purposes for which it was intended [23, 83, 
84]. 
 
The first step in the development of an HPLC method validation protocol is to determine the 
objective of the intended method [82]. A method is considered a Level I or quantitative assay 
method if it is intended to monitor blood levels in patients, for final product release, for the 
determination of potency, or for the assessment of levels of impurity or contaminants in human 
drug products [82]. If the method is to be used as a qualitative examination for identity, then it is 
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considered a Level II or qualitative assay method [81]. A variety of general validation protocols 
have been recommended by organizations such as the FDA [84], United States Pharmacopeia 
(USP) [23] and the International Conference on Harmonization (ICH) [85, 86].  
 
The FDA [84], for example, requires a manufacturer of a pharmaceutical product to establish and 
document accuracy, sensitivity, specificity and reproducibility of the analytical method [81]. The 
USP [23] specifies typical performance characteristics such as  accuracy, precision, specificity, 
limit of quantitation (LOQ), limit of detection (LOD), linearity, range and sample stability that 
should be considered in the validation of analytical methods intended for the analysis of active 
ingredients alone or in finished pharmaceutical products, i.e., a Level I assay. Consequently, the 
validation of an RP-HPLC analytical method for the analysis and characterization of CP in multi-
source topical products during formulation development and assessment was carried out as 
outlined by the FDA [84] and USP [23] guidelines with specific reference to the ICH 
recommendations [85, 86].  
 
2.4.2. Linearity and Range  
 
The linearity of an analytical method is an indication of the capability of a test method to 
produce test results that are directly proportional to the amount of analyte in a sample within a 
given concentration range [23, 83, 86]. Similarly, the working range of an analytical method 
defines the inclusive upper and lower concentrations of an analyte in a sample for which it has 
been demonstrated that the analytical procedure has a suitable level of precision, accuracy and 
linearity [23, 83, 86]. 
 
The ICH guidelines [46] specify that a minimum of five (5) samples of increasing concentration 
along with certain minimum specified ranges should be used to establish the linearity of a test 
method [86]. The linearity of the analytical method was evaluated over the concentration range 
0.10-18 µg/ml with the lower concentration representing the limit of quantitation and the upper 
concentration indicating 120% of the test target concentration (15 µg/ml) in the samples to be 
analyzed.  
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Calibration standards (0.10, 0.50, 1.0, 3.0, 6.0, 12 and 18 µg/ml) spiked with BV (IS) were 
prepared as described in Section 2.3.2.9 and were injected (n = 5) onto the chromatographic 
system described in Section 2.3.2.2 using the conditions described in Section 2.4.6. The peak 
height ratios of CP response to BV response were calculated and used to construct a calibration 
curve which was used to establish whether there was linearity of response of the analyte in 
relation to concentration. Linearity was tested using least squares linear regression analysis of the 
peak height ratios versus concentration data and the results of these studies are depicted in Figure 
2.6.  
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Figure 2.6. Calibration curve constructed for CP following least squares linear regression analysis of 
peak height ratios of CP and IS versus concentration.  
 
The acceptability of linearity data is determined by evaluation of the coefficient of determination 
(R2) of the best fit linear regression line for the response vs. concentration plot as shown (Figure 
2.6). An R2 value of greater than 0.999 is generally considered as evidence of an acceptable fit of 
the data to the regression line [81]. The calibration curve in these studies was found to be linear 
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with an R2 value = 0.9994, a slope of 0.1061 and a y-intercept of -0.0161 yielding an equation 
for the calibration line of y = 0.1061x – 0.0161. 
 
2.4.3. Precision 
 
The precision of an analytical method is a measure of the degree of scatter or closeness of 
agreement among individual test results when the method is applied repeatedly to multiple 
aliquots of the same homogeneous sample under the prescribed test conditions [23, 85]. 
Analytical method precision provides an indication of the variability of analytical results as a 
function of the analyst, manipulation of samples and the day-to-day environment in which the 
method is applied [87]. The precision of an analytical method is usually expressed as coefficient 
of variation or percentage relative standard deviation (% RSD) of a series of measurements [23, 
81, 85].  
 
The FDA [84] recommends that the precision at each concentration level should not exceed 15% 
RSD except for the LOQ, where it should not exceed 20% RSD for biological assays. It was 
anticipated that the samples that would be collected in these studies would not be subject to high 
degrees of variability and interference as would be expected for biological matrices and therefore 
the acceptance criteria for precision studies was set at less than or equal to 5% RSD at each 
concentration level, as opposed to the 15% RSD recommended by the FDA [84]. The ICH [85, 
86] recommends that precision should be performed at three different levels i.e., repeatability, 
intermediate precision and reproducibility. 
 
2.4.3.1. Repeatability 
 
Repeatability or intra-day precision of an analytical method is an indication of the performance 
of an analytical procedure conducted within a laboratory over a short time interval using the 
same analyst with similar equipment [23, 85]. The repeatability of this method was assessed by 
calculating the % RSD of peak height ratios using five (5) replicates of the calibration standards 
run on a single day. The results from repeatability studies (n = 5) are summarized in Table 2.4. 
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The data show in all cases that the % RSD values were less than 5%, indicating that the 
analytical method for the analysis of CP was repeatable. 
 
Table 2.4. Repeatability data for HPLC analysis of CP 
Conc. (µg/ml) MPHR* (n = 5) SD % RSD 
0.500 0.0498 0.00200 4.02 
1.00 0.107 0.000100 0.900 
3.00 0.332 0.00310 0.940 
6.00 0.654 0.00470 0.710 
12.0 1.18 0.00570 0.480 
18.0 1.87 0.00570 0.300 
 
* Mean peak height ratio of CP/internal standard 
 
2.4.3.2. Intermediate precision 
 
Intermediate precision or inter-day variability of an analytical method is an indication of the 
variability in results obtained within a laboratory due to random events such as analysis on 
different days, using different analysts and/or equipment [23, 81, 85]. The intermediate precision 
of this method was assessed over a period of three consecutive days using five replicates of the 
calibration standard concentrations prepared as previously described in Section 2.3.2.9.  
 
Intermediate precision (n = 5) data expressed as coefficient of variation (% RSD) of the peak 
height ratios of the calibration standards are shown in Table 2.5. The acceptance criteria for 
intermediate precision in these studies was set at less than or equal to 5% RSD at each 
concentration level and the data revealed that in all cases the % RSD values were less than 5%, 
indicating that the analytical method would be precise when employed to analyze CP in semi-
solid dosage forms on different days.  
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Table 2.5. Intermediate precision data for HPLC analysis of CP 
Day Conc. (µg/ml) MPHR* (n = 5) SD % RSD 
0.500 0.0498 0.00200 4.02 
1.00 0.107 0.00100 0.900 
3.00 0.332 0.00310 0.940 
6.00 0.654 0.00470 0.710 
12.0 1.18 0.00570 0.480 
 
 
 
1 
18.0 1.87 0.00570 0.300 
0.500 0.0474 0.00145 3.06 
1.00 0.0974 0.000200 0.170 
3.00 0.305 0.000600 0.200 
6.00 0.561 0.00130 0.240 
12.0 1.12 0.00320 0.270 
 
 
 
2 
 
18.0 1.81 0.00750 0.410 
0.500 0.0569 0.00250 4.33 
1.00 0.114 0.00320 2.70 
3.00 0.292 0.000900 0.320 
6.00 0.648 0.00140 0.220 
12.0 1.24 0.00330 0.270 
 
 
 
3 
18.0 1.96 0.00400 0.200 
 
* Mean peak height ratio of CP/internal standard 
 
2.4.3.3. Reproducibility 
 
The reproducibility of an analytical test method refers to the precision of a method following 
application of that analytical procedure in different laboratories, and is often a part of inter-
laboratory crossover studies [23, 81]. Reproducibility studies should only be considered in the 
case of standardized analytical procedures [86] and reproducibility studies are not normally 
expected if intermediate precision is performed as part of method validation studies [81]. 
Consequently, reproducibility studies were not conducted, as the data for repeatability and 
intermediate precision were considered sufficient to show that the analytical method was precise 
and appropriate for the intended purpose of analyzing CP in semi-solid dosage forms.   
 
2.4.4. Accuracy 
 
The accuracy of an analytical method or procedure is an indication of the closeness of agreement 
between a value measured or quantitated using the method and a value that is accepted to be 
either a conventional true value or an accepted reference value for that sample [85]. In 
 48
combination precision and accuracy data determine the error of an analysis, and accuracy is 
therefore an integral criterion in the validation of an analytical test method [83]. 
 
Accuracy may be determined in a number of different ways. For example, the accuracy of a 
method can be determined by analyzing a sample of known concentration and comparing the 
measured value to the true value or comparing test results from a new method with results from 
an existing alternate well-characterized procedure or spiking a known amount of analyte in blank 
matrices and calculating the percent recovery, [81]. Another approach used to assess the 
accuracy of a method is to perform a two-sided t-test to determine if any significant differences 
exist between the mean data generated by the test method and the nominal value, with a 95% 
level of confidence [83].  
 
The accuracy of the analytical method was determined by replicate analysis of samples 
containing known amounts of CP. Three (3) samples representing low (1.5 µg/ml), medium (7.5 
µg/ml) and high (15 µg/ml) concentrations prepared in mobile phase were injected in replicates 
of five (5). Accuracy was reported as the percent recovery, % RSD and % Bias. Bias is the 
difference between the mean value determined for an analyte of interest and the accepted true 
value for that sample. Bias assesses the influence of the analyst on method performance and 
accuracy measurements are designed to measure the effectiveness of sample preparation prior to 
analysis [88]. 
 
The results from accuracy studies for this procedure are listed in Table 2.6. The acceptance 
criteria for accuracy are that the mean percent recovered and the % RSD should be 100 ± 2% 
[81] and less than 2% [89, 90], respectively, at each concentration level. A percent Bias of less 
than 5% at each concentration level was considered as the test limit in our laboratory and based 
on these criteria, the data in Table 2.6 reveal that this analytical method is accurate.  
 
Table 2.6. Accuracy data for HPLC analysis of CP (n = 3) 
Theortical 
conc. (µg/ml) 
Actual 
conc. (µg/ml) 
SD % 
RSD 
% 
Bias 
% 
Recovery 
1.50 1.48 0.005000 0.360 -1.61 98.67 
7.50 7.47 0.0160 0.210 -0.360 99.60 
15.0 15.1 0.00300 0.0200 +0.460 100.7 
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2.4.5. Limit of quantitation (LOQ) and limit of detection (LOD) 
 
The limit of quantitation (LOQ), sometimes referred to as the lower limit of quantitation 
(LLOQ), is the lowest concentration of an analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated operational conditions of an analytical 
method [83, 91]. Similarly, the limit of detection (LOD) is the lowest concentration of analyte in 
the sample that can be detected but not necessarily quantitated under the stated experimental 
conditions of the analytical method [23, 83, 91]. The LOQ is normally taken as the lowest 
concentration point in the calibration curve [83] whereas the LOD is a limit test that merely 
specifies whether or not the amount of an analyte is above or below a certain level [23, 91].  
 
Four methods are commonly used to determine the LOQ and LOD of an HPLC method [83, 91]. 
The ultimate method of choice is usually left to the discretion of the analyst or the standard 
operating procedures of a specific laboratory, since all four techniques essentially yield 
equivalent results and are suitable for satisfying the USP [23] and ICH [85, 86] requirements for 
the determination of the LOQ and LOD of an analytical method [91]. Thus, the LOQ in these 
studies was determined by evaluating the lowest concentration of analyte that resulted in a 
precision of less than 5% RSD [91], in other words the LOQ is the lowest concentration for 
which the % RSD of multiple injections of a sample (n = 6) was less than 5%. By convention the 
LOD value is taken as 30% of the LOQ value [91]. 
 
Five different concentrations of CP were evaluated as potential LOQ values and the data 
generated in these studies are depicted in Table 2.7. Based on these results the LOQ for this 
analytical test method was found to be 0.10 µg/ml, with a % RSD value of 1.82% and by 
convention, the LOD value was taken as 0.03 µg/ml, which when injected into the HPLC, 
resulted in a detectable but not quantifiable peak.  
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 Table 2.7. LOQ data for HPLC analysis of CP 
Conc. (µg/ml) MPHR* (n = 6) SD % RSD 
0.25 0.0312 0.000200 0.670 
0.20 0.0261 0.000300 1.11 
0.15 0.0210 0.000400 1.70 
0.10 0.0154 0.000300 1.82 
0.050 0.0133 0.00140 10.8 
 
* Mean peak height ratio of CP/internal standard 
 
2.4.6. Specificity and selectivity 
 
2.4.6.1. Overview 
 
Specificity and selectivity are relative terms, often used interchangeably to describe the ability of 
an analytical test method to measure accurately the analyte of interest in the presence of other 
components that may be present in a sample matrix [88, 92]. However, an analytical method is 
specific if it produces a response for only a single analyte, whereas selectivity describes a 
procedure that provides a response for the target compound that is distinguishable from all other 
responses that may be generated from a sample matrix [92, 93].  
 
As most chromatographic procedures produce responses for other substances and not only for the 
analyte of interest, the term selectivity is more appropriate than specificity in this context [93]. 
Consequently, the term selectivity is applied for these studies. Selectivity was evaluated by 
analyzing a sample of a commercially available 0.05% w/w CP cream product (Dermovate®, 
Glaxo Wellcome SA (Pty) Ltd, Midrand, RSA) and an extemporaneous placebo cream 
formulation, using a simple liquid-liquid extraction procedure with hexane and acetonitrile, 
which is described in Section 2.4.6.2. 
 
2.4.6.2. Sample preparation 
 
A schematic representation of the sample preparation procedure is shown in Figure 2.7. 
Approximately 600 mg of a cream sample, equivalent to 0.30 mg of CP, was weighed and 
transferred into a 100 ml Duran® Schott round neck Erlenmeyer flask (Schott Duran GmbH, 
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Hattenbergstrasse, Germany). A standard stock solution for BV was prepared in ACN as 
previously described in Section 2.3.2.9 and used to prepare 7.5 µg/ml BV in ACN.  A 20 ml 
aliquot of the BV solution was added to a stoppered flask containing the cream, followed by the 
addition of 30 ml of n-hexane (Associated Chemical Enterprises (Pty) Ltd, Johannesburg, 
Gauteng, RSA).  
 
The mixture was shaken vigorously to disperse the semi-solid sample and sonicated for 10 
minutes to aid the dissolution of CP in ACN using a Model 8845-30 ultrasonic bath (Cole-
Parmer Instrument Comp., Chicago, IL, USA). The mixture was then transferred to a Model-NS 
19/26, 1.5 x 12.5 mm stopcock separating funnel (VIT-LAB GmbH, Seeheim-Jugenheim, 
Germany) and was shaken vigorously while venting the funnel to avoid a potential build up of 
pressure within the funnel. 
 
Following the separation of the immiscible solvents, the lower distinct ACN layer was 
withdrawn via the stopcock of the separating funnel and was collected in a clean Duran® Schott 
round neck Erlenmeyer flask. The sample was then filtered through a 0.22 µm Millipore filter 
(Millipore Co., Bedford, MA, USA) and an aliquot of the filtered sample was injected onto the 
chromatographic system in replicates of six (6). A calibration curve was constructed on the same 
day that the samples were prepared and analysed, and the concentration of CP in the sample 
filtrate was interpolated from the calibration curve.  
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Figure 2.7. Schematic representation of the sample preparation procedure 
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2.4.6.3. Extraction efficiency 
 
A commercially available 0.05% w/w CP cream product (Dermovate®, Glaxo Wellcome SA 
(Pty) Ltd, Midrand, SA) was used to evaluate the extraction efficiency or percentage recovery of 
the sample preparation procedure described in Section 2.4.6.2. The extraction efficiency was 
determined using 600 mg samples of the cream (n = 4). Based on the labelled amount of CP in 
the semi-solid dosage form (0.05% w/w CP) and assuming that the entire CP in the cream 
sample dissolved in the 20 ml ACN added, a theoretical concentration of 15 µg/ml was expected. 
The theoretical concentration was used as a reference sample to determine the actual 
concentration of CP in the sample filtrate for the calculation of the percentage recovery values. 
 
The extraction efficiency and precision data generated from these studies are tabulated in Table 
2.8. The United States Pharmacopoeia (USP) [23] specifies that CP cream formulations should 
contain not less than 90.0% and not more than 115.0% of the labelled amount of CP. The 
extraction efficiency data shown in Table 2.8 fall within this range with excellent precision and 
therefore, the cream formulation tested in these studies complied with the USP standards. 
Section 2.4.6.4 describes the validation of the extraction procedure. 
  
Table 2.8. Extraction efficiency data following the extraction of CP from Dermovate® cream (n = 6) 
Sample 
weight (mg) 
Expected 
theoretical 
conc. (µg/ml) 
Actual conc. 
(µg/ml) 
SD % RSD % Recovery 
608.9 15.22 14.85 0.04700 0.3200 97.53 
600.6 15.01 14.23 0.1314 0.9200 94.77 
601.8 15.05 14.43 0.08290 0.5700 95.94 
594.1 14.85 14.35 0.1387 0.9700 96.60 
 
2.4.6.4. Validation of the extraction procedure 
 
In order to determine the authenticity of the sample preparation procedure described in Section 
2.4.6.2 and to ensure that the data generated in the studies described in Section 2.4.6.3 and 
summarized in Table 2.8 were valid, the method was applied to the extraction of CP from a 
0.05% w/w solution. The 600 mg sample of CP cream was replaced by 600 µl of a CP solution. 
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Samples (n = 3) of the CP solution were extracted and analysed and the data generated in these 
studies are summarized in Table 2.9.  
 
Table 2.9. Extraction efficiency following extraction of 600 µl of a CP solution (0.05% w/w) (n = 3) 
Sample 
volume  
(µl) 
Expected 
theoretical 
conc. (µg/ml) 
Actual conc. 
(µg/ml) 
  
SD 
% 
RSD 
% 
Recovery 
600.0 15.00 14.98 0.04800 0.3200 99.84 
600.0 15.00 14.23 0.1314 0.9200 94.77 
600.0 15.00 15.86 0.03352 0.1200 105.8 
 
The data show excellent percentage recovery and precision values that are similar to those 
obtained when CP cream was used (Section 2.4.6.3) and are indicative of the suitability of the 
method used to prepare samples of the cream, for analysis. The extraction process was therefore 
used in subsequent studies to determine and confirm CP content in extemporaneously prepared 
0.05% w/w creams during product development and assessment studies. 
   
2.4.6.5. Selectivity studies 
 
The selectivity of the analytical method was evaluated by analyzing a sample of an 
extemporaneous placebo cream formulation, extracted with: 
a) ACN without BV, and  
b) ACN spiked with the BV.  
The selectivity was further evaluated by analyzing a sample of a Dermovate® cream extracted 
with: 
c) ACN without BV, and  
d) ACN with BV.  
 
Typical chromatograms obtained in these studies are shown in Figure 2.8. Inspection of the 
resultant chromatograms reveal that the CP and BV peaks are free from interference from other 
formulation excipients, including chlorocresol (CH), which was the preservative in the 
commercially available CP cream. The method was therefore considered selective for the 
purposes of analyzing CP in semi-solid formulations. 
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Figure 2.8. Typical chromatograms obtained following the analysis of a sample of placebo cream without 
BV (A) and with BV (B) and Dermovate® cream without BV (C) and with BV (D)  
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2.4.7. Sample stability 
 
2.4.7.1. Overview 
 
Another important consideration during method validation is the demonstration of stability of an 
analyte in a sample matrix and solvents used during the sample work-up, under the conditions to 
which the study samples will be subjected throughout the analytical procedure [93]. It has been 
reported that a compound may be considered stable under certain conditions for a certain period 
of time when there is no significant difference between the detector response for an analyte 
following analysis of solutions that have been stored, compared to the response generated from 
freshly prepared solutions of the analyte in similar matrices [83].   
 
There are numerous areas that need to be identified and stability evaluations undertaken during 
sample analysis [83, 93]. In these studies, the stability of CP in the standard stock solutions 
(Section 2.3.2.9) used to prepare the calibration standards (Section 2.3.2.9) and the stability of 
CP in process samples used during in vitro release studies (Chapter 3) were evaluated. It has 
been recommended that the stability of standard stock solutions of an analyte used to prepare 
calibration curves be evaluated over the maximum time period for which the solutions will be 
stored prior to use [83, 93, 94]. Accordingly, the stability of the stock solutions must be 
determined under the same conditions of light or dark, at the same temperature(s), and in the 
same solvent(s) and container(s) as are used during analysis [83, 93]. 
 
Buick et al., [94] suggested that in the absence of stability data, standard stock solutions must be 
freshly prepared on a daily basis during sample analysis, since failure to do so may lead to the 
preparation of calibration standards that do not represent the true concentrations of the analyte, 
which may then result in the determination of incorrect concentrations in unknown samples. 
Similarly, in-process sample stability studies are required in order to determine the stability of a 
compound in a sample matrix under specific storage conditions over the time needed to store and 
analyze the samples [95, 96]. The objective of conducting these stability studies was to 
determine if any degradation of CP occurs during the entire period of sample collection, 
processing, storing, preparation and analysis [83]. Consequently, the data obtained from in-
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process sample stability studies may be used to provide guidelines concerning the maximum 
times and conditions of sample storage prior to analysis and therefore to ensure that the integrity 
of samples is maintained up to the point of analysis [93, 94, 96]. 
 
2.4.7.2. Stability data analysis 
 
Stability data generated in these studies were analysed using a statistical test method developed 
by Timm et al., [97]. The procedure was initially developed for the evaluation of stability of 
drugs in biological fluids and takes into account the quality of the experimental procedure 
including the precision of the method and the number of replicates used during analysis of the 
stored samples [97]. The statistical interpretation of the stability data as proposed by Timm et al., 
[97] is based on the construction of a 90% confidence interval (C.I.) for the true percentage 
change (∆) in concentration or detector response generated from stored and freshly prepared 
samples. 
 
The lower limit (L.L.) and the upper limit (U.L.) of the C.I. are calculated using the measured 
percentage response difference (D) between stored and freshly prepared samples for replicate 
analyses and the true percentage change in response lies within that limit with 90% certainty 
[97]. According to Timm et al., [97] a change of response during storage may be considered 
statistically relevant if the values for both the L.L. and U.L. of the C.I. are either < -10 or > 10. 
Figure 2.9 depicts the possible outcomes that could be generated when stability data are analyzed 
using the method described by Timm et al., [97]. 
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The bars above the axis depict the ranges of the 90% CI for the % ∆ between stored and freshly prepared 
samples. 
 
a) change of response, not significant and not relevant 
b) decrease of response, significant, but not relevant 
c) decrease of response, significant and possibly relevant 
d) decrease of response, significant and relevant 
e) decrease of response, not significant, but possibly relevant 
f) increase of response, significant 
 
Figure 2.9. Interpretation of stability data, as described by Timm et al, [97]  
 
 
2.4.7.3. Stability of stock solutions 
 
The stability of CP stock solutions prepared in ACN was evaluated following storage for two 
weeks at 4˚C. CP stock solutions were prepared as previously described in Section 2.3.2.9. 75 µl 
and 1500 µl aliquots of CP stock solutions were measured using single channel model electronic 
pipettes covering the volume range of 50-1200 µl and 500-5000 µl respectively (ePET Electronic 
Pipettes Biohit, Helsinki, Finland), and transferred to a 10 ml A-grade volumetric flask and made 
up to volume with ACN, yielding solutions of 0.75 µg/ml and 15 µg/ml, representing the lower 
and upper concentrations, respectively.  
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A maximum of five (5) replicate samples at each concentration studied were prepared for 
analysis on days 1, 2, 3, 7 and 14 after storage at 4˚C, resulting in a total of twenty-five (25) 
separate samples being analyzed. On each day of analysis fresh samples at each concentration 
were prepared from a freshly made CP stock solution (Section 2.3.2.7) and analysed together 
with the five (5) stored samples. Both freshly made and stored samples were spiked with 60 µl of 
a freshly prepared 0.5 mg/ml BV solution (measured using a 50-1200 electronic pipette) prior to 
analysis, and for each sample analyzed, the peak height was measured and the ratio of CP to BV 
was used as the response.  
 
The results obtained from stability studies of CP stock solutions at both the lower and upper 
concentrations stored at 4˚C for 1, 2, 3, 7 and 14 days are depicted in Figure 2.10. These data 
reveal that at the lower (0.75 µg/ml) and upper (15 µg/ml) concentrations, stored at 4˚C for 14 
days the change of response for CP was neither significant nor relevant. The wide confidence 
interval calculated for the 0.75 µg/ml sample on days 2 and 3 may be indicative of the poor 
precision of the assay procedure at these low levels [97].  Nevertheless, these studies reveal that 
CP was stable in acetonitrile at 4˚C following storage for two weeks. Consequently, stock 
solutions of CP were prepared in acetonitrile, stored at 4˚C and used within a period of two 
weeks, after which fresh solutions were made. 
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Figure 2.10. Stability of CP in ACN at two different concentrations, stored at + 4ºC for 1, 2, 3, 7, and 14 
days 
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2.4.7.4. In-process sample stability 
 
In-process sample stability studies were also conducted by evaluating CP stability in the receptor 
medium to be used for in vitro release studies. A receptor medium of 50% v/v propylene 
glycol/water (Chapter 3, Section 3.2.6.2.3.3) was to be used during the in vitro release studies at 
room temperature (22˚C). Stock solutions of CP were prepared as previously described in 
Section 2.3.2.9 but in this case propylene glycol rather than ACN was used as the solvent of 
choice. A 75 µl and 1500 µl aliquot of the CP stock solution measured as described in Section 
2.5.7.3 was diluted and made up to 10 ml using the receptor phase, yielding concentrations of 
0.75 µg/ml and 15 µg/ml concentrations as previously described in Section 2.5.7.3. 
  
A maximum of five (5) replicate samples were prepared at both the lower and upper 
concentration and stored for 1, 2 and 3 days, resulting in a total of fifteen (15) separate samples 
for each concentration being studied. The samples were stored at room temperature (22˚C) and 
on each day of analysis stored and freshly prepared samples (n = 5) spiked with 60 µl of a freshly 
prepared 0.5 mg/ml internal standard (BV) were analysed. The percentage response differences 
between these samples were calculated and used to construct a 90% CI as described by Timm et 
al., [97] and the data generated from these studies are depicted in Figure 2.11. 
 
The results indicate that the change of response of CP at both the lower (0.75 µg/ml) and upper 
(15 µg/ml) concentrations prepared in 50% v/v propylene glycol/water and stored at room 
temperature (22˚C) for three (3) consecutive days was not significant and not relevant. CP was 
therefore considered to be stable when prepared in 50% v/v propylene glycol/water and stored at 
room temperature (22˚C) for three days. Consequently, CP samples from in vitro release studies 
were stored at 22˚C after removal of each sample and analyzed immediately at the conclusion of 
the in vitro release studies, i.e. within three days of the commencement of the study.  
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Figure 2.11. Stability of CP in 50 %v/v propylene glycol/water stored at + 22ºC for 1, 2 and 3 days 
 
  
2.5. METHOD REVALIDATION 
 
2.5.1. Overview 
 
According to the FDA guidance document on Analytical procedures and methods validation: 
Chemistry, manufacturing and controls documentation [98], it is vital that an analytical method 
is revalidated when changes are made to an original procedure or to the original operating 
conditions of a validated method. Such revalidation studies are intended to ensure that the 
method maintains the appropriate performance characteristics as specified prior to the 
implementation of the changes to the method [95, 98].   
 
Although the extent of the revalidation procedure to be undertaken depends on the nature of the 
change to a method, it is not necessary to conduct extensive revalidation studies when an 
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analytical method has been previously fully validated according to an international protocol [99]. 
Therefore, the decision concerning which parameters require revalidation is based on logical 
consideration of those specific validation attributes that are more than likely to be affected by the 
change in question [95]. However, as a minimum requirement, linearity, precision and accuracy 
studies should be undertaken in most cases [99].  
 
The revalidation of this analytical method was necessary since a change was made to the solvent 
delivery module of the system as outlined in Section 2.3.2.2.  The definitions and acceptance 
criteria of the relevant performance characteristics discussed below have been previously 
described in Section 2.4.2.  
 
2.5.2. Linearity 
 
A calibration curve was constructed by plotting the peak height ratios of CP to BV versus CP 
concentration within the concentration range 0.10-18 µg/ml and performing least squares linear 
regression of the constructed calibration curve. The data revealed that the calibration curve was 
linear with an R2 value = 0.9999, a slope of 0.1093 and a y-intercept of 0.0026 yielding a curve 
of y = 0.1357x + 0.0015 and this is depicted in Figure 2.12.  
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Figure 2.12. Calibration curve for CP following revalidation of the method  
 
 
2.5.3. Precision 
 
2.5.3.1. Repeatability 
 
Repeatability was determined by calculating the coefficient of variation of the peak height ratios 
of CP to BV of the calibration standards (n =5). The data summarized in Table 2.10 revealed that 
in all cases, the relative standard deviations were less than 5%, indicating that the analytical 
method for the analysis of CP was precise in terms of the repeatability criterion.  
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Table 2.10. Repeatability data for the revalidation of the HPLC method for CP 
Conc. (µg/ml) MPHR* (n = 5) SD % RSD 
0.250 0.0260 0.000400 1.47 
1.00 0.127 0.000600 0.460 
6.00 0.883 0.00180 0.200 
12.0 1.56 0.00230 0.150 
18.0 2.47 0.00580 0.230 
 
* Mean peak height ratio of CP/internal standard 
 
2.5.3.2. Intermediate precision 
 
Intermediate precision was assessed over a period of three consecutive days and was expressed 
as coefficient of variation (% RSD) of the peak height ratios of the calibration standards (n = 5). 
The data summarized in Table 2.11 revealed that all % RSD values were less than 5%, indicating 
that the analytical method conforms to the requirements for intermediate precision.  
 
Table 2.11. Intermediate precision data for the revalidation of the HPLC method for CP 
Day Conc. (µg/ml) MPHR* (n = 5) SD % RSD 
0.250 0.0260 0.000400 1.47 
1.00 0.127 0.000600 0.460 
6.00 0.883 0.00180 0.200 
12.0 1.57 0.00230 0.150 
 
 
1 
18.0 2.47 0.00580 0.230 
0.250 0.0281 0.000400 1.59 
1.00 0.128 0.000400 0.330 
6.00 0.720 0.000300 0.050 
12.0 1.64 0.00170 0.100 
 
 
2 
 
18.0 2.52 0.00120 0.0500 
0.25 0.0326 0.000700 2.08 
1.00 0.133 0.000300 0.260 
6.00 0.712 0.000200 0.0300 
12.0 0.542 0.00110 0.0700 
 
 
3 
18.0 2.59 0.00350 0.140 
 
* Mean peak height ratio of CP/internal standard 
 
2.5.3.3. Reproducibility 
 
Reproducibility studies were not conducted for the same reasons as discussed in Section 2.4.3.3.  
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2.5.4. Accuracy 
 
Accuracy was assessed at three concentrations viz., 1.5 µg/ml (low), 7.5 µg/ml (medium) and 15 
µg/ml (high), (n = 5) and was reported as % recovery, % RSD and % Bias. The data summarized 
in Table 2.12 show that the analytical method can be considered accurate for the analysis of CP 
in these studies.   
 
Table 2.12. Accuracy data for the revalidation of the HPLC method for CP (n = 3) 
Theortical 
conc. (µg/ml) 
Actual 
conc. (µg/ml) 
SD   % 
RSD 
% 
Bias 
% 
Recovery 
1.50 1.46 0.00200 0.120 -2.39 97.33 
7.50 7.47 0.0140 0.230 -0.360 99.60 
15.0 14.6 0.0270 0.190 +2.84 97.20 
 
 
2.6. APPLICATION OF THE ANALYTICAL METHOD 
 
Following development and validation studies, the RP-HPLC method was applied to the 
quantitative determination of CP in samples obtained following in vitro release testing of CP 
proprietary cream product (Dermovate®, Glaxo Wellcome SA (Pty) Ltd, Midrand, RSA). A 
typical in vitro release profile (n = 6) generated during these studies is depicted in Figure 2.13.  
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Figure 2.13. In vitro release profile of CP 
 
 
2.7. CONCLUSIONS 
 
A suitable RP-HPLC analytical method with UV detection at 240 nm has been developed, 
optimized and validated for use in the in vitro analysis of CP in topical formulations. Method 
development studies included the selection of a suitable detection wavelength, analytical column, 
and internal standard (I.S.), as well as the selection of mobile phase components.  
 
The ultraviolet (UV) absorption spectrum of CP revealed that the wavelength of maximum 
absorption (λmax) of CP is 240 nm. Consequently, the UV detector in these studies was set at 240 
nm. The selection of the analytical column was based on the physicochemical properties of CP, 
the type and size of column packing materials, column dimensions and the column efficiency as 
determined by the number of theoretical plates (N). Based on these features a Nova-Pak® C18 4 
µm (150 mm x 3.9 i.d.) cartridge column was selected as a suitable column for the analysis of 
CP.  
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Betamethasone 17-valerate (BV) was selected as the most suitable I.S. from amongst the various 
compounds that were tested. Analysis using RP-HPLC is best achieved with non-polar stationary 
phases such as n-octadecylsilane (ODS or C18) and with mobile phases consisting of a polar 
solvent i.e. water or a mixture of water and water-miscible organic modifier such as methanol 
(MeOH) and/or acetonitrile (ACN). A binary mixture of water and an organic modifier was 
considered the most suitable mobile phase composition and ACN was chosen over MeOH as the 
most appropriate organic modifier.   
 
The method was optimized by manipulation of ACN concentration in the mobile phase and 
mobile phase flow rates of the optimal mobile phase composition selected. The effects of mobile 
phase composition and flow rate on retention time and resolution of CP and BV were assessed. 
The separation of CP and BV was best achieved using a mobile phase composition consisting of 
a binary mixture of ACN-water (50:50) and a mobile phase flow rate of 1 ml/min. These 
chromatographic conditions resulted in retention times of 5.6 min and 8.2 min for BV and CP 
respectively, and the total run time for sample analysis was within 10 min.   
 
The RP-HPLC analytical method was validated in terms of the guidelines recommended by 
various organizations such as the United States Pharmacopeia (USP) [23], the United States 
Food and Drug Administration (FDA) [84] and the International Conference on Harmonization 
(ICH) [85, 86]. Based on these guidelines, the analytical method was found to be linear, precise, 
accurate, selective and sensitive and CP was found to be stable in acetonitrile and 50% w/w 
propylene glycol-water binary mixture following storage at 4˚C and room temperature (22˚C), 
respectively, for a maximum of 14 days and 3 days, respectively.  
 
Following changes to the modular HPLC system used to develop, optimize and validate the RP-
HPLC analytical method described herein, a mini-revalidation of the analytical method was 
carried out so as to ensure that the method maintained its performance characteristics as reported 
prior to the implementation of the changes. The data from revalidation studies revealed that the 
analytical method was linear, accurate, and precise for the in vitro analysis of CP in semi-solid 
dosage forms.  
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A RP-HPLC has been developed, optimized and validated RP-HPLC for the quantitation of CP 
in cream formulations and can be applied to the assessment of in vitro performance of CP in 
pharmaceutical semi-solid dosage forms 
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CHAPTER THREE 
 
DEVELOPMENT AND VALIDATION OF AN IN VITRO TEST METHOD FOR THE 
ASSESSMENT OF CLOBETASOL 17-PROPIONATE RELEASE FROM TOPICAL 
CREAM FORMULATIONS 
 
3.1. INTRODUCTION 
 
In vitro dissolution testing of solid oral dosage forms is a well-established technique used to 
assess drug release from tablets and capsules for the purposes of assessing quality [100, 101]. 
Dissolution testing is considered the single most valuable in vitro test method that can be used to 
guide formulation development, assess product quality and ensure batch-to-batch uniformity 
[102]. In addition, in vitro dissolution testing may be used as a pre-formulation tool and it has 
been suggested that dissolution testing is a useful surrogate measure for the prediction of 
bioavailability for extended-release oral dosage forms using pre-established in vitro-in vivo 
correlations (IVIVC) [101, 103]. 
 
Official dissolution test methods have been developed and reported for in vitro dissolution 
studies of solid oral dosage forms and for the investigation of  in vitro release characteristics of 
active pharmaceutical ingredients (API) from transdermal patches [22, 23]. However, there are 
currently no official guidelines or requirements for the performance evaluation of drug release 
from semi-solid dosage forms [104, 105]. Nevertheless, a variety of physical and chemical 
quality control tests have been traditionally used to provide reasonable evidence of consistent 
product performance [49]. These tests include the determination of solubility, particle size and 
size distribution and crystalline form of an API and evaluation of the intrinsic viscosity and 
homogeneity of a final product [49, 104-108].  
 
These tests, however, provide little information about the drug release characteristics from the 
product or the effects of processing and manufacturing variables on the performance of a 
finished product [106]. As an API must first be released from a formulation and then permeate 
through the stratum corneum in order to exert a therapeutic effect [109], it may be more 
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appropriate to use in vitro drug release characterization in conjunction with traditional quality 
control tests to determine the quality and consistency of topical formulations that are 
manufactured during product development studies [109].   
 
The FDA issued a Guidance document [49] in 1997, in which issues relating to scale-up and 
post-approval formulation changes of semi-solid dosage forms were addressed [49]. This 
guidance document outlines the requirements that the pharmaceutical industry must meet to 
maintain certification of previously approved semi-solid dosage forms, following post-approval 
formulation changes [49]. A key element in the guidance document is the requirement that an in 
vitro release test method be used to determine if the diffusional rate of release of a drug from a 
formulation is the same following changes to that formulation as it was prior to the 
implementation of the changes being made [49]. 
 
Despite the issuance of this Guidance document [49] by the FDA, an official in vitro release test 
is still not mandatory and is not applied industry-wide as a quality control test when compared to 
the utility and requirements for in vitro dissolution testing of solid and liquid oral dosage forms 
[107].  This is more than likely due to the fact that a universally acceptable in vitro release test 
protocol that can be applied to all semi-solid dosage forms has yet to be established [108, 110]. 
With the exception of the recommendations of the FDA, there are currently no apparatus, 
procedures or requirements that have been described in any pharmacopoeias for in vitro release 
test of topical semi-solid preparations [103, 107, 110, 111].  
 
Another point relevant to in vitro release testing is that it cannot be considered as a surrogate test 
for establishing bioequivalence of a generic product relative to an innovator semi-solid 
formulation [49, 107, 112]. This is more than likely due to the fact that at this time there is no 
convincing evidence for IVIVC of release tests for semi-solid dosage forms as that for in vitro 
dissolution of tablets and capsules [49]. Moreover, measurement conditions during in vitro 
release testing do not usually mimic physiological reality since in vitro release test equipment 
does not include a membrane resembling the stratum corneum and the barrier functions of the 
skin, which are essential determinants of the skin penetration characteristics of an API of interest 
in semi-solid dosage form bases [113].  
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The type of membrane usually chosen for in vitro release testing should have the least possible 
diffusional resistance, whereas, clinically dosage forms are applied to the stratum corneum, a 
high resistance membrane that, when intact invariably controls the delivery rate of API from 
semi-solid dosage forms [112]. Furthermore it should be noted that in vitro release testing is 
performed in a manner in which the dosage form being tested is applied so that an infinitely thick 
layer is present, which is in stark contrast to the thin films usually applied during conventional 
clinical use of these products [114].  
 
Nevertheless, many manufacturers of topical drug products have devoted significant resources to 
developing and validating in vitro release tests during the product development process [108]. 
Such tests can be used to detect the effects of changes in a formulation on the release rate of API 
from a dosage form in which the API is suspended and/or dissolved and therefore can be used to 
ensure that the manufacture of semi-solid products is consistent and fulfils a similar role as 
dissolution testing does for tablets and capsules [115].  
 
The objective of these studies was therefore to develop and validate a reliable, reproducible and 
discriminatory in vitro release test method. The method would be applied in formulation 
development studies in order to assess product quality and ensure batch-to-batch consistency of 
topical formulations manufactured to contain 0.05% w/w clobetasol 17-propionate (CP). 
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3.2. METHOD DEVELOPMENT  
 
3.2.1. Overview 
 
Various protocols that may be used in the development of an in vitro release test method for a 
semi-solid drug product have been outlined and reported in the literature [108, 113, 115]. 
Essentially, method development studies are designed to: 
 
a) facilitate the selection of a diffusion cell system, 
b) determine an appropriate receptor medium with adequate sink characteristics, 
c) evaluate synthetic support membranes with minimal reactivity with the drug and 
formulation components, and 
d) determine appropriate sampling times [108, 113, 115]. 
 
In addition, conditions such as finite or infinite dosing and sample occlusion or non-occlusion 
that may have considerable effects on the in vitro release characteristics of a drug should be 
investigated and optimized during method development studies [115]. During in vitro release 
method development studies, the aforementioned criteria were evaluated to produce a test system 
for the assessment of CP release from topical semi-solid formulations.  
 
3.2.2. Diffusion cell test system 
 
3.2.2.1. Overview 
 
In vitro dissolution testing in the pharmaceutical industry is a widely used tool in formulation 
development and quality control testing [111]. Consequently as dissolution testing has evolved 
different apparatus have become official and have been included in the United States 
Pharmacopoeia (USP) [23] and the British Pharmacopoeia (BP) [22] for such purposes. The USP 
[23] for example makes provision for the dissolution testing of tablets and capsules, specifying 
and describing official apparatus as USP Apparatus I (basket), USP Apparatus II (paddle), USP 
Apparatus III (reciprocating cylinder or Bio-Dis®) and USP Apparatus IV (flow-through). In 
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addition, the USP [23] specifies and describes methods and equipment for transdermal delivery 
patch systems such as USP Apparatus V (paddle over disk), USP Apparatus VI (cylinder) and 
USP Apparatus VII (reciprocating holder).  
 
Although the FDA Guidance document [49] outlines the general methodology and description of 
diffusion systems, no single device has been universally accepted for measuring in vitro drug 
release rates from semi-solid dosage forms. Due to the variety of formulation type, sites of 
application and release rates required from semi-solid dosage forms, a single test method would 
not be appropriate for the development, biopharmaceutical characterization and quality control of 
such formulations, and hence the inclusion of a single apparatus in pharmacopoeias may not be 
possible [111].  
 
Numerous apparatus of different design have been reported in the literature for studying API 
diffusion from semi-solid dosage forms [23, 49, 102-107, 109-131]. The general design of the 
test systems is such that they consist of a donor cell in which a semi-solid material is placed and 
a receptor compartment in which a chosen receptor medium is contained and from which 
samples are withdrawn for analysis at appropriate intervals. The system may or may not include 
a membrane that separates the two compartments and would also include a mechanism by which 
the receptor fluid is stirred and a means to control the temperature of the receptor medium [113].  
 
Several reviews have alluded to the many significant considerations that must be taken into 
account when designing such test devices [113, 115, 119, 124]. An in vitro diffusion cell must be 
made from an inert, non-reactive material such as, for example, glass, stainless steel or Teflon® 
[122]. All components of a cell, including flow-through lines and the collection chambers, must 
have their inert nature established by experimental means and it should be shown that there is no 
loss of drug due to volatility during the permeation test procedure [122]. If volatility of an API or 
receptor and/or product being tested is an issue, a quantitative account of the volatility must be 
undertaken and reported [113, 122].  
 
A receptor medium must provide effective sink conditions for the appropriate assessment of the 
rate of release of a permeant, penetrant or API [115]. The cell in which the medium is placed 
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should ideally contain a minimum volume of fluid to facilitate analysis, since the more 
concentrated a drug in the collection medium is, the easier the analytical process [122]. The 
design of a cell must allow for efficient mixing of the receptor fluid at a controlled temperature 
[113, 122] and the system should be versatile and accommodate a diverse range of membranes 
that are routinely used in diffusion studies [124]. The current trend is towards the development 
and use of systems with automated operations with better instrument control and minimal 
instrument-related variability [128]. 
  
3.2.2.2. Franz diffusion cell 
 
Studies using a diverse range of in vitro release systems have been reported [23, 49, 102-107, 
109-131]. Of those reported the vertical diffusion cell, commonly known as the Franz and/or 
modified Franz cell has shown the most potential for use as a standardized system that may be 
adapted for use as a compendial test method [111, 113]. Initially designed and described by 
Franz in 1975 [132], the vertical Franz diffusion cell has been widely used to study in vitro drug 
release from semi-solid dosage forms [102, 107, 114-118, 121, 123, 126, 127, 129, 133-135].  
 
The original Franz cell has a bichamber arrangement that includes a dumb-bell-shaped receptor 
compartment [133] and a schematic of this apparatus is shown in Figure 3.1. An unstoppered 
sampling port is connected to the upper section of the receptor chamber and only the central, 
cylindrical portion of the receptor compartment is jacketed. A stirrer bar is placed in the lower, 
ellipsoid bulb chamber to provide a means of agitation of the receptor medium. 
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Figure 3.1. Schematic representation of an original Franz diffusion cell apparatus (redrawn from 127) 
 
3.2.2.3. Modified Franz diffusion cell 
 
Keshary and Chien [127, 136] identified and reported deficiencies associated with use of the 
original Franz diffusion cell. They reported that the design of the Franz cell did not provide for 
adequate solution hydrodynamics, mixing efficiency and temperature control that are necessary 
for quantitative permeation studies. Due to these shortcomings, Keshary and Chien [127, 136] 
proposed several modifications to the original design of the Franz cell. A schematic 
representation of a modified Franz diffusion cell is illustrated in Figure 3.2.  
 
The diffusion cell has a cylindrical receptor compartment that is shorter than the receptor 
compartment of the original Franz cell (Figure 3.1) and is completely enclosed by a water jacket. 
A star-head magnetic stirrer as opposed to a stirrer bar is used to agitate the receptor fluid. As a 
result of these modifications, the equilibrium temperature of the receptor fluid is better 
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maintained, while solution-mixing efficiency is improved and the thickness of boundary 
diffusion layer is reduced [127]. 
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Figure 3.2. Schematic representation of a modified Kenshary-Chien Franz glass diffusion cell (redrawn 
from 127) 
 
3.2.2.4. Selection of diffusion cell test system 
 
A modified Franz glass diffusion cell system (Crown Glass Company Inc., Branchburg, NJ, 
USA) was selected for use in these studies. Each jacketed cell has an opening of 15 mm with an 
associated area available for diffusion of 1.767 cm2 and a receptor fluid volume of 12.5 ml. The 
cells were positioned in a multiple-cell drive unit (Figure 3.3), which permitted efficient stirring 
with a 2x2 mm star head magnetic stirrer bar (Merck Chemicals (Pty) Ltd, Darmstadt, Germany) 
agitating the receptor medium at a controlled rate. The jacketed portions of the multiple cells 
were connected in series to a temperature-controlled circulating water bath (Grant Instruments 
Ltd, Cambridge, England) with Tygon® tubing (Eagle Electric, Cape Town, Western Cape, 
RSA).  
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Figure 3.3. Schematic representation of a modified Franz cell multiple-cell drive unit 
 
3.2.3. Number of samples 
 
In vitro release testing of CP from topical formulations was conducted using a modified Franz 
glass diffusion cell system, containing housings for six cells (Figure 3.3). Although systems with 
three cells have been used [126, 129], a minimum of six cells or samples is recommended when 
characterizing release rate profiles of an API from semi-solid products [49]. The use of six 
samples is recommended so as to minimize the variability associated with individual sample 
application to the donor compartments of diffusion cell systems [108].  
 
3.2.4. Sampling times  
 
The FDA species that at least five sampling times must to be used over a suitable time period in 
order to ensure that an adequate in vitro release profile is generated and can be used to determine 
API release rates from semi-solid products [49]. Sampling times may be varied depending on the 
formulation matrix, but in most cases samples can be taken over the course of one day, unless the 
release of the drug from the formulation is extremely slow or a sustained or controlled-release 
profile is expected [115].  
 
It has been reported that there is a specific time window during which samples for release 
experiments should be taken [113]. Ideally, samples should be removed at times when the 
influence of the membrane and its associated stagnant layer disappears and before excessive drug 
depletion from the semi-solid dosage form being tested has taken place [17]. Two main reasons 
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have been put forward in an attempt to explain the rationale behind withdrawing samples during 
this time window.  
 
Firstly, it has been reported that the migration of an API from a semi-solid matrix to a receptor 
medium occurs as a series of successive diffusional steps [137, 138]. In the initial stages the 
membrane, together with an unstirred layer at its surface, have been reported to provide some 
resistance to the permeation of API and thus affect the release rate of an API [113]. However, 
over time, a diffusional layer is formed within the semi-solid matrix and thus becomes the rate-
controlling element [113]. As a consequence, samples should be withdrawn when the influence 
of the membrane and its associated stagnant layer has disappeared [113], or otherwise the early 
sampling time points should be ignored when calculating API release rates derived from such 
systems [113].   
 
Secondly, according to theoretical diffusion models a plot of the amount of API released vs. the 
square root of time should be linear if drug release from a semi-solid matrix is diffusion 
controlled or diffusion is the rate controlling element within the dosage form [137, 138]. 
However, it has been shown that API release from semi-solid dosage forms tends to deviate from 
linearity at extended times [113] and the deviation is usually observed when more than 
approximately 35-45% of the API in the dosage form has been released from the semi-solid 
sample placed in the donor chamber [113]. Therefore, when choosing the upper time limit for 
sample collection, this factor must be taken into consideration [113]. 
  
Preliminary in vitro release studies were undertaken over a three-day period using a 
commercially available CP cream product viz., Dermovate® cream (Glaxo Wellcome SA (Pty) 
Ltd, Midrand, Gauteng, RSA), a 0.1 µm Polycarbonate membrane filter (Millipore Co., Bedford, 
MA, USA) and a receptor phase consisting of 50% v/v propylene glycol/water mixture (Section 
3.2.6.2.3.3 and Section 3.2.6.3).  
 
The data generated from these studies are shown in Figure 3.4. These data reveal that 
approximately 3 % of CP in the semi-solid sample applied to the membrane was released after 2 
hours. Therefore, it appears that two (2) hours was an adequate time for the influence of the 
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membrane and its associated stagnant layer to disappear, as the plot does not appear to show a 
significant lag phase. Approximately 32% of CP contained in the formulation applied to the 
membrane was released at the end of the 72-hour test period and this value is below the 35-45%, 
after which non-linearity of release was expected to occur [17]. 
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Figure 3.4. In vitro release of CP from Dermovate® cream (n = 6)  
 
Least squares linear regression analysis was used to determine the linearity of the in vitro release 
profile for CP during the time period of 2 to 72 hours and the resultant coefficient of 
determination (R2) of 0.9962, shown in Figure 3.5, reveals that a plot of % CP released vs. square 
root of time was linear. In light of the constraints relating to the monitoring of API release from 
semi-solid dosage forms, samples of the receptor medium were removed at  2, 4, 8, 12, 24, 48 
and 72 hours in order to generate satisfactory CP release profiles and to characterize the 
mechanism and type of release of CP from semi-solid dosage forms.   
 
 
 81
y = 4.2173x - 2.1687
R2 = 0.9962
0
5
10
15
20
25
30
35
40
0 2 4 6 8 10
Time (h)0.5
C
um
ul
at
iv
e 
%
 r
el
ea
se
d
 
Figure 3.5. Least squares linear regression best fit line of the in vitro release profile of CP from 
Dermovate® cream (n = 6)  
 
3.2.5. Temperature  
 
The temperature of the receptor medium is generally set to 32 ± 0.5˚C in an attempt to 
approximate the natural surface temperature of the skin [102, 107, 111, 113, 115, 122, 123, 126]. 
An increase in temperature normally results in an increase in drug release rate and hence some 
deviation from using 32˚C, for example the use of 37˚± 0.5˚C may be justifiable. However the 
use of excessively high temperatures may melt the base or the product being tested or cause 
significant physical changes to such a product, which in turn may change the resistance of the 
matrix to drug diffusion into the receptor medium and should therefore, be avoided [113]. 
 
In vitro release experiments conducted at 32°C and 37˚C showed no significant differences in the 
in vitro release rates of triamcinolone acetonide from various commercial cream and ointment 
formulations [106]. Therefore the in vitro release profile characterization of CP release from 
semi-solid formulations manufactured in these studies was conducted at 32° ± 0.5˚C.  
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3.2.6. Receptor medium 
 
3.2.6.1. Overview 
 
One of the most important considerations when developing an in vitro release test method is the 
selection of a receptor medium that has adequate sink characteristics throughout the course of an 
experiment [115]. In order to achieve favourable sink conditions and to ensure that the lower 
surface of the membrane remained in contact with the receptor phase over the entire 
experimental time period, each diffusion cell was completely emptied and refilled immediately 
with fresh receptor fluid at each sampling time. 
  
However, it is also worth noting that a receptor medium must have a high capacity to dissolve 
the active ingredient that has been released from the formulation being tested [112]. This may be 
accomplished by maintaining the thermodynamic activity of an API in a receptor fluid at less 
than 10% of its thermodynamic activity in a donor medium, thereby maintaining a favourable 
driving force for permeation and ensuring reasonable and efficient transfer and collection of the 
permeant of interest [122]. Therefore, another important factor to consider when selecting a 
receptor fluid is the solubility of an API being tested in a receptor fluid or medium [108]. It is 
therefore critical that a drug substance has sufficient solubility in a receptor medium without 
impacting on the sink conditions of that system [121].  
 
Ideally, receptor media should be aqueous systems [115] and for most studies isotonic solutions, 
buffered to a pH of 7.4 are preferred for use as receptor fluids [122]. However, for products 
formulated with water-insoluble drugs, the selection of an appropriate receptor medium to 
maintain sink characteristics is a challenge [121], and in order to facilitate and monitor drug 
release from such topical formulations it may be necessary to alter receptor fluid pH, add 
surfactants and/or complexing agents such as cyclodextrins [115] or use non-aqueous media in 
which the drug is more soluble to efficiently dissolve the API that has been released from the 
matrix during release studies [122].  
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3.2.6.2. Selection of receptor medium 
 
3.2.6.2.1. Aqueous systems 
 
CP is a hydrophobic corticosteroid with a limited aqueous solubility (Chapter 1, Section 1.3.1.1). 
Consequently, the use of a purely aqueous receptor fluid was not considered. In addition, since 
the drug is non-ionisable (Chapter 1, Section 1.3.2) altering the pH of an aqueous receptor 
solution would not have an effect on its aqueous solubility and therefore the use of other solvent 
systems was considered appropriate.  
 
3.2.6.2.2. Water-immiscible systems 
 
The hydrophobic nature of CP and the associated difficulties in selecting an appropriate receptor 
medium might persuade researchers to use non-aqueous solvents such as acetone, chloroform or 
dichloromethane in which the drug would be freely soluble as the receptor medium (Chapter 1, 
Section 1.3.1.1). However, the use of such media in release studies is undesirable since these 
solvents are likely to interfere with the analytical method of choice, especially if the analytical 
procedure requires direct injection of the receptor medium onto the HPLC system as was desired 
in these studies. 
 
3.2.6.2.3. Water-miscible systems 
 
3.2.6.2.3.1. Overview 
 
A further practical consideration in the selection of an appropriate receptor medium is to 
consider the use of water-miscible solvents such as ethanol and propylene glycol (PG) or 
propane-1,2-diol. Ethanol, PG and aqueous solutions of various concentrations are widely used 
as solvents in pharmaceutical formulations and cosmetics [139, 140]. Ethanol is a clear, 
colourless, mobile and volatile liquid with a slight characteristic odour and burning taste [139] 
and PG is a clear, colourless, viscous, practically odourless solvent with a sweet, slightly acrid 
taste resembling that of glycerine [140].   
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Ethanol has a specific gravity or density of 0.8119-0.8139 g/cm3 at 20˚C [139] and the specific 
gravity of PG is 1.038 g/cm3 at 20˚C [140]. These materials are generally regarded as relatively 
non-toxic and chemically stable when stored in well-closed containers at cool temperatures [139, 
140]. Since CP is relatively soluble in ethanol and PG (Sections 1.3.1.1 and 1.3.1.2.1, Chapter 1), 
the use of ethanol and PG aqueous mixtures as potential receptor fluids for CP was considered in 
preliminary studies. 
 
3.2.6.2.3.2. Alcohol/water mixtures 
 
The use of hydro-alcoholic solutions as receptor media for lipophilic drugs such as triamcinolone 
acetate [106, 126], betamethasone dipropionate [121] and rooperol tetra-acetate [123] has been 
reported. Consequently, ethanol ABS (Protea Chemicals, Port Elizabeth, Eastern Cape, RSA) at 
a concentration of 30% v/v was assessed as a receptor medium for CP, using Silatos™ silicone 
sheeting, REF 7458 (Atos Medical, Hőrby, Sweden) as a supporting membrane.  
 
The data generated from these studies are illustrated in Figure 3.6., and are reported as the 
cumulative amount of CP released per unit area (Q) vs. time (t). However the use of aqueous 
ethanol solutions as a receptor medium for CP were not considered ideal because of the presence 
of excessive air bubbles that were observed beneath the synthetic support membrane. Air bubbles 
have been reported to interfere with the contact between the receptor medium and the supporting 
membrane that is required, resulting in a reduced surface area available for drug diffusion to 
occur [121].  
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Figure 3.6. In vitro release profile of CP from Dermovate® cream, using 30% v/v ethanol solution as 
receptor medium (n = 6) 
  
Visual inspection of the Franz cells at the end of the experiment also revealed noticeable 
evaporation of the receptor medium, which resulted in a decrease in the volume of the receptor 
fluid in some cells. The extent of evaporation of the receptor medium might have contributed to 
the large standard deviations observed at the longer sample times such as 48 and 72 hours.  
 
3.2.6.2.3.3. Propylene glycol/water mixtures 
 
The use of PG as a receptor fluid has also been reported [141]. Therefore in preliminary studies 
the in vitro release of CP through Silatos™ silicone sheeting, REF 7458 (Atos Medical, Hőrby, 
Sweden) into a 30% v/v PG:water receptor medium was evaluated and the data from these 
studies are shown in Figure 3.7. Unlike aqueous ethanol, the use of 30% v/v PG did not lead to 
the formation of excessive of air bubbles beneath the surface of the membrane used in these 
studies. Inspection of the Franz cells at the end of the experiment also revealed little evidence of 
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receptor medium evaporation and therefore this solution was considered promising as an 
appropriate receptor medium for CP release studies.  
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Figure 3.7. In vitro release profile of CP from Dermovate ® cream using 30% v/v PG solution as receptor 
medium (n = 6) 
 
3.2.6.3. Saturation solubility 
 
Following the selection of 30% v/v PG:70% v/v water as the most promising receptor medium 
for CP release studies, saturation solubility studies of CP in water, PG and PG:water binary 
mixtures were conducted in order to determine the optimal concentration of PG for use in a 
receptor medium for CP.  
 
The saturation solubility of CP was determined in 0, 30, 40, 50, 60 and 100% v/v PG. 
Approximately 50 mg of CP was accurately weighed and placed into a test tube and 2.0 ml of the 
different solvents to be tested were added. Samples were agitated at 120 oscillations per minute 
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in a Model-123 Labotec Oscillating water bath (Labotec (Pty) Ltd, Johannesburg, Gauteng, 
RSA), maintained at 32○C for 48 hours.  
 
The solutions were then filtered through a 0.22 µm Millipore filter (Millipore Co., Bedford, MA, 
USA) and a 1.0 ml aliquot of the filtrate was diluted to 10 ml with acetonitrile and analysed 
using a specific and sensitive, previously validated HPLC method with UV detection at 240 nm 
(Chapter 2, vide infra).  
 
A list of the experimentally determined saturation solubility values for CP in various solutions of 
different concentrations of PG concentrations is listed in Table 3.1, and the saturation solubility 
profile of CP in the various solutions, plotted as log solubility vs. PG concentration, is depicted 
in Figure 3.8.  
 
Table 3.1. Solubility data for CP in various concentrations of PG at 32˚C (n = 3) 
PG concentration (%v/v) Mean saturation solubility 
(mg/ml) 
SD 
0 0.003600     0.0009000 
30 0.01760      0.001680 
40 0.05880  0.0007800 
50 0.1983  0.0002900 
60 1.334  0.2300 
100 8.550  2.500 
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Figure 3.8. Saturation solubility profile of CP in PG:water solutions of different proportions (n = 3) 
 
The resultant data show that CP is poorly soluble in water, but relatively soluble in PG. It is clear 
that as the PG content of the dissolution or receptor medium is increased, the saturation solubility 
of CP also increases. The objective of conducting these studies was to determine the saturation 
solubility of CP in a PG concentration that was greater than ten (10) times that of the maximum 
achievable concentration that may be attained during the course of in vitro release experiments.  
 
In the pilot study conducted and reported in Section 3.2.6.2.3.3 (Figure 3.7), approximately 300 
mg of 0.05% w/w Dermovate® cream was applied to the synthetic membrane and the volume of 
the receptor medium used was 12.5ml. Assuming that CP is freely soluble in the receptor 
medium, the theoretical maximum concentration that would be achieved during the course of an 
in vitro release study is calculated to be 12 µg/ml. 
 
The saturation solubility data summarized in Table 3.1 reveal that CP has a saturation solubility 
of 198.27 ± 0.29 µg/ml in a 50% v/v PG:water solution, corresponding to nearly 16.5 times the 
estimated maximum concentration of 12 µg/ml that could be achieved. Therefore based on the 
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saturation solubility of CP in this solvent system and the fact that the receptor medium was 
replaced at each sampling time during the course of the experiment, it was considered that 
adequate sink conditions would prevail for the duration of all studies. Therefore a 50% v/v 
PG:water solution was selected as an appropriate receptor phase for use in future in vitro release 
studies of CP creams. 
 
3.2.6.4. Preparation of the receptor medium 
 
The receptor medium was prepared by carefully adding equal parts by volume of  propane-1,2-
diol (Merck Chemicals (Pty) Ltd, Darmstadt, Germany) and HPLC-grade water generated from a 
Milli-RO® 15 water purification system (Millipore Co., Bedford, MA, USA), to a Schott Duran® 
glass solvent mixing bottle (Schott Duran GmbH, Hattenbergstrasse, Germany) using a 
measuring cylinder. Following mixing, the mixture was allowed to equilibrate to room 
temperature and then the receptor phase was degassed under vacuum with the aid of a Model A-
2S Eyela Aspirator (Rikakikai Co., Ltd, Tokyo, Japan) and filtered through a 0.45 µm Millipore® 
HVLP filter (Millipore Co., Bedford, MA, USA) prior to use. The receptor phase was degassed 
in order to remove dissolved air, thereby minimising the potential formation of air bubbles 
beneath the supporting membrane, which have been reported to adversely affect the in vitro 
release of an API from semi-solid dosage forms [122]. 
 
3.2.7. Synthetic membranes  
 
3.2.7.1. Overview 
 
Synthetic membranes have been used extensively to determine the in vitro release characteristics 
of an API from topical formulations [102, 115, 117, 121, 134, 142]. These membranes are not 
intended to mimic the barrier properties or the heterogeneous nature of the skin [113]. Instead, 
they are designed to provide a physical support and maintain constant contact between the 
formulation and dissolution medium and to prevent bulk transfer of the dosage form, whilst 
allowing for the monitoring of API release from a formulation into a receptor medium [113, 
115].  
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It has been reported that it is possible to study the in vitro release of a drug from rigid topical 
formulations such as ointments into an aqueous medium in the absence of a separating 
membrane [142]. However, creams and gels invariably contain an aqueous phase and/or adjuvant 
components that are aqueous in nature, are water-miscible or water-soluble. Therefore a 
membrane must be placed between the formulation being tested and the receptor medium in 
order to maintain the physical integrity of individual formulations and/or dosage forms [112].  
 
3.2.7.2. Characteristics of membranes  
 
Synthetic membranes that have been commonly used for in vitro release studies are those with 
porous characteristics such as cellulose acetate [102, 103, 107, 134], nitrocellulose [105, 121] 
and polycarbonate membrane filters [104, 105 123], or alternatively homogeneous permeable 
polymers such as silicone based filter membranes [102, 107, 129, 134].  
 
Important considerations that must be taken into account when selecting a synthetic membrane 
for use in in vitro drug release experiments include the requirement for the membrane to be 
commercially available and have little or no capacity to bind the API of interest [112, 113]. In 
addition, the membrane should have low reactivity with formulation components, be compatible 
with the receptor medium and offer the least possible diffusional resistance to the permeant of 
interest [112, 113, 119, 125].  In short, the membrane of choice should be inert and provide a 
holding surface without barrier properties for the active ingredient and test formulation(s) [108]. 
 
The effects of several membranes on the in vitro release of CP from Dermovate® cream were 
investigated. The membranes tested were a non-porous synthetic membrane, Silatos™ silicone 
sheeting REF 7458 (Atos Medical, Hőrby, Sweden) and porous synthetic membranes such as  
Isopore™ Membrane Filters (Millipore Co., Bedford, MA, USA) and MF-Millipore™ Membrane 
Filters (Millipore Co., Bedford, MA, USA). The characteristics of the membranes used in these 
studies are summarized in Table 3.2. 
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Table 3.2. Summary of the characteristics of synthetic membranes 
Membrane Pore size (µm) Thickness (µm) Nature 
Silatos™ (Silicone)           NA 120 Hydrophobic 
Isopore™ (Polycarbonate) 0.10 20 Hydrophilic 
Isopore™ (Polycarbonate) 0.40 20 Hydrophilic 
MF-Millipore™ (Nitrocellulose) 0.025 105 Hydrophilic 
MF-Millipore™ (Nitrocellulose) 0.45 150 Hydrophilic 
 
3.2.7.3. Assessment of membranes 
 
The effects on in vitro release of CP of each membrane were assessed using a modified Franz 
diffusion cell system (Section 3.2.2) and a receptor medium comprised of 50% v/v PG:water  
prepared as described in Section 3.2.6.3. The purpose of these studies was to determine the most 
suitable membrane to be used as a support synthetic medium for the assessment of semi-solid 
products containing 0.05% w/w CP. Each membrane was cut to approximately 30 mm in 
diameter to fit the circumference of the membrane holder on the diffusion cell system and was 
soaked in the receptor medium prior to use.  
 
Cellulose membranes are believed to contain a number of water-soluble softeners, preservative 
and plasticizer additives which may affect drug permeation [143]. To ensure the removal of these 
substances, pieces of cellulose-based membranes were rinsed with distilled water prior to 
soaking in the receptor fluid. After one hour, the membranes were carefully removed from the 
receptor medium with the aid of a pair of tweezers, wiped with adsorbent tissue to remove excess 
surface liquid and mounted between the donor and the receptor compartments of the Franz cell 
assembly.  
 
Parafilm ‘M’® Laboratory Film (Pechiney Plastic Packaging, Chicago, IL, USA) was used to 
ensure that a leak-proof seal was formed between the flanges of the upper and lower components 
of the diffusion cell assembly that was held together with a screw clamp. Following equilibration 
of the cell to 32˚C an infinite dose of approximately 300 mg of the test formulation was applied 
evenly to the entire surface of the membrane with the aid of a glass rod and the final dose was 
determined by weighing the rod before and after application. The donor compartment was 
covered with Parafilm® in order to achieve occlusive conditions throughout the experiment.  
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The receptor chamber of each diffusion cell was filled with 12.5 ml of the receptor medium and 
stirred by means of a 2x2 mm star-head magnetic stirrer (Merck Chemicals (Pty) Ltd, Darmstadt, 
Germany). The receptor compartment was examined for the presence of air bubbles and if 
present bubbles were removed by manually tapping or rotating the diffusion cell apparatus 
assembly. Aliquots of receptor medium were removed at the appropriate sampling times as 
discussed in Section 3.2.4.  
 
Following the removal of a sample to be analyzed, each diffusion cell was completely emptied 
and refilled immediately with fresh receptor fluid. Samples were stored at room temperature 
(22˚C) until analyzed. The samples were analyzed immediately after the conclusion of the 
release studies i.e. within three days (72 hours) of the commencement of the study. These 
samples were found to be stable at these storage conditions as investigated and reported in 
Chapter 2, Section 2.5.2.6.3.2.  
 
At the conclusion of release experiments, no physical changes to any of the membranes tested 
were observed following exposure of the membrane to the PG-water receptor medium or the 
semi-solid formulation applied to the membrane. These results were considered indicative of the 
compatibility between the membranes and the receptor medium used, as well as the components 
of the topical formulation containing CP. A specific, sensitive and validated HPLC method with 
UV detection at 240 nm (Chapter 2) was used to analyze the samples and to determine the 
amount of drug released per unit area. The cumulative amount of CP released (Q) over the 72 
hour time period was plotted against time. 
  
The results obtained following membrane selection studies are depicted in Figure 3.9. It is 
immediately apparent that the in vitro release rate of CP through the silicone membrane was 
significantly slower than through any of the nitrocellulose and polycarbonate membranes tested. 
The highest amount of CP that was released was 56.37 ± 5.02 µg/cm2 and was released through 
the 0.45 µm nitrocellulose membrane, whereas the lowest amount of 6.69 ± 1.11 µg/cm2 was 
released through the silicone membrane. These data are discussed further in Section 3.2.7.4. 
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Figure 3.9. Effect of membrane type on the in vitro release of CP from Dermovate® cream (n = 3) 
 
3.2.7.4. Membrane selection 
 
The migration of a drug from a semi-solid matrix into a receptor medium is essentially a function 
of one or a combination of the following three processes: 
 
a) drug release from the semi-solid matrix itself, 
b) passage of the drug through the membrane, and, 
c) clearance of the drug from below the membrane.  
 
In cases where neither of the last two processes are rate-limiting it is only the thermodynamic 
activity of the drug in the semi-solid matrix that is an important determinant of drug release 
[144]. Since the physical properties of the product itself are of interest, diffusion through the 
base should be the rate-limiting step [113]. It is therefore critical that the membrane and the 
receptor medium be highly permeable and accessible to the drug in the formulation to effect drug 
release. 
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3.2.7.4.1. Silicone membrane 
 
Silicone is a relatively inert, lipophilic and non-porous membrane as summarized in Table 3.2. 
The lipophilic nature of silcone provides an ideal environment for partitioning and permeation of 
lipophilic drugs, whilst its aporosity provides some rate-limiting function to this process [143]. 
Consequently, these membranes are useful for use as surrogate membranes for human skin when 
evaluating in vitro release characteristics of a drug from topical or transdermal formulations.  
 
The in vitro release profile of CP release generated through the silicone membrane suggested that 
the membrane behaves as a rate-limiting component of the test system, since the passage of only 
4.42 ± 1.11% of the applied dose into the receptor medium over the 72 hour test period was 
allowed. This percentage release was considered low and appeared to indicate the lack of free 
passage of CP through the membrane into the receptor medium.  
 
The objective of these studies was to find a synthetic membrane with the least possible resistance 
to CP diffusion. Therefore the use of a silicone membrane in this test system was considered 
inappropriate for these studies as the use of this membrane would not provide relevant 
information pertaining to CP release from test formulations but would inhibit release and provide 
information pertaining to the flux of the drug molecule via membrane-limited release. 
 
3.2.7.4.2. Porous membranes 
 
Cellulose membranes have been used extensively in diffusion cell test systems for quality control 
studies [102, 103, 105, 107, 121, 134]. It is worth noting that pure cellulose acetate membranes 
are no longer commercially available, due to an Environmental Protection Agency (EPA) ban on 
one of the chemicals needed to manufacture the membranes [102]. The membranes currently 
referred to as cellulose acetate membranes contain a mixture of mixed esters of cellulose acetate 
and cellulose nitrate, unlike the pure cellulose acetate membrane which contained cellulose 
acetate only. Generally these membranes are reported to be more permeable than biological 
membranes or aporous synthetic media and to allow the passage of diffusing molecule(s) 
irrespective of the physicochemical characteristics of the compound under investigation [143].  
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Similarly porous polycarbonate filter membranes generally appear to be useful for use as a 
dividing medium or as a supporting screen in test systems, where the release rate of a drug from 
a delivery system is under investigation, as opposed to the evaluation of the kinetics of release of 
a permeant from a formulation [143]. These filter media do not simulate the skin and provide no 
significant barrier to the diffusion of a drug molecule but rather provide a relevant support for a 
test formulation as is required for these types of studies.  
 
The highest rate and amount of CP release was observed when using a 0.45 µm nitrocellulose 
membrane, implying that it had the lowest resistance to the diffusion of CP. It would therefore 
seem appropriate to select a 0.45 µm nitrocellulose membrane as the support membrane of 
choice. However, a series of assumptions have to be made when selecting a membrane that 
offers little resistance to drug penetration for use in in vitro release studies [138]. Among these 
assumptions is the fact that there should be no more than 30% of the total amount of an applied 
dose released into a receptor medium at the end of an experiment [138]. The cumulative 
percentage CP released through each of the hydrophilic membranes studied over the 72 hour 
period is summarized in Table 3.3. 
 
Table 3.3. Cumulative percentage CP released after 72 hour (n = 3) 
Membrane Pore size (µm) Mean % CP 
released/cm2 
SD 
Nitrocellulose 0.025 26.75   0.6100 
Polycarbonate 0.40 29.53   2.720 
Polycarbonate 0.10 32.53   1.970 
Nitrocellulose 0.45 37.38  5.020 
 
It is evident from the data summarized in Table 3.3 that the 0.45 µm nitrocellulose membrane 
allowed for the passage of more than 30% of the drug placed in the donor chamber and therefore, 
based on the assumption that less than 30% should be released as reported by Higuchi [138], this 
membrane was deemed inappropriate for use. Similarly the 0.1 µm and 0.4 µm polycarbonate 
membranes were also deemed inappropriate for the assessment of CP release from semi-solid 
formulations. The cumulative percent CP released during in vitro release testing with a 0.025 µm 
nitrocellulose was approximately 27% and therefore the 0.025 µm nitrocellulose membrane was 
considered the membrane of choice for further studies (Section 3.2.7.5).  
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3.2.7.5. Membrane resistance 
 
Following selection of the 0.025 µm nitrocellulose membrane as the most suitable synthetic 
membrane for formulation development studies, membrane resistance to free permeation of CP 
was evaluated by assessing the release of CP from a 0.05% w/v solution of CP made up in the 
receptor medium (50% v/v PG: 50% v/v water). In addition 300 µl of the 0.05% w/v solution 
was substituted for 300 mg of semi-solid formulation in the donor compartment. The release 
profile generated from the CP solution was then compared to the profile generated following 
testing CP release from Dermovate® cream.  
 
The data generated in these studies are depicted in Figure 3.10. The results revealed that the in 
vitro release of CP through a 0.025 µm nitrocellulose membrane was significantly slower from 
the cream formulation than from the 0.05% w/v CP solution. Within the first 8 hours of the 
release experiment, 4.82 ± 0.98% and 29.16 ± 1.92% of CP had been released from the cream 
and solution respectively. A total of 24.4 ± 3.75% and 46.04 ± 2.07% of CP were released from 
the cream and solution, respectively, at the end of the 72 hour experiment.  
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Figure 3.10. Comparison of in vitro release of CP from a 0.05% v/v CP solution and Dermovate® cream 
using a 0.025 µm nitrocellulose membrane (n = 6) 
  
The fact that the permeation of CP across the 0.025 µm nitrocellulose membrane was faster from 
the CP solution than from the cream suggested that the membrane was not a rate-limiting factor 
in diffusion and did not affect CP release from the cream formulation and test solution. The 
differences observed in the release rate profiles for CP could therefore be directly attributed to 
the characteristics of the semi-solid formulation and not the membrane used in the release rate 
studies. Consequently the 0.025 µm nitrocellulose membrane was selected as an appropriate 
inert, porous and commercially available synthetic membrane for the assessment of in vitro 
release from topical formulations containing 0.05% w/w CP. 
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3.2.8. Sample Application  
 
3.2.8.1. Overview 
 
Depending on the method used to interpret the release data, either a finite or infinite dose may be 
applied to the donor compartment of a test system [115]. The use of finite dosing results in the 
release of the majority of the drug applied to the surface of a membrane into the receptor 
medium, whereas with infinite dosing only a small percentage of the drug that is applied to the 
membrane is released into the receptor medium over the course of the experiment [115]. 
 
Generally, data analysis is far less complicated when using infinite dosing or in situations in 
which less than 30% of the applied dose is released during a test period [115]. Consequently the 
effects of the amount of formulation applied to a membrane on the in vitro release rate of CP 
were investigated. The objective was to determine an appropriate amount of formulation to be 
applied to the membrane in order to correspond to an infinite dose condition or application. 
 
3.2.8.2. Effects of sample application 
 
The effect of applying different amounts of a sample to be tested into the donor compartment 
was studied using a modified Franz glass diffusion cell system (Section 3.2.2.4), a 50% v/v 
PG:water receptor medium (Section 3.2.6.3) and a 0.025 µm nitrocellulose membrane (Section 
3.2.7.2). Approximately 50 mg, 100 mg, 200 mg and 300 mg of 0.05% Dermovate® cream was 
accurately weighed and spread evenly over the entire surface of the membrane using a glass-
stirring rod. The glass rod was weighed before and after application and an accurate weight of 
cream applied to the membrane was recorded. This technique was found to be reproducible with 
respect to the sample weight applied to the membrane in all tests. The results obtained from these 
studies are shown in Figure 3.11.   
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Figure 3.11. Effect of sample loading on the in vitro release of CP from Dermovate® cream 
 
The results shown in Figure 3.11 are reported as the amount released per unit area (Q) vs. the 
square root of time (t1/2) as opposed to time. In this manner the effect of sample amount on in 
vitro release rates of CP may be explained using theoretical diffusion models. The data reveal 
that the amount of drug released (Q) vs. t1/2 increased as the amount of semi-solid applied to the 
membrane was increased. The Higuchi diffusion model [137, 144] which can be described using 
Equation 3.1 may be used to describe the release characteristics of a drug from a suspension or in 
solution in a semi-solid base.  
 
( )[ ] 2/12 tDCCAQ sss−=      Equation 3.1 
 Where:       
Q = the cumulative amount of drug released, 
Ds = the diffusivity of drug in the semi-solid matrix, 
A = the amount of drug in the formulation, and 
Cs = the saturation solubility of the drug in the semi-solid matrix. 
 t = time  
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The Higuchi equation predicts that a plot of Q vs. t1/2 would be linear for a drug in suspension in 
a semi-solid matrix with an infinite dose application provided that such release is diffusion-
controlled by the matrix material that comprises the semi-solid dosage form [137].  
 
Least squares linear regression analysis was used to determine the degree of linearity of the plots, 
and the resultant coefficients of determination (R2) indicate that all the plots were linear over the 
time period studied. The data are summarized in Table 3.4.  
 
Table 3.4. In vitro release characteristics from four loading doses applied to the test membrane 
 
The data shown in Table 3.3 imply that any of the amounts of semi-solid (50, 100, 200 and 300 
mg) applied to the membrane in these studies conformed to Higuchi kinetics and although the 
results suggest that an infinite dose condition was achieved with all four amounts of formulation 
tested, 300 mg was selected for use in these studies due to the ease of experimental set-up, for 
example weighing 300 mg by difference was considered much quicker and easier than weighing 
smaller quantities. 
 
3.2.9. Sample occlusion 
 
3.2.9.1. Overview 
 
The FDA guidance document [49] recommends that the amount of the semi-solid preparation 
applied uniformly onto a membrane should be kept occluded during the assessment of the in 
vitro release characteristics of a drug from that formulation. Occlusion is preferred in order to 
prevent solvent evaporation and compositional changes of a formulation that is applied to the test 
membrane [49].  
 
The term occlusion refers to the use of a moderately impermeable barrier to cover the donor 
compartment of a diffusion cell assembly [115]. Experiments were performed in the sample 
Loading dose (mg) R2 
50 0.9846 
100 0.9896 
200 0.9873 
300 0.9881 
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occluded or non-occluded mode to determine whether the degree of occlusion affects the in vitro 
release of CP and to select the appropriate conditions for future studies.  
 
3.2.9.2. Effects of occlusion 
 
The effect of occlusion on the in vitro release of CP from Dermovate® cream was investigated 
using approximately 300 mg of the cream formulation. Diffusion cells were occluded by placing 
a piece of Parafilm® over the donor compartment of the diffusion cell and sealing the cell.  
 
The effects of occlusion and non-occlusion of the donor cell on the in vitro release characteristics 
of CP from an infinite dose condition are shown in Figure 3.12. These data reveal that the 
amount of CP released in the in vitro release profiles from an infinite dose condition under 
occlusion was greater than from an un-occluded test system.  
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Figure 3.12. Effect of occlusion on the in vitro release of CP from Dermovate® cream (n = 6) 
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Many semi-solid formulations contain solvents such as ethanol, water and propylene glycol and 
it has been reported that ethanol and water evaporate rapidly, whereas propylene glycol only 
evaporates appreciably over a 24 hour period [112]. The composition of a semi-solid formulation 
being tested would therefore change over the experimental period, should the test system not be 
occluded for the duration of the experiment.  
 
It is possible that the use of non-occluded cells resulted in the evaporation of water as well as 
propylene glycol over 24 hours which might have led to an increase in the intrinsic viscosity of 
the formulation, thereby causing an increased resistance to the diffusion of CP and a subsequent 
lower overall release rate as shown in Figure 3.12. Consequently the in vitro release profile of 
CP release from the topical formulation was markedly decreased and the deviation between the 
two curves was more noticeable for the period 24-72 hours of the diffusion experiment.  
 
As a result of the improved extent of release observed when using occluded cells, all future in 
vitro release experiments for the assessment of CP release from semi-solid formulations were 
carried out under occlusive conditions to prevent solvent evaporation and compositional changes 
of the formulations being tested as such changes may influence the overall cumulative amount of 
CP released during testing. 
 
3.2.10. Sample Analysis 
 
A sensitive, selective, accurate and precise previously validated HPLC method with UV 
detection at 240 nm (Chapter 2) was used to analyze the samples withdrawn from the receptor 
chambers at each time-point. The concentration of CP in each receptor cell was determined by 
interpolation of the peak height ratios of CP to I.S. from a calibration curve. A typical calibration 
curve is shown in Figure 3.13 and each calibration curve was prepared on the day on which 
samples were analysed. 
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 Figure 3.13. CP calibration curve used to determine the amount of CP released in in vitro release 
experiments 
 
3.2.11. Comparison of diffusion or release rate profiles 
 
The in vitro release profiles generated from two semi-solid products (test and reference) were 
compared using a statistical test recommended by the FDA to assess product sameness when 
changes are made to an approved topical semi-solid product [49]. The analysis involves non-
parametric assessment of release rate profiles by statistical means and is based on the calculation 
of an appropriate confidence interval (C.I.).  
 
The test is related to the Wilcoxon Rank Sum/Mann-Whitney Rank Test that is applied to the log 
of the slope of the release profiles or the release rate. The in vitro release profiles of two 
formulations are generated for a test and a reference  (T and R) product (n = 6) and the resulting 
slopes of the profiles or estimated in vitro release rates for each of the formulations are 
calculated. A 90% C.I. for the ratio of the median in vitro release rate or population for the test 
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product over the in vitro release rate or population for the reference product is computed and 
expressed in percentage terms.  
 
The computation of the C.I. is achieved by evaluation of 36 (6 x 6) individual ratios of  T/R in 
vitro release rates and are ordered in sequence, i.e. all possible T/R ratios (36 in total) are 
arranged in ascending order from lowest to highest with respect to relative release rates. The 
eighth (8th) and twenty-ninth (29th) individual ratios are then established and are assigned as the 
lower and upper limits of the 90% C.I. for the T/R release rate ratio respectively and converted 
into percentages. In order to accept that the in vitro release rate of a test product (T) is within the 
90% C.I. of a reference product (R), the values for T/R ratios should fall within the limits of a 
0.75 or 75% to 1.33 or 133% C.I.  
 
An example of the calculation of the confidence interval is shown in Appendix 1. The data 
shown were generated in in vitro release studies in which CP release from an extemporaneously 
manufactured CP cream (T) and from Dermovate® cream (R) were assessed (Chapter 4, vide 
infra). The eighth and twenty-ninth ordered individual T/R ratios are 101.6% and 125.3%, which 
fall within the 75% -133% limits. Therefore the release rates from the two semi-solid 
formulations in this example are considered identical and as a result the two formulations can be 
considered equivalent. 
 
3.2.12. Optimal in vitro release test conditions 
 
The optimal in vitro release test conditions established for the assessment of CP release from 
topical formulations are summarised in Table 3.5.  
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Table 3.5. Summary of optimal in vitro release test conditions  
Parameter Condition 
Apparatus 
Sample number 
Average diffusional surface area 
Average receptor volume 
Receptor medium 
Temperature 
Synthetic membrane 
Dosing conditions 
Sample occlusion/non-occlusion 
Magnetic stirrers 
Sampling time 
Sample analysis 
Comparison of diffusion profiles 
Vertical glass Franz cell diffusion cell 
6 cells 
1.921 ± 0.056 cm2 
12.50 ± 0.38 ml 
50% propylene glycol:50% water 
32 ± 0.5˚C. 
0.025 µm nitrocellulose 
Infinite (300 mg sample application) 
Occlusion 
2x2 mm star-headed magnetic stirrers 
0, 2, 4, 8, 12, 24, 48, and 72 hours 
HPLC with UV detection at 240 nm 
Non-parametric statistical test 
 
 
3.3. METHOD VALIDATION 
 
3.3.1. Overview 
 
The fundamental principle on which the validation of an in vitro release test method is based is 
that following validation there is an assurance that the test method is performing as expected and 
that when changes are made to the formulation composition, batches or sources of ingredients 
and method of manufacture, changes in drug release rates can be detected [113, 115].  
 
The integrity of this in vitro release method was therefore interrogated by investigating the effect 
of changing various formulation attributes on the CP release rate from a prototype 
extemporaneous cream. The variables validated in these studies were changes in: 
 
a) dose strength,  
b) composition, and, 
c) viscosity of the semi-solid dosage form.  
 
The use of these attributes as parameters in validation protocols for in vitro release test methods 
have been previously reported [108, 113, 115]. 
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The slope of the linear portion of the cumulative amount of drug released vs. the square root of 
time (Q vs. t1/2) plot has been reported as the most logical, meaningful and accurate parameter for 
comparing in vitro release characteristics of a drug from different topical formulations [113]. 
Thakker and Wendy [108] used flux values in the validation of a typical in vitro release test 
method and reported flux values as the average slope of the best fit line of a Q vs. t1/2 plot [108].  
 
The approach adopted by Thakker and Wendy [108] was used to calculate flux values for CP 
release from the test product and flux values were used to confirm the ability of the in vitro 
release test method to differentiate between semi-solid formulations of CP that differed in 
strength, excipient composition and viscosity. 
 
3.3.2. Changes in dosage strength 
 
The effects of changes in strength of CP in the formulation on in vitro release rate of CP were 
evaluated using extemporaneously manufactured cream formulations at three different 
concentrations levels, specifically, 0.01, 0.025 and 0.05% w/w of CP.  
 
According to theoretical principles, the release rate and ultimate amount of drug released from a 
specific formulation should be proportional to the amount of drug in the formulation if the 
diffusion of the drug within the semi-solid matrix is the rate-controlling mechanism in drug 
release [138, 144]. Data generated in these studies are summarized in Table 3.6 and shown in 
Figure 3.14 and are in agreement with the theory. The higher the concentration of CP in the 
semi-solid formulation, the greater the flux and ultimately the total cumulative amount of CP 
release per unit area.  
 
Table 3.6. Effect of changes in the CP concentration on the total cumulative amount released and the 
associated flux values (n = 3) 
 
Dosage strength  (%w/w) Q (µg/cm2) Flux (µg/cm2/h1/2) 
0.010 11.22 1.470 
0.025 26.09 3.540 
0.050 41.81 5.410 
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Figure 3.14. Effect of changes in CP content on the in vitro release rate of CP from an extemperaneous 
cream base (n = 3) 
  
 
The data suggest that the selected receptor phase, support membrane and other experimental 
conditions are suitable to show discrimination between different formulations since the rate-
controlling mechanism for drug release is diffusion of CP within the semi-solid base and not 
through the membrane used in the cell assembly. Consequently, the impact of formulation 
changes that may result in drug loading differences can be assessed using this in vitro release 
method. 
 
3.3.3. Changes in composition 
 
The effect of changes in formulation composition on the in vitro release rate of CP was examined 
using two extemporaneously manufactured creams formulations (Formulations 1 and 2). Both 
formulations were manufactured using the same method of manufacture and contained the same 
amount of CP (0.05% w/w). The difference between the two formulations was that a different 
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primary emulsifier was used in each case. Formulation 1 contained 1% w/w Ritapro® 200 (Rita, 
Crystal Lake, IL, USA) and Formulation 2 contained 1% w/w Emulcire® 61 WL (Gattefossé 
SAS, Saint-Priest Cedex, France) as the primary emulsifier. The data generated from these 
studies are summarized in Table 3.7 and shown in Figure 3.15 and reveal that alterations in the 
composition of the CP formulation do in fact result in changes in flux in addition to the total 
cumulative amount of CP released. These data confirm the ability of this in vitro release method 
to detect the impact of changes of formulation constituents on the in vitro release of CP from 
such formulations.  
 
Table 3.7. Effect of changes in formulation composition on flux and cumulative amount of CP released 
(n = 3) 
 
CP cream 
Formulation 
Dose strength 
(%w/w) 
Primary 
Emulsifier 
Q 
(µg/cm2) 
Flux 
(µg/cm2/h1/2) 
1 0.05 Ritapro® 200 63.06 ± 4.84 8.63 
2 0.05 Emulcire® 44.47 ± 3.63 6.14 
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Figure 3.15. Effect of changes in formulation composition on CP in vitro release rate (n = 3). 
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3.3.2.3. Changes in viscosity  
 
3.3.2.3.1. Overview 
 
In order for a drug molecule to be released across a membrane from a semi-solid vehicle, it has 
to reach the membrane surface prior to partitioning and mass transport of the drug from the 
formulation. Mass transport occurs by diffusion of drug molecules through the formulation base 
[145] and API diffusion depends on the properties of the drug, the diffusion medium and the 
extent of vehicle-drug interactions that may be present [146]. The extent and degree of these 
interactions will in turn determine the rate and extent of drug release and the overall shape of the 
drug release profile.  
 
It is well established that the diffusivity of a drug molecule through a semi-solid material 
decreases progressively as the viscosity of the base material increases [146]. The converse is also 
true and the implication is that any alteration in the intrinsic viscosity of a topical formulation 
would have an effect on the rate and extent of release of an active ingredient from a vehicle. It 
follows therefore that the intrinsic viscosity of a formulation is a key attribute of semi-solid 
dosage forms and a parameter that can be monitored for quality control purposes during and after 
formulation development. 
 
The effect of changes in the intrinsic viscosity of the semi-solid formulation base on the in vitro 
release of CP was therefore investigated using formulations of different viscosity. Two prototype 
cream formulations (Formulations A and B) were manufactured extemporaneously using similar 
exicipients and method of manufacture. The formulation compositions differed in the amount of 
consistency modifier, viz., white beeswax that was added to each formulation. Formulation A 
was manufactured using 0.6% w/w white beeswax whereas formulation B contained 2% w/w 
white beeswax. The exact intrinsic viscosity of each formulation was ascertained as described in 
Section 3.3.2.3.2, vide infra. 
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3.3.2.3.2. Determination of viscosity 
 
The intrinsic viscosity of Formulations A and B were measured using a Model-RVDI+ 
Brookfield Viscometer (Brookfield ENG Labs Inc., Stoughton, MA, USA). The viscometer was 
operated at 100 rpm using a T-F (code 96) spindle and a Helipath stand and the spindle was 
chosen to maintain a torque between 10% and 90%. In order to obtain stable display readings, all 
measurements were recorded 60 sec after the commencement of spindle rotation and a maximum 
of three (3) readings were taken to obtain an average viscosity value.   
 
The intrinsic viscosity readings obtained were 14.83 ± 0.05773 KcP and 21.37 ± 0.1071 KcP for 
Formulations A and B, respectively. These results indicate that Formulation B has a higher 
intrinsic viscosity than Formulation A. In vitro release studies were conducted as previously 
described in order to ascertain whether the intrinsic viscosity resulted in a different flux for CP in 
addition to total cumulative amount CP released.    
 
3.3.2.3.3. Effects of viscosity  
 
The effects of viscosity of the semi-solid formulation on the in vitro release of CP are tabulated 
in Table 3.8 and shown in Figure 3.16.  
 
Table 3.8. Cumulative amount of CP released and the average in vitro release rate (flux) from CP cream 
formulations of different intrinsic viscosity (n = 3) 
 
CP cream 
Formulation 
Dose strength 
(%w/w) 
Viscosity 
(KcP) 
Q 
(µg/cm2) 
Flux 
(µg/cm2/h1/2) 
A 0.05 14.83 ± 0.05773 41.81 ± 0.54 5.41 
B 0.05 21.37 ± 0.1071 36.21 ± 1.71 4.95 
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Figure 3.16. Effect of changes in the intrinsic viscosity of a formulation on the in vitro release rate of CP 
(n = 3).  
 
These data indicate that there was a decrease in CP flux as well as the total cumulative amount of 
CP released from the semi-solid formulation of higher viscosity. However, the CP release rates 
from Formulation A and Formulation B, respectively, appear to be similar, probably more than 
likely due to the small difference in the intrinsic viscosity values obtained for these two 
formulations. Nevertheless, the results show that this in vitro release method is suitable and 
capable of detecting the impact of small changes of the physical properties of CP semi-solid 
formulations on the rate and extent of CP release from these products. 
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3.4. CONCLUSIONS 
 
An in vitro release method for the assessment of clobetasol 17-propionate (CP) release from 
topical semi-solid dosage forms has been developed and validated in terms of protocols reported 
[108, 113, 115]. Method development studies entailed the selection of a suitable diffusion cell 
system, appropriate sampling times, receptor medium and appropriate synthetic membranes in 
addition to investigating the effects of sample application and sample occlusion or non-occlusion 
on the in vitro release of CP from semi-solid dosage forms. 
 
A modified Franz glass diffusion cell system (n = 6) was selected and used in these studies since 
it has the most potential for use as a standardized test system that may be adapted for use as a 
compendial method. Various solvent systems and compositions were investigated for use as 
receptor fluids during the course of these experiments and a 50% propylene glycol: 50% water 
mixture was deemed to be the optimal receptor medium as it was shown to have appropriate sink 
characteristics for CP following saturation solubility studies.  
 
There are certain constraints that are associated with the selection of sampling times and these 
must be considered and investigated when monitoring the rate and extent of API release from 
semi-solid dosage forms. Samples of the receptor medium were withdrawn at 2, 4, 8, 12, 24, 48 
and 72 hours in order to generate a satisfactory CP release profile and to characterize the release 
of CP from semi-solid topical formulations. 
 
Various synthetic membranes were evaluated as potential physical barriers between the semi-
solid sample being tested in the donor chamber and the receptor medium in the receptor chamber 
of the modified Franz cell assembly. A 0.025 µm nitrocellulose membrane was found to be the 
most appropriate, inert, porous and commercially available synthetic membrane for the 
assessment of in vitro release of CP from topical formulations. This synthetic membrane was 
shown to have no resistance to the free diffusion of CP when tested using a solution of CP in a 
propylene glycol water mixture. 
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The temperature of the test system was set at 32° ± 0.5˚C to approximate the usual surface 
temperature of the skin and a 2 x 2 mm star head magnetic stirrer was used to agitate the receptor 
medium. About 300 mg of the semi-solid preparation, which corresponded to an infinite dose, 
was applied uniformly to the membrane, and the formulation was occluded for the duration of 
testing, to prevent solvent evaporation and compositional changes to the formulation.  
 
At the conclusion of studies to define the optimal parameters for in vitro release testing, the 
method was assessed for its ability to detect the effects of changes in formulation characteristics 
on CP release. The effects of changes of strength, composition and intrinsic viscosity of topical 
formulations on in vitro release of CP were then evaluated. The results obtained indicated that 
the in vitro release method that has been developed is able to detect the effects of changes in 
formulation in which CP is suspended and/or dissolved on CP release and was therefore applied 
in all future formulation development studies. 
 
It is evident, from the data presented that the in vitro release test method is simple, reliable, 
reproducible and discriminatory. It can therefore be used in conjunction with traditional quality 
control tests to determine the quality and consistency of extemporaneously manufactured CP 
topical formulations in addition to the assessment of the associated rate and extent of release of 
the API during product development studies.  
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CHAPTER FOUR 
 
DEVELOPMENT AND IN VITRO CHARACTERIZATION OF CLOBETASOL 17-
PROPIONATE CREAM FORMULATIONS  
 
4.1. INTRODUCTION 
 
The elevated costs of brand name or innovator pharmaceutical products has been reported as one 
of the major contributing factors to the rapidly escalating costs of health care services worldwide 
[147-150]. As a consequence, there has been a growing international trend for the demand of 
safe, effective and, more importantly, affordable medicines [151]. A number of mechanisms 
have been evaluated in an attempt to make pharmaceutical products more affordable and more 
accessible, especially in the developing world where lifesaving medicines are reported to be 
financially out of reach of the wider population [152-154].  
 
In the Republic of South Africa (RSA) for example, generic prescribing and generic substitution 
have been identified and targeted as some of the possible strategies to contain the escalating 
costs of brand name pharmaceutical products, and these are currently being implemented [147, 
149, 155, 156]. Generic prescribing refers to the prescription of multi-source (generic) medicines 
by authorized prescribers, such as for example, medical doctors [155], whereas generic 
substitution refers to the replacement of an innovator product with a multi-source (generic) 
product by pharmacists [155].  
 
Generic medicinal products have been described as products that  are equivalent to brand name 
products in terms of the strength of active pharmaceutical ingredients (API), dosage form, route 
of administration, quality, safety, efficacy, performance characteristics and therapeutic indication 
[151, 157]. However, generic products are typically sold at much lower prices than brand name 
products and therefore are more affordable than innovator products [151]. It has been reported 
that the low cost of generic pharmaceutical products is usually attributed to the fact that an 
Abbreviated New Drug Application (ANDA) process [151, 157] does not require the generic 
product manufacturer or sponsor to repeat costly and time-consuming clinical and non-clinical 
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studies on an API or dosage form (s) in order to demonstrate the safety and efficacy of the drug 
or drug product(s) in question [151, 157].  
 
Sponsors of generic drug products are required to satisfy specific criteria for the registration of 
generic drug products as set by relevant regulatory authorities such as, for example, the office of 
generic drugs of the Food and Drug Administration in the United States (FDA) [157], the 
European Agency for the Evaluation of Medicinal Products (EMEA) [158] and the Medicines 
Control Council (MCC) in South Africa [159].  
 
It has been argued that the time, risk and cost associated with the development of brand name 
pharmaceutical products are responsible for the high costs of innovator medicinal products [160]. 
According to a report compiled by the European Federation of Pharmaceutical Industries and 
Associations (EFPIA) [161], an average of between 12-13 years is required for a medicinal 
product to reach pharmacy shelves from discovery, costing an estimated € 870 million during the 
research and development (R&D) phase for a product [161]. Furthermore, the EFPIA report 
[161] alludes to the fact that only one (1) or two (2) out of ten thousand (10000) potential drug 
substances synthesized in laboratories are able to pass the extensive testing in the R&D stages of 
drug development to produce a marketable pharmaceutical product [161].  
 
As a consequence, innovator medicinal products are developed under patent protection, which 
protects the investment in the development of the drug product by giving the innovator company 
the sole right to sell the product while the patent is in effect [151, 157]. As a matter of interest, 
innovator pharmaceutical companies may apply and obtain patent rights from the United States 
Patent and Trademark Office at anytime during the lifetime of the drug or drug product [151]. 
When the intellectual property rights for a product have been exhausted, normally after a period 
of twenty (20) years from the date of filing for the patent [151, 160] generic medicinal product 
manufacturers may then apply to the relevant authorities, such as the  FDA for permission to 
produce and sell a generic version of the branded product [151, 157].  
 
Shargel and Kanfer [151] discussed various aspects that should be considered when selecting a 
generic drug product for manufacture. They [151] argue that the estimated sales volume for the 
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innovator product and the potential market share the manufacturer of the generic product expects 
to achieve once the multi-source product is manufactured and approved for marketing is the main 
driving force for the selection of drug candidates for generic product manufacture [151].  
 
Shargel and Kanfer [151] also argue that patent expiration and exclusivity as well as other legal 
issues must be considered carefully prior to selecting an innovator drug and/or drug product for 
generic manufacture. The manufacturers of a generic drug product will continue to face various 
legal and patent challenges from innovator companies, which in the opinion of Shargel and 
Kanfer hinder the entry of generic products into the marketplace [151].   
 
Eczema or dermatitis is a common dermatological disorder affecting approximately one-third of 
a given population [162] and may be defined as superficial inflammation of the skin, that is 
characterized histologically by epidermal oedema and clinically by vesicles, poorly marginated 
redness, oedema, oozing, crusting, scaling, pruritis and lichenification and that is usually caused 
by scratching or rubbing of the skin [163]. Hartshorne [162] reported that eczema is the most 
common skin condition in the RSA accounting for approximately 34.5%, 32.7%, 30.4% and 
17.8% of the dermatological outpatients in the coloured, black, Indian and white populations, 
respectively. Topical corticosteroid formulations such as creams or ointments applied three (3) 
times daily have been reported to be the primary therapy for the treatment of eczema [163, 164].  
 
Topical corticosteroids are, however, reportedly considered expensive for the majority of the 
population, and as a consequence the supplemental use of other substances such as white 
petrolatum and hydrogenated vegetable oil has been reported [163]. The high costs of therapy are 
especially a result of the use of super-potent topical corticosteroids such as clobetasol 17-
propionate (CP) that are required for the treatment of severe or chronic eczema, especially of the 
hands and feet (Section 1.5.2, Chapter 1). The elevated costs of super-potent topical 
corticosteroid products, such as CP, especially in developing countries such as the RSA, may be 
ascribed to the lack of a variety of generic versions of the product on the local market. For 
example, despite the expiration of the patent for CP in 1990 [165], only one generic version of 
Dermovate® cream and Dermovate® ointment (GlaxoSmithKline plc, Brentford, Middlesex, 
U.K) has been registered for marketing in the RSA [166].  
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The objective of these studies was therefore to design and develop a generic version of 
Dermovate® cream and to evaluate the product in terms of a number of in vitro performance 
characteristics. The successful development and subsequent determination of equivalence 
between the generic product and the innovator formulation in terms of in vitro performance 
characteristics would form the basis for future studies, such as the evaluation of bioequivalence 
of the generic CP product relative to Dermovate® cream, potentially resulting in the development 
of a marketable generic CP cream.     
 
It has been reported that pharmaceutical manufacturers frequently manufacture topical 
preparations of a drug in both cream and ointment vehicles to satisfy the preference of the patient 
and dermatologist [167]. It has been argued that many patients and physicians prefer creams to 
ointments, because the former are easier to apply and remove and may have a cooling sensation 
on the skin [167-170]. Ointments are usually more difficult to apply or to remove, but are 
expected to act as a barrier and increase the hydration of the skin [168].  
 
The development of a generic version of Dermovate® cream rather than Dermovate® ointment 
was  considered most appropriate, since it was assumed that a generic version of Dermovate® 
cream would have a larger market share than a generic Dermovate® ointment, based on patient 
preference for cream rather than ointment formulations.    
 
4.2. CREAM FORMULATIONS 
 
4.2.1. Overview 
 
Pharmaceutical emulsions have been described as systems that contain at least two immiscible 
liquids, such as an oil and water and in which one of the phases is dispersed as globules viz., the 
internal or dispersed phase, within the other phase viz., the external or continuous phase [168, 
171, 172]. Since emulsions are formed from two incompatible liquids, they are considered to be 
thermodynamically unstable colloidal systems and therefore usually require the addition of a 
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third component such as an emulsifying agent or surfactant to impart stability to the system [171, 
172].  
 
Emulsions are thermodynamically unstable since the two immiscible phases that exist in close 
conjunction impart a positive interfacial free energy to the emulsion system [171-173]. As a 
consequence of the positive interfacial free energy, the two immiscible liquids will always tend 
to divide into their separate components in an attempt to achieve thermodynamic equilibrium 
[173]. Therefore by use of an emulsifying agent, that is a compound possessing both polar and 
non-polar characteristics that aligns itself at the interface between the oil and water phases, the 
interfacial free energy between the phases can be reduced [171, 174]. The film structures formed 
by an emulsifying agent at the interface between phases forms the basis of homogenous and 
stable emulsions [171, 174].  
 
Emulsions may be classed as either oil-in-water (o/w) or water-in-oil (w/o) systems [168, 171-
173] and a schematic representation of such emulsions is depicted in Figure 4.1. Other types of 
emulsions that have been reported are the so-called multiple emulsions such as, for example, 
water-in-oil-in-water (w/o/w) emulsions [175-178] and oil-in-water-in-oil (o/w/o) emulsions 
[177-180]. Essentially, o/w emulsions contain oil droplets dispersed in an aqueous continuous 
phase, whereas w/o emulsions contain aqueous or polar droplets dispersed in an oily continuous 
phase [168, 171-173]. Molecules of an emulsifying agent assemble at the oil/water interface and 
the hydrophilic or polar group of the emulsifying agent is orientated towards the water phase and 
the hydrophobic or non-polar tail aligns itself towards the oil phase [171] as depicted in Figure 
4.1. 
 
Multiple emulsions such as w/o/w emulsions are emulsions in which a w/o emulsion is dispersed 
as droplets in an aqueous phase [175, 176, 178], whereas o/w/o emulsions occur as emulsions in 
which an o/w emulsion is dispersed in an oil phase [178-180]. In order to stabilize multiple 
emulsions, two surfactants are invariably used, with a hydrophobic surfactant designed to 
stabilize the interface of the w/o internal emulsion and a hydrophilic surfactant to stabilize the 
external interface of the oil globules for w/o/w multiple emulsions, and the converse is true for 
o/w/o multiple emulsions [178]. 
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Figure 4.1. Schematic representation of the principles of oil-in-water (o/w) and water-in-oil (w/o) 
emulsions (redrawn from 181).  
 
The most common type of emulsions used in dermatological therapy are creams [171]. Creams 
are described as emulsions of a semi-solid consistency [172, 182] or emulsions of a high 
apparent viscosity [172, 182] with a typical creamy white appearance [183] that are 
manufactured for topical application [172, 182]. However, more recently Buhse et al. [168] 
classified and reported creams as semisolid dosage forms that contain >20% water and volatile 
ingredients and/or <50% of hydrocarbon, wax or polyethylene glycol constituents as a vehicle 
and that are intended for external application to the skin. 
 
Buhse et al., [168] also described creams as semi-solid systems that display plastic flow 
behaviour and in total contrast to other semi-solid formulations such as ointment bases, creams 
exhibit two or more transition states when evaluated using thermogravimetric analysis (TGA). 
The transition states are indicative of a system composed of at least two phases and cream 
formulations can be classified as semi-solid systems that appear opaque, are viscous and have a 
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non-greasy to mildly greasy texture and tend to evaporate or get absorbed when rubbed onto the 
skin [168].  
 
Similar to liquid emulsions, creams usually contain a third component viz., an emulsion-
stabilizing system or an emulsifier [171]. However, in contrast to liquid emulsions, creams are 
reported to contain more emulsifier than that required to form a condensed monomolecular 
surfactant film at a droplet interface in liquid emulsions [172]. It has been argued that excess 
emulsifiers in cream formulations interact with other components of these formulations either at 
the droplet interface or in the bulk phase to produce complex, multiphase structures and these 
complex multiphase structures are reported to be essential for the formation of creams that are 
stable for extended periods of time [172] (Section 4.2.3.3., vide infra). 
 
Pharmaceutical creams may contain one or more APIs dissolved or dispersed in either an o/w or 
a w/o system [167]. Oil-in-water creams are usually referred to as “vanishing creams” as when 
rubbed into the skin the formulation disappears without leaving any trace of their presence on the 
skin [172].  
 
4.2.2. Instability mechanisms in creams 
 
4.2.2.1. Overview 
 
The physical instability of creams has been reported to occur through various time- and 
temperature-dependent physicochemical destabilizing mechanisms [171, 184-189] and these 
mechanisms are summarized schematically in Figure 4.2.  
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Figure 4.2. Schematic representation of the mechanisms by which creams show instability (adapted from 
184) 
 
4.2.2.2. Flocculation 
 
In order for a cream to form, two immiscible liquid phases must be mechanically agitated in the 
presence of an emulgent [171]. It has been reported that when agitation occurs in the absence of 
any form of interfacial stabilization both phases of the cream will form droplets that will rapidly 
flocculate and separate into two distinct phases [171, 184]. Flocculation may therefore be 
described as the close accumulation of two or more individual droplets of a dispersed phase to 
form loose assemblies or flocs, without loss of the interfacial film [171, 184]. In other words, in 
flocculated cream systems the single droplets of the dispersed phase become replaced by twin 
droplets or multiple flocs separated by a thin interfacial film [171, 184].  
 
It has been reported that flocculation occurs as a result of van der Waal’s attractive forces that 
take place in the absence of adequate repulsion between the droplets of the dispersed phase [171, 
184]. Usually, individual dispersed phase droplets move through the external phase due to 
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diffusion or agitation [184]. If resistance between the droplets is not sufficient, flocculation 
occurs and for example individual droplets may aggregate to form flocs [184] Flocculation does 
not lead to an increase in the average size of the emulsion droplets, indicating that individual 
droplets do not lose their integrity [186, 190].  
 
4.2.2.3. Coalescence 
 
The term coalescence is used to describe the aggregation of flocculated droplets into one large 
droplet [171]. It has been argued that thinning and/or disruption or loss of the interfacial film 
between approaching droplets in a cream layer is the main driving force for coalescence [171, 
184]. Tadros [184] reported that when two flocculated droplets are in close proximity to each 
other, the liquid surfaces undergo fluctuations forming what Tadros referred to as “waves”.  
 
The apices of these fluctuations become the point at which strong van der Waal’s forces of 
attraction are prevalent and when these fluctuations grow in amplitude the distance separating 
the apices of the interfacial film may reach a critical value that will cause the film to collapse 
[184]. Subsequently the two flocculated droplets combine to form a single larger droplet [184]. 
Unlike flocculation coalescence invariably leads to an increase in the average size of the droplets 
[186, 190] as seen in Figure 4.2.  
 
4.2.2.4. Creaming or sedimentation 
 
Creaming refers to the process by which buoyant droplets of a dispersed phase rise to the top of a 
container [184, 188, 189], and sedimentation takes place when dispersed droplets sink to the 
bottom of a container [184]. Creaming or sedimentation occurs due to differences in the densities 
of the dispersed and continuous phases [184, 188]. The dispersed phase is usually less dense than 
the continuous phase and therefore droplets will cream or sediment in a gravitational field [184, 
188]. Creaming or sedimentation does not involve an increase in the average size of the 
dispersed droplets, although both creaming and sedimentation may occur prior to coalescence, 
since coalescence requires the droplets of the dispersed phase to be in close proximity [186].  
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4.2.2.5. Ostwald ripening 
 
Another relatively important but often neglected cream or emulsion instability is known as 
Ostwald ripening [184-186, 190]. Ostwald ripening has been described as the growth of large 
emulsion droplets at the expense of smaller ones due to differences in the solubility [184] or the 
chemical potential [185, 186, 190] of small and large droplets. 
 
The difference in chemical potential arises from the difference in the radius of curvature of the 
droplets [184-186, 190]. Ostwald ripening may also be described as a mass transfer between 
drops of different curvatures through a surrounding continuous phase [185]. The chemical 
potential of a droplet is reported to increase with a decreasing radius of curvature and, as a 
consequence, the solubility of the dispersed material at the surface of the droplet also increases 
[185, 190].  
 
It follows that materials at the surface of smaller droplets tend to dissolve and subsequently 
diffuse through the continuous phase down a concentration gradient and are deposited on the 
surface of larger droplets [185, 186, 190]. As a result of mass transfer from small droplets to 
large droplets the small droplets shrink and ultimately disappear, whereas large droplets grow 
eventually leading to the formation of a cracked or separated cream [185, 186, 190].  
 
Ostwald ripening does not require the droplets to be in close proximity, since the process takes 
place by transport of dissolved matter from one droplet to another, through the external phase 
[186]. Ostwald ripening generally proceeds with the cube of the average radius of a droplet 
varying linearly with time and this is one of the reasons why Ostwald ripening is usually not 
considered as being an important phenomenon when considering macroemulsions, since droplets 
in macroemulsions have radii in excess of between 1-2 µm [190]. Nevertheless, Ostwald ripening 
is an important cause of instability in creams. 
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4.2.2.6. Phase inversion 
 
Phase inversion is a phenomenon that occurs when one of the two phases of a cream, for 
example the internal phase, becomes the external phase as the droplets of the internal phase 
coalesce faster than the droplets of the external phase [171]. Phase inversion may also be caused 
by an increase in the volume fraction of a dispersed phase or by a transition produced by 
changing temperature and/or the addition of an electrolyte to a previously stable cream 
formulation [184].  
 
4.2.3. Stabilization of creams 
 
4.2.3.1. Surfactants 
 
The physical instability of creams invariably occurs due to the tendency of formulations to revert 
back to the original distinct two phase systems that have a minimum interfacial free energy 
(Section 4.2.2) [186]. Since interfacial free energy is the driving force for the irreversible fusion 
of droplets as seen with flocculation and coalescence (Section 4.2.2), creams may be stabilized 
by the inclusion of an appropriate emulsion-stabilizing system that will concentrate at the oil-
water interface [172, 173].. The use of emulsion stabilization results in a lowering of the 
interfacial tension between oil and water phases [171, 182]. The stabilizing systems used in most 
creams consist of surfactants or surface active agents (SAA) or amphiphiles [191].  
 
SAA tend to settle at the boundary between two immiscible phases due to their chemical 
structure [182]. SAA are characterized by having two distinct regions in their chemical structure 
viz., a hydrophilic and hydrophobic region [182] as shown in Figure 4.1. The hydrophilic 
portions may be ionic or non-ionic, whereas hydrophobic regions are invariably saturated or 
unsaturated hydrocarbon chains or, less commonly, heterocyclic or aromatic ring structures 
[182]. Generally, SAA are classified according to the nature of the hydrophilic group, therefore 
SAA can be anionic, such as for example sodium alkyl sulphates, cationic, such as for example 
alkylammonium halides, or non-ionic, such as polyoxyethylene alkyl ethers or polysorbates [182, 
191].  
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Non-ionic SAA are reported to be the most widely used group of surfactants in cosmetic and 
pharmaceutical creams [182]. Non-ionic surfactants do not possess a charged group in their 
hydrophilic polar group, and therefore have a greater degree of compatibility with other 
components of cream formulations than do the ionic surfactants [182]. In addition non-ionic 
surfactants are reportedly less sensitive to changes in pH or to the addition of electrolytes, and 
when used in topical cream formulations non-ionic surfactants tend to cause less skin irritation 
than ionic surfactants [182]. However, it has been suggested that the main disadvantage of using 
non-ionic surfactants is that they tend to be more expensive than ionic surfactants [182].  
 
When incorporated into a cream formulation, the hydrophilic region of an SAA is orientated 
towards the aqueous phase and the hydrophobic portion towards the oil phase [171] (Figure 4.1). 
The resultant cream that is formed is either an o/w or a w/o emulsion and the specific 
configuration that is formed depends on the properties of the emulgent system used to stabilize 
the interface between the dispersed droplets and the continuous phase [171, 191]. The 
emulsification capacity of SAA is reported to be determined by the relative difference in the size 
and strength of the polar and non-polar groups that make up the molecule [182]. 
 
Oil in water creams are prepared if the hydrophilic characteristics of a SAA are slightly more 
dominant than the hydrophobic characteristics since the SAA molecule will orientate at the 
interface in such a way that the hydrophobic portion is forced to the centre  of the unit [171, 182] 
(Figure 4.1). Similarly, it has been reported that w/o creams are prepared if the hydrophobic 
properties of an amphiphile are slightly more dominant than the hydrophilic characteristics of 
that molecule [171, 182] (Figure 4.1).  
 
4.2.3.2. Mixed emulgents 
 
In the preparation of simple liquid emulsions, it has been suggested that surfactants alone can 
stabilize such formulations and mixtures of surfactants have the ability to form more stable 
emulsions than individual surfactants [171]. However the manufacture of a consistent cream 
product with a realistic shelf-life may only be achieved by incorporating a specific mixed 
emulsifying system into the cream formulation [173]. By definition, a mixed emulsifier is an 
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emulsifying system that consists of a combination of an ionic or non-ionic SAA and a fatty 
amphiphile, such as a fatty alcohol, fatty acid or monoglyceride [173]. 
 
The combination of a surfactant with a fatty amphiphile in the correct ratio is able to produce a 
powerful emulsifying system of the o/w type with excellent stabilization and thickening 
properties [172]. It has been suggested that nine (9) parts by weight of fatty alcohol to one (1) 
part by weight of an ionic surfactant (12:1 molar ratio) or four (4) parts by weight of a fatty 
alcohol to one (1) part by weight of a non-ionic surfactant (20:1 molar ratio) may also be used to 
prepare appropriate emulsifying blends for use in o/w creams [173]. The components of mixed 
emulsifying systems may be added to a cream formulation separately during the manufacturing 
process or alternatively as a previously blended mixture of emulsifying wax [172, 173].  
 
In its simplest form a cream consists of an oil phase, a water phase and a mixed emulsifying 
system [171, 192]. Commercial pharmaceutical o/w creams, however, are complex polydispersed 
systems usually manufactured with several emulgents which complement the properties of each 
other [172, 173]. Mixed emulgents that are used in  o/w creams are usually water-soluble and 
may consist of anionic or cationic SAA, such as sodium lauryl sulphate or cetrimide respectively, 
and/or a non-ionic SAA, such as cetomacrogol 1000 in combination with fatty amphiphiles 
[173].  
 
The amphiphiles are usually higher fatty alcohols having chain lengths of between fourteen (14) 
and eighteen (18) carbon atoms (C14 to C18) and may include substances such as cetyl, stearyl 
and cetostearyl alcohols, glycerol monosterate and stearic acid [172, 173]. Typical 
pharmacopoeial and commercially available emulsifying waxes and their respective 
compositions are summarized in Table 4.1 [172, 173].  
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Table 4.1. Pharmacopoeial and commercially available emulsifying waxes [172, 173] 
Emulsifying wax Constituents 
Emulsifying wax BP Cetostearyl alcohol and sodium lauryl sulphate 
Emulsifying wax USNF Cetostearyl alcohol and polysorbate-60 
Cationic emulsifying wax BPC Cetostearyl alcohol and cetrimide 
Cetomacrogol emulsifying wax BPC Cetostearyl alcohol and cetomacrogol-1000 
Glyceryl monostearate S.E. Glycerol monostearate and sodium citrate 
Lecithin Phosphatidylcholine, phosphatidylethanolamine,   
phosphatidylinositol and phosphatic acid 
 
4.2.3.3. Theory of cream emulsification 
 
It has been argued that a reasonable and coherent explanation for the manner in which mixed 
emulsifiers or emulsifying waxes stabilize oil droplets and control the consistency of o/w creams 
may be given using the gel network theory of emulsion stability [171-173]. The gel network 
theory relates the consistencies and stabilities of o/w creams to the presence or absence of 
crystalline viscoelastic gel networks in the external phase of cream formulations [171-173].  
 
The amount of mixed emulgent added to an o/w semi-solid pharmaceutical cream is usually in 
excess of that required to form a monomolecular interfacial film in a simple model emulsion 
[171, 173]. The surplus emulsifying wax in a cream formulation interacts with the aqueous 
continuous phase to form strong crystalline viscoelastic gel networks at the oil-water interface of 
the dispersed droplet [171, 173]. In general, the gel network theory illustrated schematically in 
Figure 4.3 implies that a cream formulated to contain a mixed emulsifier system consisting of 
combination of a fatty amphiphile, such as cetostearyl alcohol, and an ionic or a non-ionic 
surfactant may be composed of at least four (4) phases [171, 173] viz.: 
 
a) a bulk water phase, 
b) a dispersed oil phase, 
c) a crystalline hydrate phase, 
d) a crystalline gel phase. 
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Figure 4.3. Illustration of the gel network theory (adapted from 171). 
 
Eccleston [173] reported that fatty amphiphiles such as cetostearyl alcohol usually exhibit 
marked crystalline polymorphism and have the capacity to form an α-crystalline polymorph 
under specific conditions. Eccleston [173] argued that in the α-form, the hydrocarbon chains of 
the amphiphile are hexagonally packed and there is a rotation about the long axis of the 
molecule. Eccleston [173] further argued that in the presence of water (a) the α-crystalline 
polymorph will form hydrated crystalline phase (b) in which the thickness of the water layers 
incorporated in the polar groups of the amphiphile is approximately eighteen (18) Å and is 
limited by the considerable strength of the van der Waal’s attractive forces balancing osmotic 
repulsion in the system.  
 
The presence of very small quantities of ionic or non-ionic surfactant affect the degree of 
swelling in the system and the swelling is enhanced giving rise to a swollen crystalline gel phase 
(d) [172].. The swelling capacity of the crystalline gel phase depends on the hydrophilic 
properties of the intrinsic polar groups of the amphiphile used in the emulsifier system [171]. It 
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has been suggested that the gel phase is characterized by a lamellar structure of alternating 
bilayers of fatty amphiphile and surfactant separated by layers of interlamellar and fixed water 
[171, 173].  
 
The swelling properties and the concentration of the crystalline gel phase are factors that dictate 
the overall consistency of a cream structure [171, 172]. The interlamellar-fixed water located 
between the bilayers of the gel and crystalline hydrate phases enhances the volume ratio of the 
dispersed phase to the free bulk water phase, resulting in stiffening of the system [173]. In order 
to maintain the stability of a system it is vital to maintain a dynamic equilibrium between the 
fixed water in the interlamellar gel and the bulk water phases [171, 172]. 
 
At low mixed emulsifier concentrations, such as for example 2-4% w/w, stiffening is sufficient 
to produce a structured lotion [173]. However, at high mixed emulsifier concentrations, such as 
for example > 4% w/w, the crystalline hydrate and the gel phases link to form strong a crystalline 
viscoelastic gel phase and the system becomes a structured semi-solid cream [173]. 
 
The swelling capacity of the α-crystalline polymorphic form of an amphiphile that leads to the 
formation of the crystalline viscoelastic gel phase is greater in the presence of ionic surfactants 
than in the presence of non-ionic surfactants [171]. This has been ascribed to that fact that 
swelling in the presence of an ionic surfactant is due to an electrostatic phenomenon, whereas in 
the presence of a non-ionic surfactant, swelling is attributed to hydration of the polyoxythylene 
chains of the surfactant and is usually limited by the length of the chain [171]. Nevertheless, the 
underlying principles of the gel network theory apply whichever surfactant and fatty amphiphile 
is used, albeit to different extents [173].  
 
The gel network theory reveals that mixed emulsifiers through swelling of the α-crystalline form 
of an amphiphile and subsequent formation of crystalline viscoelastic gel networks introduce an 
electrostatic repulsive force between dispersed droplets [173]. Consequently, there is a reduction 
in van der Waal’s forces of attraction between dispersed oil droplets which subsequently 
prevents or delays the processes of flocculation, coalescence and/or Ostwald ripening (Section 
4.2.2) from occurring [173]. Furthermore, the resultant stiffening of a cream structure due to the 
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formation of a crystalline viscoelatic gel phase invariably inhibits or reduces creaming or 
sedimentation (Section 4.2.2) in a cream formulation [184].  
 
The formation of a crystalline viscoelastic gel network phase in a cream formulation is 
dependent on the type of amphiphile and the nature of the ionic or non-ionic surfactant, the 
concentration of the mixed emulsifier and the molar ratios of amphiphile to surfactant used in 
that formulation [173]. 
 
4.2.3.4. Hydrophilic-lipophilic balance (HLB) 
 
Sections 4.2.3.2 and 4.2.3.3 report that the physical stability of pharmaceutical creams may be 
best achieved using mixed emulsifiers rather than by use of a single SAA. In addition the 
components of a mixed emulsifier may be added separately to a cream formulation during 
manufacture, or alternatively as a previously blended emulsifying wax (Table 4.1). When the 
components of a mixed emulsifier system are added separately, it is vital that the formulation 
scientist determines the appropriate ratio of each component necessary to produce a physically 
stable cream [182]. 
 
The relative quantities of individual emulgents may be calculated using a tool referred to as the 
hydrophilic-lipophilic balance (HLB) [171, 182]. Essentially each emulgent is allocated an HLB 
number representing the relative balance between the hydrophilic and lipophilic characteristics 
within a SAA molecule [171, 182]. The HLB number is an arbitrary value ranging between 0-20, 
which is then assigned to a particular SAA [171].  
 
According to the HLB system, hydrophilic surfactants have high HLB values, whereas 
hydrophobic surfactants have low HLB values [171, 182]. Generally emulgents with HLB values 
ranging between 4-6 are w/o emulsifiers and the use of these emulsifiers tends to favour the 
formation of w/o creams [171, 182].  SAA with HLB values ranging between 8-18 are reported 
to be o/w emulsifiers and their use will favour the formation of o/w creams [171, 182]. Although 
the HLB system was originally applied to non-ionic SAA its successful use has been extended 
and applied to ionic emulgents [182].  
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The HLB number of a polyoxyethylene-based non-ionic SAA may be calculated using Equation 
4.1 [171]: 
 
5
% cgrouphydrophobimolHLB =   Equation 4.1. 
  
The HLB value of a polyhydric alcohol fatty acid ester, such as glyceryl monostearate may be 
derived from Equation 4.2 [171]: 
 
⎟⎠
⎞⎜⎝
⎛ −=
A
SHLB 120     Equation 4.2. 
 Where, 
 S = the saponification value of the ester 
 A = the acid value of the fatty acid 
 
When it is impossible to obtain a saponification value of a compound as is the case with lanolin 
derivatives, the HLB may be calculated using Equation 4.3 [171]:  
 
⎟⎠
⎞⎜⎝
⎛ +=
5
PEHLB     Equation 4.3. 
 
Where, 
 E = the weight percent (wt %) of the polyoxyethylene chain 
 P = the wt % of the polyhydric alcohol group 
 
When using a mixed emulsifier system, the overall HLB value of a surfactant mixture (HLBM) 
may be calculated using Equation 4.4 [171]:  
 
( ) BAM HLBffHLBHLB −+= 1   Equation 4.4. 
Where, 
 f = the weight fraction of emulsifier A. 
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The HLB system and theory may be used as an approximation in the design of a cream 
formulation, however the stability of a cream may not be guaranteed by the use of a mixed 
emulsifier system with an appropriate HLB value [171]. This is more than likely due to the fact 
that a typical destabilization process, such as for example creaming, may be much more 
dependent on other variables, such as viscosity of the continuous phase, rather than the 
characteristics of the interfacial film [171]. Thus such factors should be taken into consideration 
when designing complex pharmaceutical cream formulations. 
 
4.3. EXPERIMENTAL 
 
4.3.1. Characterization of CP creams 
 
4.3.1.1. Overview 
 
Prior to the development of a generic CP cream formulation, it was considered essential to select 
physicochemical quality control tests for use in conjunction with an in vitro release test method 
(Chapter 3) to characterize the commercial and extemporaneously manufactured CP cream 
formulations. In addition the assessment of quality and consistency of extemporaneously 
manufactured CP topical formulations form an integral part of formulation development studies.  
 
Physicochemical tests such as the determination of solubility, particle size, size distribution and 
crystalline form of an API and evaluation of the intrinsic viscosity and homogeneity of cream 
products, have been traditionally used to provide reasonable evidence of consistent product 
performance (Chapter 3). However, for the purposes of these studies, innovator and generic 
cream products were characterized for CP content, apparent intrinsic viscosity, pH and in vitro 
release.  
4.3.1.2. Assay of CP content 
 
The United States Pharmacopoeia (USP) [23] specifies that CP cream formulations should 
contain not less than 90.0% and not more than 115.0% of the labelled amount of CP. As a 
consequence, it was considered essential to assay CP content in all generic formulations 
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manufactured extemporaneously in these studies in order to ensure that the formulations 
manufactured contained CP within this specified range. The CP content of all extemporaneously 
manufactured and innovator cream products was assayed using the sample preparation procedure 
described in Section 2.4.6.2 (Chapter 2) and as illustrated in Figure 2.7 (Chapter 2). 
 
4.3.1.3. Intrinsic viscosity  
 
The intrinsic viscosity of a semi-solid formulation invariably affects the rate and extent of release 
of an active pharmaceutical ingredient (API) from a vehicle (Section 3.3.2.3). Therefore, the 
evaluation of the intrinsic viscosity values of extemporaneously manufactured generic CP cream 
products and the intrinsic viscosity value of the innovator product was considered essential in 
these studies.  
 
Any similarity or difference in the intrinsic viscosity values between the innovator and 
extemporaneously manufactured CP cream products may be used as a basis for the discussion of 
similarity or differences in the in vitro release rates of CP from the generic and innovator cream 
products.  
 
The intrinsic viscosity values of all extemporaneously manufactured CP products and the 
intrinsic viscosity value of the innovator formulation were measured as described in Section 
3.3.2.3.2. 
 
4.3.1.4. pH-determination 
 
The pH of dermatological semi-solid vehicles has been reported to affect the extent of 
dissociation of ionisable API molecules and therefore the thermodynamic activity of the API, 
partitioning and skin penetration [193]. CP is a non-ionisable molecule and does not dissociate 
(Section 1.3.2). Therefore, it is highly unlikely that the pH of a CP topical formulation would 
affect the release rate of CP from the vehicle or penetration and partitioning of CP into the skin.  
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Healthy human skin reportedly has a surface pH that ranges between 4-6 [193, 194] and a pH 
gradient exists within the skin [193]. Although the pH of a topical formulation of CP may not 
have any influence on the performance characteristics of the product, it was nevertheless 
considered vital to develop a drug delivery system that would be pH-sensitive to the human skin. 
Consequently the pH of the innovator and extemporaneously manufactured cream formulations 
was determined to ensure that the manufactured products had an appropriate pH. 
 
The pH of extemporaneously manufactured CP cream formulations and the innovator product 
was measured using a Model GLP 21 Crison pH meter (Crison Instruments, Barcelona, Spain). 
The pH was evaluated using 100 g of the cream and the measurements were taken within twenty-
four (24) hours of manufacture of the extemporaneous formulations. The pH measurements were 
recorded in triplicate to generate an average pH value for each formulation.  
 
4.3.1.5. In vitro release rate  
 
The role of in vitro release rate testing during the development of topical semi-solid formulations 
has been discussed in Chapter 3. In this chapter the equipment and conditions suitable for 
assessing the in vitro release rate of CP from cream formulations were developed and validated. 
The in vitro release test was essentially used as a marker for the successful development of the 
generic cream formulation relative to the commercially available innovator product (Dermovate® 
cream). Furthermore, the in vitro release test was used to determine batch-to-batch consistency 
as well as in the evaluation of cream formulations used in accelerated stability studies (Chapter 
5).  
 
The in vitro release studies were conducted using the in vitro release test conditions presented in 
Table 3.5 (Section 3.2.12). In vitro release rate profiles of CP were plotted as cumulative amount 
of CP released per unit area (Q) vs. the square root of time (t1/2) or Q vs. t1/2 (Section 3.3.1). 
Similarities or differences in the in vitro release rates of CP from the test formulations (generic 
products) vs. Dermovate® cream were determined theoretically using Q and flux values (Section 
3.3.1) and statistically using a non-parametric test which was described and reported in Section 
3.2.11.  
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4.3.2. Innovator product characterization 
 
4.3.2.1. Overview 
 
Kanfer et al. [195] suggest that during the development of a generic drug product, it may be 
beneficial to critically evaluate the innovator product with respect to qualitative and/or 
quantitative assessments. Thus, prior to the development of a generic CP cream formulation, the 
in vitro performance characteristics of the innovator product were evaluated and the data 
generated from these studies were used as a general guide for the successful development of a 
generic formulation. The purpose of conducting these studies was to ensure that the in vitro 
performance characteristics of the generic CP cream formulations produced during the 
development phase were equivalent to those of the innovator product.  
 
4.3.2.2. Qualitative composition 
 
The formulator of a generic product may consider using the same or similar inactive excipients 
as in the innovator product [151]. Consequently, as part of the characterization phase of 
Dermovate® cream, it was considered essential to evaluate the qualitative composition of the 
product, as this could give an indication of the inactive excipients that could be considered for 
use in the formulation of a generic CP cream product. The qualitative composition of 
Dermovate® cream [196] is listed in Appendix 2.  
 
4.3.2.3. CP content 
 
Dermovate® cream was assayed for CP content using the sample preparation procedure described 
and reported in Section 2.4.6.2 and from these studies, Dermovate® cream was found to have a 
CP content of 103.9 ± 2.797% (2.69% RSD) (n = 3). These data reveal that Dermovate® cream 
complies with the USP specifications for clobetasol proprionate cream [23], which states that 
formulations should contain not less than 90.0% and not more than 115.0% of the labelled 
amount of CP. The small % RSD is indicative of the homogeneity of the product and the 
precision of the analytical method. 
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4.3.2.4. Intrinsic viscosity 
 
The intrinsic viscosity of Dermovate® cream was measured as described in Section 3.3.2.3.2 and 
it was found that Dermovate® cream has an apparent intrinsic viscosity value of 44.467 ± 1.026 
KcP (2.31% RSD) (n = 3). The measurements were recorded at room temperature (22˚C).  
 
4.3.2.5. pH-determination 
 
The apparent pH of Dermovate® cream was determined at room temperature (22˚C) as described 
in Section 4.3.1.4 and from these studies, it was found that Dermovate® cream has an apparent 
pH value of 5.05 ± 0.0321 (0.00637% RSD) (n =3). These data reveal that the apparent pH of 
Dermovate® cream lies within a pH range of between 4-6, which is considered to be the pH 
range of a healthy human skin (Section 4.3.1.4).  
 
4.3.2.6. In vitro release rate studies 
 
The in vitro release rate of CP from Dermovate® cream was assessed using the in vitro release 
test conditions described in Table 3.5 and the resultant in vitro release rate profile of CP from 
Dermovate® cream plotted as Q vs t½ is shown in Figure 4.4. These data reveal that the 
cumulative amount of CP released (Q) over the 72-hour in vitro release studies was 36.69 ± 
5.720 µg/cm2, which was equivalent to a cumulative % release of 24.19 ± 3.750%. The average 
in vitro release rate of CP from Dermovate® cream or flux (n = 6) was found to be 4.924 
µg/cm2/hr1/2. 
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Figure 4.4. In vitro release rate profile for CP from Dermovate® cream (n = 6) 
 
The in vitro release rate or flux of CP from Dermovate® cream of 4.924 µg/cm2/h1/2 appears to be 
fairly slow. Moreover the extent of CP release of 36.69 ± 5.720 µg/cm2 or 24.19 ± 3.750% seems 
to be low considering the fact that the experiments were conducted over a 72-hour time period. 
The apparent slow in vitro release rate of CP from Dermovate® cream and the relatively small 
cumulative amount of CP released over the 72-hour experiment may be attributed to the 
seemingly high apparent intrinsic viscosity value of Dermovate® cream (Section 4.3.2.4).  
 
CP release from Dermovate® cream formulation, however, appears to fit the Higuchi model 
described and reported in Section 3.2.8.2. According to the Higuchi model, a plot of Q vs. t1/2 
would be linear for a drug in suspension in a semi-solid matrix with an infinite dose application 
provided that such release is diffusion-controlled by the matrix material that comprises the semi-
solid dosage form. Therefore, judging from the R2 value viz., R2 = 0.9941 shown in Figure 4.4, 
CP release from Dermovate® cream may be diffusion-controlled.  
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4.3.3. Generic product development 
 
4.3.3.1. Overview 
 
In order to gain market approval, a generic product cannot be superior to or better than the 
innovator product against which it is tested and the product must meet certain criteria [151] to be 
considered bioequivalent and therefore therapeutically equivalent to the brand name product 
[151]. During the development of generic drug product formulations, it is vital to ensure that the 
developed formulation will have the same therapeutic efficacy, safety and performance 
characteristics as the innovator product it is tested against [151].  
 
Although the objective of the current research work was not to determine bioequivalence or 
therapeutic equivalence of the extemporaneously manufactured generic CP cream formulation 
relative to Dermovate® cream, it was vital to ensure that the generic formulation was at least 
equivalent to the innovator cream product in terms of the in vitro tests conducted on these 
products.  
 
Essentially formulation development studies for the generic CP cream product were comprised 
of three stages: 
 
a) Preliminary studies for which the objective was to manufacture a formulation that 
remained physically stable for at least twenty-four (24) hours after manufacture.  
b) In vitro release studies for which the objective was to establish whether the 
formulation tested had an in vitro release rate that was similar to that of the innovator 
product. 
c) Characterization of the generic formulation for that formulation that had an in vitro 
release rate profile similar to that of the branded product.  
 
In addition, the best generic CP formulation was then manufactured on a relatively larger scale to 
produce a batch with a sufficient number of samples for accelerated stability studies. The 
purpose of the latter studies was to determine whether the formulation development process was 
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successful in producing a stable generic CP cream product. The data generated from these 
studies are described and reported in Chapter 5 vide infra.  
 
4.3.3.2. Excipients 
 
4.3.3.2.1. Overview 
 
The excipients used in formulation development studies of generic CP cream products and their 
sources are listed in Appendix 3. The physicochemical characteristics and functions of each 
excipient used in these formulation development studies are described in detail in the following 
Sections.  
 
4.3.3.2.2. Clobetasol 17-propionate 
 
The description, physicochemical characteristics, structural activity relationships, clinical 
pharmacology and pharmacokinetic aspects of clobetasol 17-propionate (CP) have been reported 
and described previously (Chapter 1).  
 
4.3.3.2.3. Propylene glycol  
 
Propylene glycol, chemically known as 1,2-propanediol, has been described as a clear, 
colourless, viscous liquid with a sweet, slightly acrid taste resembling that of glycerin [19, 140, 
197, 198]. Propylene glycol may be used as a preservative, humectant, plasticizer, solvent or 
stabilizer in a variety of pharmaceutical formulations [19, 140]. However in these studies 
propylene glycol was used mainly as a water-miscible co-solvent for CP. Propylene glycol has a 
better ability than glycerine to dissolve drugs such as the corticosteroids [140, 198]. Propylene 
glycol is generally regarded as a relatively non-toxic material and is considered to be minimally 
irritant when used in topical formulations [19, 140]. Propylene glycol has also been reported to 
be chemically stable when stored in well-closed containers at cool temperatures [197, 140]. 
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4.3.3.2.4. Sodium citrate 
 
Sodium citrate is the non-proprietary name for sodium citrate dihydrate [199] and occurs as 
odourless, colourless, monoclinic crystals or as a white crystalline powder with a cooling saline 
taste [19, 199]. The solubility of sodium citrate dihydrate has been reported to be 1 in 1.5 parts of 
water at room temperature (20˚C) [19, 197, 199] and 1 in 0.6 parts of boiling water (100˚C) [19, 
199]. Sodium citrate is generally regarded as a stable, non-toxic and non-irritant excipient that 
can be used as a pH adjusting agent [199]. Sodium citrate was used as a pH adjusting agent to 
adjust the pH of the CP cream formulations.   
 
4.3.3.2.5. Citric acid 
 
Citric acid is also known as citric acid monohydrate and occurs as colourless or translucent 
crystals, or as a white crystalline efflorescent powder [19, 200]. Citric acid is odourless [19, 200] 
and has a strong acidic taste and an orthorhombic crystal structure [200]. The solubility of citric 
acid is 1 in less than 1 part of water at room temperature (20˚C) [19, 197, 200]. Citric acid was 
used in conjunction with sodium citrate as a buffering agent [200].  
 
4.3.3.2.6. Geleol® 
 
Geleol® (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for glyceryl 
monostearate.  Glyceryl monostearate is a white or almost white to cream-coloured, wax-like 
solid in the form of beads, flakes or powder [19, 201]. Glyceryl monostearate is waxy to the 
touch and has a slight fatty odour and taste [19, 201]. Commercially available glyceryl 
monostearate contains a mixture of variable proportions of glyceryl monostearate and glyceryl 
monopalmitate [19, 201]. Glyceryl monstearate is insoluble in water but is soluble in mineral and 
fixed oils [19, 201]. Glyceryl monostearate can be used as an emollient, emulsifying agent, 
solubilising agent and/or stabilizing agent in topical pharmaceutical formulations, [201].  
 
Glyceryl monostearate and other fatty acid monoesters are however reported to be inefficient 
emulsifiers, but may be useful emollients that can be readily emulsified by common emulsifying 
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agents by the addition of other fatty materials to a formulation [19, 201]. When incorporated in 
topical formulations, glyceryl monostearate is generally regarded as a non-toxic and non-irritant 
material [201] and should be stored in a tightly closed container in a cool, dry place protected 
from light [201]. Self-emulsifying grades of glyceryl monostearate are available and have been 
reported to be incompatible with acidic substances [201]. Glyceryl monostearate has a melting 
point of ≥ 55˚C [19, 201].  
 
4.3.3.2.7. Cetostearyl alcohol 
 
Cetostearyl alcohol occurs as a white or cream-coloured unctuous mass or as almost white flakes 
or granules and has a faint characteristic sweet odour [19, 202]. When heated, cetostearyl alcohol 
melts to a clear, colourless or pale yellow-coloured liquid that is free of suspended matter [19, 
202]. Cetostearyl alcohol is practically insoluble in water and is soluble in oils [19, 197, 202]. 
Cetostearyl alcohol may be used as an emollient, emulsifying agent or as a viscosity-increasing 
agent in semi-solid formulations [19, 202].  
 
Cetostearyl alcohol has been used to increase the viscosity of topical pharmaceutical 
formulations and imparts body to both w/o and o/w creams [19, 202]. Furthermore cetostearyl 
alcohol stabilizes creams and can act as a co-emulsifier, thereby reducing the amount of 
surfactant required to form a stable emulsion [202]. When used in combination with surfactants, 
cetostearyl alcohol forms creams with very complex microstructures, including liquid crystals, 
lamellar structures and gel phases (Section 4.2.3.3) [202].  
 
Cetostearyl alcohol is stable when stored in a well-closed container in a cool, dry place [202]. 
Cetostearyl alcohol is incompatible with strong oxidizing agents and metal salts, but is generally 
a non-toxic material [202] and has a melting range of between 49-56˚C [19, 202] or between 48-
55˚C [19].  
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4.3.3.2.8. White beeswax 
 
White beeswax is a chemically bleached form of yellow beeswax [19, 197, 203] and occurs as 
tasteless, white or yellow or slightly yellow-coloured sheets or fine granules with some 
translucence [203]. White beeswax has an odour similar to that of yellow beeswax although the 
odour is less intense [203]. White beeswax is practically insoluble in water, but soluble in fixed 
and volatile oils and can be used as a stabilizing and stiffening agent in semi-solid formulations 
[19, 197, 203]. White beeswax stabilizes w/o emulsions [203] and increases the consistency of 
semi-solid formulations, such as creams and ointments [19, 197, 203].  
 
White beeswax is a non-toxic and non-irritant material [203], however hypersensitivity which 
has been ascribed to contaminants in the wax has been reported [19, 203]. White beeswax is 
incompatible with strong oxidizing agents and is stable when stored in well-closed containers 
protected from light [203]. White beeswax has a melting point range of between 61-65˚C [19, 
197, 203] and when heated to above 150˚C esterification occurs with a consequent lowering of 
the acid value and elevation of the melting point of the material [203]. 
 
4.3.3.2.9. Chlorocresol 
 
Chlorocresol occurs as colourless or almost colourless dimorphous crystals or as a crystalline 
powder with a characteristic phenolic odour [19, 197, 204]. Chlorocresol is soluble as 1 in 260 
parts of water at room temperature (20˚C) [19, 197, 204] and 1 in 50 parts of boiling water [19, 
204] and is soluble in fixed oils [19, 197, 204]. Chlorocresol is primarily used as a preservative 
in topical formulations and has bactericidal activity against both Gram-positive and Gram-
negative organisms, spores, moulds and yeasts [19, 197, 204]. Chlorocresol is stable at room 
temperature (22˚C) and should be stored in a well-closed container, protected from light, in a 
cool, dry place [204]. Chlorocresol on contact with strong alkali agents produces heat and fumes 
that ignite explosively [204]. The melting point range of chlorocresol is between 55.5-65˚C [204] 
or between 63-67˚C [19] 
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4.3.3.2.10. Estol® 1474 
 
Estol® 1474 (Uniqema (Pty) Ltd, Bryanston, Johannesburg, Gauteng SA) is the proprietary name 
for glyceryl stearate. Estol® 1474 is a white powder at 25˚C [205] and is reported to be oil 
soluble and has an HLB value of 2.0-3.0 [205, 206]. According to the manufacturers of Estol® 
1474 the material may be used as an emulsifier for o/w or w/o creams and can modify the 
consistency of such formulations thereby increasing the stability of cream products [205]. 
 
4.3.3.2.11. Ritapro® 200 
 
Ritapro® 200 (Rita, Crystal Lake, IL, USA) is the proprietary name for an emulsifying wax 
containing a mixture of stearyl alcohol and ceteareth-20 [207]. Ritapro® 200 is sold as a white 
flaky or wax-like material and is odourless [207]. Ritapro® 200 may be used as an emulsifier for 
o/w creams and has a melting range of between 55-63˚C [207]. 
 
4.3.3.2.12. Emulcire® 61 WL 
 
Emulcire® 61 WL (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name for a 
self-emulsifying wax containing a mixture of cetyl alcohol, ceteth-20 and steareth-20 [208, 209]. 
Emulcire® 61 WL is sold as white pellets [209] and has a melting range of between 45.6-50.5˚C 
[208]. Emulcire® 61 WL is considered to be an o/w emulsifier that may be used for emulsifying 
difficult-to-formulate, unstable active ingredients and can yield creams with excellent heat 
stability [208]. 
 
4.3.3.2.13. Gelot® 64 
 
Gelot® 64 (Gattefossé SAS, Saint-Priest Cedex, France) is the proprietary name of a self-
emulsifying base containing a mixture of glyceryl monostearate and polyethylene glycol-75 
stearate (PEG-75 stearate) [208]. The physical appearance of Gelot® 64 has not been reported but 
visual observation of Gelot® 64 reveals that the material occurs as yellow or off-yellow pellets. 
Gelot® 64 has a melting range of 55.5-62.5˚C [208] and is an o/w emulsifier that may be used for 
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emulsifying difficult-to-formulate, unstable active ingredients and can yield creams with 
excellent heat stability [208]. 
 
4.3.4. Formulation composition 
 
All formulation compositions developed and tested during the development of generic CP cream 
are listed in Table 4.2. The qualitative and quantitative formulae were adapted from a published 
formulation [210] which is listed in Appendix 4. The main modification made to the formulation 
summarized in Appendix 4 was the use of different primary mixed emulsifiers. 
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Table 4.2. Percentage composition of generic CP cream formulations developed and assessed in these studies  
Component # Excipient CP001   CP002 CP003 CP004 CP005 CP006 
1 Clobetasol 17-propionate 0.05000 0.05000 0.05000 0.05000 0.0500 0.0500 
2 Propylene glycol    44.50 44.50 44.50 44.50   44.50   44.50 
3 Sodium citrate 0.05000 0.05000 0.05000 0.05000 0.0500 0.0500 
4 Citric acid 0.050000 0.050000 0.050000 0.050000 0.0500 0.0500 
5 Geleol® pastilles 5.000 5.000 5.000 5.000 5.000 5.000 
6 Cetostearyl alcohol 4.000 4.000 4.000 4.000 4.000 4.000 
7 White beeswax BP 0.6000 0.6000 0.6000 0.6000 0.6000 0.6000 
8 Chlorocresol 0.07500 0.07500 0.07500 0.07500 0.07500 0.07500 
9 Estol® 1474* 1.000 - - - - - 
10 Ritapro® 200* - 1.000 - - - - 
11 Emulcire® 61 WL* - - 1.000 - - - 
12 Gelot® 64* - - - 1.000 1.000 1.000 
13 Propylene glycol 7.000 7.000 7.000 7.000 7.000 7.000 
14 Propylene glycol 2.675 2.675 2.675 2.675 2.675 2.675 
15 Purified water 35.00 35.00 35.00 35.00 35.00 35.00 
 
* Primary emulsifier 
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4.3.5. Manufacturing methods 
 
4.3.5.1. Overview 
 
Generic CP cream formulations were manufactured using a manufacturing process adapted from 
a manufacturing method that has been published [210]. This method of manufacture was used for 
the preparation of all CP cream formulations developed and tested in these studies and is 
described in the following sections and illustrated in Figure 4.5. All items were weighed using a 
Model AE-163 Mettler top-loading analytical balance (Mettler Instruments, Zurich, 
Switzerland).  
 
4.3.5.2. Aqueous phase 
 
Purified water (item 15) was heated to 90˚C in a beaker using a Model RCH IKA-Combimag 
hotplate magnetic stirrer (Jankel & Kunkel KG, Staufen, Germany). The temperature of the 
heated purified water was brought down to and maintained at 60˚C using a Model NB-34980 
Colora Ultra-Thermostat water bath (Colora, Lorch, Germany) that had been previously set at 
60˚C. Sodium citrate and citric acid (items 3 and 4) were dissolved in item 15 at 60˚C and the 
resultant solution was mixed with propylene glycol (item 2). The temperature of the aqueous 
phase was maintained at 60˚C using the water bath. 
 
4.3.5.3. Oil phase 
 
Geleol® pastilles (item 5) and Estol® 1474 (item 9) or Ritapro® 200 (item 10) or Emulcire® 61 
WL (item 11) or Gelot® 64 (item 12) were melted together with cetostearyl alcohol (item 6), 
white beeswax BP (item 7) and chlorocresol (item 8) while stirring in a beaker previously heated 
to and maintained at 75˚C using the IKA-combimag hotplate magnetic stirrer (Section 4.3.5.2). 
Once melted, the temperature of the molten oil phase was allowed to cool to 60°C and was 
maintained at that temperature using a Colora Ultra-Thermostat water bath (Section 4.3.5.2). 
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4.3.5.4. Dispersed phase 
 
The aqueous phase (Section 4.3.5.2) was then transferred to the oil phase (Section 4.5.5.3) 
maintained at 60˚C. The mixture was stirred manually with a glass stirring rod for ten (10) 
minutes at that temperature and was then homogenized at approximately 15,000 rpm using a 
Model 6-105 AF Virtis homogenizer (Virtis Co., Gardiner, N.Y. USA) for five (5) minutes. The 
temperature of the mixture was allowed to cool to 50˚C while stirring manually with the 
manufacturing beaker placed in a water bath at 20˚C.  
 
4.3.5.5. Drug phase 
 
Clobetasol (item 1) was mixed with propylene glycol (item 13) in a beaker and sonicated using a 
Model 8845-30 ultrasonic bath (Cole-Parmer Instrument Co., Chicago, IL, USA) for 
approximately twenty-five (25) minutes or until a clear solution was obtained. The solution was 
heated to and maintained at 50˚C using a Colora water bath. Once the temperature of the solution 
had reached 50˚C the solution was added to the dispersed phase (Section 4.3.5.4) whilst 
maintaining the temperature at 50˚C. The beaker that had previously contained the drug phase 
was rinsed with propylene glycol (item 14), which had been heated and maintained at 50˚C. The 
rinse solution was added to the dispersed phase (Section 4.3.5.4) and the mixture was manually 
mixed for a further ten (10) minutes and then homogenized at 15,000 rpm for an additional five 
(5) minutes at 50˚C.  
 
4.3.5.6. Cream formulation 
 
The formulation prepared as described in Section 4.3.5.5 was cooled to 30˚C with continual 
manual stirring with the manufacturing beaker placed in a water bath at 20˚C. After cooling, the 
cream was passed through a Model-HO valve type of homogenizer (Erweka-Apparatebau, 
G.m.b.H, Heusenstamm, Germany) in order to generate a smooth formulation of improved 
consistency. The cream was then packaged into 100 g ointment jars and stored at room 
temperature (22˚C) until required for further analysis. 
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Figure 4.5. Schematic illustration of the manufacturing method for the CP cream formulation 
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4.3.6. Preliminary studies 
 
In the preliminary stages of these studies, the objective was to manufacture a CP cream 
formulation extemporaneously that showed no visible signs of physical instability, such as, for 
example, cracking, creaming, phase inversion and/or bleeding of the cream base from the 
container. Physical instability was evaluated immediately after manufacture and then twenty-four 
(24) hours after manufacture and storage at room temperature (22˚C). Initial formulation 
development was undertaken on small batches of only 200 g and any formulation that showed 
signs of physical instability immediately and/or after twenty-four (24) hours of storage at room 
temperature (22˚C) was considered unsuitable and therefore not considered for further 
investigation.  
 
The initial prototype cream formulation, Batch CP001 containing Estol® 1474 as the primary 
emulsifier, was extemporaneously manufactured. However, although Batch CP001 appeared 
homogenous, smooth and physically stable immediately after manufacture, signs of instability, 
such as phase separation or cracking and bleeding of the base from the container were observed 
twenty-four (24) hours after storage at room temperature (22˚C). Consequently, Batch CP001 
was not characterized further in these studies. A batch summary record for Batch CP001 is 
reported in Appendix 4.  
 
It is possible that Batch CP001 failed to remain physically stable over the twenty-four (24) hour 
storage period because Estol® 1474 is not a suitable primary emulsifier for CP cream 
formulation. Despite the manufacturers of Estol® 1474 [205] stating that the emulsifier may be 
used for the preparation of w/o and o/w in emulsions, the compound may only be useful for the 
manufacture of liquid emulsions and not semi-solid emulsions, such as creams. This 
characteristic may be due to the fact that Estol® 1474 contains no surfactant but only a single 
amphiphile, glyceryl stearate (Section 4.3.3.2.10).  
 
Estol® 1474 therefore cannot be considered as a mixed emulsifier and considering the fact that no 
surfactant was incorporated into Batch CP001 as a separate ingredient, Estol® 1474 was not able 
to form a mixed emulsification system in situ. Consequently, viscoelastic gel networks at the oil-
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water interface that are reported to provide and maintain the stability of o/w creams (Section 
4.2.3.3) were not formed. The apparent stability of Batch CP001 observed immediately 
following manufacture may possibly be attributed to the presence of amphiphiles in the 
formulation that thickened the formulation immediately on production. However, on standing the 
formulation was not sufficiently viscous to maintain the physical stability over a prolonged 
period due to the fact that no surfactant was included in the formulation.   
 
In order to manufacture a physically stable generic CP cream extemporaneously that would 
remain stable over a longer period of time, it may be necessary to add an appropriate surfactant 
to the formulation or substitute Estol® 1474 for a commercially available mixed emulsifier 
system, which would be the ideal approach. Consequently, three (3) batches of cream, Batches 
CP002, CP003 and CP004 were manufactured using the commercially available mixed 
emulsifiers Ritapro® 200 (Section 4.3.3.2.11), Emulcire® 61 WL (Section 4.3.3.2.12) and Gelot® 
64 (Section 4.3.3.2.13). The quantitative compositions of these three batches are shown in Table 
4.7 and the batch summary records for these formulations are shown in Appendix 4. 
 
Batches CP002, CP003 and CP004 also appeared to be homogenous, smooth and physically 
stable immediately after manufacture as had been observed for Batch CP001. However, unlike 
Batch CP001 all three batches in which mixed emulsifiers were incorporated showed no signs of 
physical instability twenty-four (24) hours after manufacture and storage at room temperature 
(22˚C). A possible explanation for the immediate prolonged stability of these formulations could 
be that Ritapro® 200, Emulcire® 61 WL and Gelot® 64 are all emulsifying waxes, containing 
mixtures of fatty amphiphiles and surfactants. Therefore Ritapro® 200, Emulcire® 61 WL and 
Gelot® 64 provided consistency and stability to the creams due to their ability to form crystalline 
viscoelastic gel networks in the external phase of the cream formulations. 
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4.5.7. In vitro release studies  
 
4.5.7.1. Overview 
 
Once physically stable creams had been manufactured using Ritapro® 200 (Batch CP002), 
Emulcire® 61 WL (Batch CP003) and Gelot® 64 (Batch CP004), the effects of these 
commercially available synthetic mixed primary emulsifiers on the in vitro release rate of CP 
from the creams were investigated. The purpose of conducting these studies was to determine 
which of the cream formulations produced an in vitro release rate profile for CP that is similar to 
that of Dermovate® cream. The similarity assessment was based on a statistical evaluation using 
a non-parametric test described and reported in Section 3.2.11. Based on the results of these in 
vitro release studies the most suitable mixed primary emulsifier system was selected and used to 
manufacture additional generic CP cream formulations. 
 
4.5.7.2. Effects of Ritapro® 200 
 
The in vitro release of CP from a prototype formulation, Batch CP002, was evaluated and the 
results are summarised in Table 4.3 and compared with the in vitro release data obtained for 
Dermovate® cream. The resultant in vitro release rate profile of CP from Batch CP002 and from 
Dermovate® cream is depicted in Figure 4.6. 
 
Table 4.3. Cumulative amount of CP released and the average in vitro release rate (flux) of CP from 
Batch CP002 and Dermovate® cream (n = 6) 
 
Product Q  
(µg/cm2) 
Cumulative % 
released 
Flux 
(µg/cm2/hr1/2 
Batch CP002 63.54 ± 7.050 42.09 ± 4.700  8.681 
Dermovate® cream 42.50 ± 6.540 27.50 ± 4.660 5.888 
 
In vitro release rate data summarised in Table 4.3 and depicted in Figure 4.6 reveal that the in 
vitro release rate of CP from Batch CP002 may not be considered equivalent to the in vitro 
release of CP from Dermovate® cream. 
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Figure 4.6. In vitro release rate profile for CP from Batch CP002 and Dermovate® cream 
 
The lower limit (L.L.) and upper limit (U.L.) of a confidence interval (C.I.) calculated as 
described in Section 3.2.11 (Chapter 3) with Batch CP002 (test) and Dermovate® cream 
(reference) are summarised in Table 4.4. If the products are to be considered equivalent then the 
resultant limits for the C.I. calculated from experimental data should lie within the 75%-133% 
limits for the products to be considered equivalent [49]. 
 
Table 4.4. The lower limit (L.L.) and upper limit (U.L.) of the confidence interval (C.I) calculated using 
Batch CP002 (test) and Dermovate® cream (reference)  
 
 Confidence intervals (C.I.) 
 L.L. (%) U.L. (%) 
C.I. limits 75.00 133.00 
Dermovate® cream  vs. Batch CP002  123.85 166.36 
 
The data summarised in Table 4.4 reveal that the L.L. and U.L. of the C.I. calculated for Batch 
CP002 do not fall within the 75% -133% C.I. limits. Consequently, the in vitro release rate 
profile of CP for Batch CP002 is not equivalent to that of CP release from Dermovate® cream. 
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Based on these findings, Ritapro® 200 was not considered to be an ideal mixed emulsifier for use 
in manufacturing CP cream formulations.  
 
4.5.7.3. Effects of Emulcire® 61 WL 
 
The in vitro release rate of CP from a prototype formulation, Batch CP003, was assessed and the 
results are summarised in Table 4.5 and compared with the in vitro release data obtained for 
Dermovate® cream. The resultant in vitro release rate profile of CP from Batch CP003 and from 
Dermovate® cream is depicted in Figure 4.7. 
  
Table 4.5. Cumulative amount of CP released and the average in vitro release rate (flux) of CP from 
Batch CP003 and Dermovate® cream (n = 6) 
 
Product Q  
(µg/cm2) 
Cumulative % 
released 
Flux 
(µg/cm2/hr1/2) 
Batch CP003 67.28 ± 5.040 51.04 ± 3.010  8.334 
Dermovate® cream 42.50 ± 6.540 27.50 ± 4.660 5.888 
 
In vitro release rate data summarised in Table 4.5 and depicted in Figure 4.7 reveal that the in 
vitro release rate of CP from Batch CP003 may not be considered equivalent to the in vitro 
release of CP from Dermovate® cream. 
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Figure 4.7. In vitro release rate profile for CP from Batch CP003 and Dermovate® cream 
 
The lower limit (L.L.) and upper limit (U.L.) of a confidence interval (C.I.) calculated with 
Batch CP003 (test) and Dermovate® cream (reference) are summarised in Table 4.6. If the 
products are to be considered equivalent then the resultant limits for the C.I. calculated from 
experimental data should lie within the 75%-133% limits for the products to be considered 
equivalent [49] 
 
Table 4.6. The lower limit (L.L.) and upper limit (U.L.) of the confidence interval (C.I.) calculated for 
using Batch CP003 (test) and Dermovate® cream (reference) 
  
 Confidence intervals (C.I.) 
 L.L.(%) U.L. (%) 
C.I. limits 75.00 133.00 
Dermovate® cream vs. Batch CP003 122.68 153.74 
 
The data summarised in Table 4.6 reveal that although the L.L. the C.I. calculated for Batch 
CP003 does fall within the 75% -133% C.I. limits, the U.L. does not lie within these limits. 
Consequently, the in vitro release rate profile of CP for Batch CP003 is not equivalent to that of 
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CP release from Dermovate® cream. Based on these findings, Emulcire® 61 WL was not 
considered to be an ideal mixed emulsifier for use in manufacturing CP cream formulations. 
 
4.5.7.4. Effects of Gelot® 64 
 
The in vitro release rate of CP from a prototype formulation, Batch CP004, was evaluated and 
the results are summarised in Table 4.7 and compared with the in vitro release data obtained for 
Dermovate® cream. The resultant in vitro release rate profile of CP from Batch CP004 and from 
Dermovate® cream is depicted in Figure 4.8. 
 
Table 4.7. Cumulative amount of CP released and the average in vitro release rate (flux) of CP from 
Batch CP004 and Dermovate® cream (n = 6) 
 
Product Q  
(µg/cm2) 
Cumulative % 
released 
Flux 
(µg/cm2/hr1/2 
 Batch CP004 49.46 ± 4.010 32.98 ± 2.640  6.515 
Dermovate® cream 42.50 ± 6.540 27.50 ± 4.660 5.888 
 
 
In vitro release rate data summarised in Table 4.7 and depicted in Figure 4.8 reveal that the in 
vitro release rate of CP from Batch CP004 may be considered equivalent to the in vitro release of 
CP from Dermovate® cream. 
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Figure 4.8. In vitro release rate profile for CP from Batch CP004 and Dermovate® cream 
 
The lower limit (L.L.) and upper limit (U.L.) of a confidence interval (C.I.) calculated with 
Batch CP004 (test) and Dermovate® cream (reference) are summarised in Table 4.8. If the 
products are to be considered equivalent then the resultant limits for the C.I. calculated from 
experimental data should lie within the 75%-133% limits for the products to be considered 
equivalent [49]. 
 
Table 4.8. The lower limit (L.L.) and upper limit (U.L.) of the confidence interval (C.I) calculated using 
Dermovate® cream (reference) and Batch CP004 (test)  
 
 Confidence intervals (C.I.) 
 L.L. (%) U.L. (%) 
C.I. limits 75.00 133.00 
Dermovate® cream vs. Batch CP004 95.50 126.12 
 
The data summarised in Table 4.8 reveal that the L.L. and U.L. of the C.I. calculated for Batch 
CP004 do fall within the 75% -133% C.I. limits. Consequently, the in vitro release rate profile of 
CP for Batch CP004 is equivalent to that of CP release from Dermovate® cream. Based on these 
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findings, Gelot® 64 was considered to be a suitable mixed emulgent for use in manufacturing CP 
cream formulations.  
 
4.3.8. Generic product characterization 
 
4.3.8.1. Overview 
 
Following the selection of the most suitable synthetic mixed emulsifier for use and the 
development of a generic cream formulation containing CP which had the desirable in vitro 
release rate profile, the next step was to characterize the physico-chemical properties of the 
generic formulation and compare the data to those obtained for Dermovate® cream. Therefore 
three (3) batches of 500 g viz., Batches CP004, CP005 and CP006, all containing equal amounts 
of Gelot® 64 and manufactured using the manufacturing method described in Section 4.5.5, were 
evaluated for CP content, viscosity, pH and in vitro release rate. The data generated from these 
studies were also used to determine batch-to-batch uniformity and therefore the consistency of 
the manufacturing method that had been developed. Batch summary records for Batches CP005 
and CP006 are shown in Appendix 4.  
 
4.3.8.2. CP content 
 
The assay for CP content in Batches CP004, CP005 and CP006 was evaluated using the sample 
preparation procedure described in Section 2.4.6.2 and the resultant data are listed in Table 4.9 
and compared to the CP content of the innovator product Dermovate® cream.  
 
Table 4.9. CP content of Dermovate® cream and Batches of generic cream formulations (n = 3) 
Product CP content (%) SD % RSD 
Dermovate® cream 103.9 2.797 2.69 
Batch CP004  109.8 1.114 1.06 
Batch CP005  109.8 2.474 2.25 
Batch CP006  113.1 2.605 2.30 
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The data reveal that the CP content in all the three generic batches manufactured comply with the 
USP specifications [23] as does Dermovate® cream. Therefore the manufacturing process is 
suitable for the production of the generic cream.  
 
4.3.8.3. Intrinsic viscosity 
 
The intrinsic viscosity of Batches CP004, CP005 and CP006 was investigated using the 
procedure described and reported in Section 3.3.2.3.2 (Chapter 3). The results generated from 
these studies are summarised in Table 4.10 and compared to the intrinsic viscosity data of 
Dermovate® cream. It appears that there is little difference in the intrinsic viscosity values among 
the three batches manufactured, implying that the method of manufactured was consistent.   
 
Table 4.10. Intrinsic viscosity readings for Dermovate® cream and generic cream products (n = 3) 
Product Intrinsic viscosity (KcP) SD % RSD 
Dermovate® cream 44.47 1.026 2.31 
Batch CP004 15.50 4.359 2.81 
Batch CP005 12.37 0.3214 2.60 
Batch CP006 11.43 0.05774 0.505 
 
 
The data in shown in Table 4.10 clearly reveal a marked difference between the intrinsic 
viscosity of Dermovate® cream and of any of the three extemporaneously manufactured generic 
batches.  
 
The intrinsic viscosity of Dermovate® cream is approximately three (3) times greater than the 
intrinsic viscosity of Batches CP004, CP005 and CP006. The difference in the intrinsic viscosity 
of the innovator formulation and of the three extemporaneously manufactured batches may be 
attributed to either the gel network theory or to manufacturing process variables such as 
homogenization speed and mode of cooling.  
 
The gel network theory relates the consistency and stability of o/w creams to the presence or 
absence of viscoelastic gel networks in the external phase of cream formulations. The crystalline 
viscoelastic gel networks form in the continuous phase of a cream formulation when a fatty 
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amphiphile in a mixed emulsifier swells in the presence of water and in the presence of a 
surfactant in a cream formulation. The presence of swollen crystalline gel networks and their 
concentration in the continuous phase of a cream are reported to be responsible for the overall 
consistency of a cream structure [171, 172] as well as the self-bodying action of the mixed 
emulsifier [173].  
 
Although an amphiphile will swell in the presence of any type of surfactant to form gel 
networks, the amount of swelling of an amphiphile is reportedly greater in the presence of ionic 
surfactants than in the presence of non-ionic surfactants [171]. In the presence of a non-ionic 
surfactant, swelling has been reported to be attributed to the hydration of hydrophilic chains of 
the non-ionic surfactant and is usually limited by the length of the chain [171]. 
 
The composition of the innovator formulation (Appendix 2) reveals that Arlacel® 165 is the 
mixed emulsifier in Dermovate® cream. The mixed emulsifier in the extemporaneously 
manufactured CP generic formulations is Gelot® 64. Both Arlacel® 165 [206] and Gelot® 64 
(Section 4.3.3.2.13) contain a mixture of an amphiphile and a non-ionic surfactant. Essentially, 
Arlacel® 165 is a mixture of glyceryl monostearate and polyethylene glycol-100 stearate or PEG-
100 stearate [206] whereas Gelot® 64 consists of glyceryl monostearate and polyethylene glycol-
75 stearate or PEG-75 stearate (Section 4.3.3.2.13).  
 
It is clearly evident that both Arlacel® 165 and Gelot® 64 are comprised of similar ingredients, 
the only difference being attributed to the chain length of the non-ionic surfactant. It is therefore 
possible that the higher viscosity of Dermovate® cream compared to that of the generic CP 
creams may be due to the increased length of the chain of the non-ionic surfactant in Arlacel® 
165. The increased chain length more than likely resulted in greater swelling of the glyceryl 
monostearate and subsequent formation of a large amount of the crystalline viscoelastic gel 
phases in the continuous aqueous phase of the cream markedly increasing the viscosity of the 
formulation.  
 
The apparent high intrinsic viscosity of Dermovate® cream may also be attributed to 
manufacturing process variables, such as the homogenization speed and mode of cooling. It has 
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been reported [170, 192] that the apparent intrinsic viscosity of a semi-solid formulation is 
influenced by the size of the droplets of the dispersed phase and it follows that droplets of small 
sizes will produce creams of higher viscosity than those of dispersed phases with large droplet 
sizes [170, 192, 211].    
 
A reduction in the size of dispersed droplets of a dispersed phase may be achieved by increasing 
the speed of homogenization during manufacture [170, 192, 211]. The higher shearing forces 
provided by increased homogenization speeds disrupts the hydrocarbon chains of the oil and wax 
droplets, thereby exposing surfactant chains to water which in turn results in the formation of an 
additional gel phase and subsequently further increases the intrinsic viscosity of a cream 
formulation [170].  
 
Although the speed of the laboratory homogenizer used in the manufacture of generic CP batches 
(Section 3.3.5) was set to approximately 15,000 rpm it is likely that the laboratory homogenizer 
does not provide the same shear as would be expected from high speed homogenizers used in the 
large scale manufacture of cream products. Consequently, the apparent intrinsic viscosity values 
of the extemporaneously manufactured CP batches did not match the apparent intrinsic viscosity 
value of the commercially available Dermovate® cream.  
 
As far as mode of cooling is concerned, Niellound et al, [212] established and reported that a 
progressive mode of cooling of cream formulations at room temperature (25˚C), corresponding 
to 45 minutes of homogenization time, appears to lead to the production of creams with higher 
viscosity, better homogeneity and better stability than what Niellound et al, [212] referred to as 
brutal mode of cooling with a water bath at 15˚C, corresponding to 30 minutes of 
homogenization time.  
 
It possible that at an industrial scale, a progressive mode of cooling corresponding to longer 
homogenization time is adopted, resulting in cream formulations with higher viscosity as seen in 
the case of Dermovate® cream. However, progressive cooling at a laboratory scale would be a 
time-consuming and laborious process, especially in these studies where manual mixing while 
cooling was used. Nevertheless, it is probable that the rapid cooling with a water bath at 20˚C as 
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was done in these studies and which corresponded to approximately 20 minutes of manual 
mixing may have contributed to the formation of less viscous creams compared to Dermovate® 
cream.   
 
4.3.8.4. pH-determination 
 
The pH of Batches CP004, CP005 and CP006 cream products was determined at room 
temperature (22˚C) as described in Section 4.3.4. The data generated from these studies are listed 
in Table 4.11 and compared to the apparent pH determined for Dermovate® cream. The pH 
values for all three CP cream batches fall within the pH range of 4-6 of a healthy human skin and 
therefore all the three formulations are unlikely to exert pH effects on pH-sensitive human skin. 
The pH data of all three batches is consistent, implying that the method of manufacture was 
consistent.  In addition the pH of the creams is similar to that of Dermovate®. 
 
Table 4.11. pH readings for Dermovate® cream  and generic cream formulations (n = 3) 
Product  pH SD % RSD 
Dermovate® cream 5.05 0.0321 0.00637 
Batch CP004 5.20 0.01527 0.294 
Batch CP005 5.11 0.005770 0.113 
Batch CP006 5.15 0.0264 0.514 
 
4.3.8.5. In vitro release rate  
 
The in vitro release of CP from Batches CP004, CP005 and CP006 was assessed and the 
resultant data generated from these in vitro release studies are summarised in Table 4.12 and are 
compared with the in vitro release data generated for Dermovate® cream. The resultant in vitro 
release rate profiles of CP from Batches CP004, CP005 and CP006 and from Dermovate® cream 
are depicted in Figure 4.9. 
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Table 4.12. Cumulative amount of CP released and the average in vitro release rate (flux) of CP from 
Dermovate® cream and generic cream formulations (n = 6) 
 
Product Q  
(µg/cm2) 
Cumulative % 
released 
Flux 
(µg/cm2/hr1/2 
Dermovate® cream 42.50 ± 6.540 27.50 ± 4.660 5.888 
Batch CP004 49.46 ± 4.010 32.98 ± 2.640 6.515 
Batch CP005 56.73 ± 2.82 37.83 ± 3.39 7.532 
Batch CP006 43.99 ± 5.270 29.36 ± 3.740 5.796 
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Figure 4.9. In vitro release rate profile for CP release from CP generic cream products and Dermovate® 
cream 
 
From the in vitro release rate profile data for CP depicted in Figure 4.8 and summarised in Table 
4.12, it appears that there is no significant difference in the in vitro rate of release of CP from 
Batches CP004, CP005 and C006 and the release rate of CP from the innovator product, 
Dermovate® cream. These data are consistent with the results of the non-parametric statistical 
test (Table 4.13), which reveal that all the three manufactured batches are equivalent to 
Dermovate® cream in terms of their CP in vitro release rate profiles. 
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Table 4.13. The lower limit (L.L.) and upper limit (U.L.) of the confidence interval (C.I.) calculated using 
Dermovate® cream (reference) and generic formulations (tests) 
 
 Confidence intervals (C.I.) 
 L.L. (%) U.L. (%) 
C.I. limits 75.00 133.0 
Dermovate® cream vs. Batch CP004 95.50 126.1 
Dermovate® cream vs. Batch CP005 107.9 131.9 
Dermovate® cream vs. Batch CP006 81.40 113.4 
 
It is interesting to note that the in vitro release profile for CP from all three generic batches 
appears to be similar to that of CP release from Dermovate® cream despite the apparent viscosity 
of the innovator formulation being three times higher than the viscosity of any of the three 
generic Batches (Table 4.10). From these observations, it may be implied that the intrinsic 
viscosity of the cream formulation does not influence the in vitro release rate of CP in these 
formulations significantly, which contradicts well-established theories on drug release from 
semi-solid dosage forms [213].  
 
It has been established that the rate and extent of release of an active pharmaceutical ingredient 
(API) from a semi-solid vehicle decreases progressively as the intrinsic viscosity of the base 
material increases, and the converse is also true [213]. Therefore it was expected that the 
difference in the intrinsic viscosity of Dermovate® cream and the extemporaneously 
manufactured CP cream batches would result in significantly different in vitro release rates for 
CP from each of the products.  
 
It has also been reported that for an API molecule to be released from a semi-solid vehicle, it 
first has to reach the surface of the formulation and that mass transport in the cream formulation 
may occur by diffusion of the API molecules or by diffusion and convection of oil droplets 
[214].  
 
The apparent intrinsic viscosity or macro-viscosity of a semi-solid product influences the 
diffusion of oil droplets in the dosage form when the diffusion length is greater than the diffusion 
length scale of the structure elements of a formulation [214]. In addition it has been suggested 
that diffusion of API molecules through a semi-solid formulation is also influenced by the micro-
viscosity of a topical formulation and that the formulation environment may affect an API 
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molecule, such as for example the physical properties of the emulsifier used to manufacture a 
stable dosage form [214].  
 
It is possible that the in vitro release of CP from cream formulations may to a large extent be 
affected by the physical properties of the mixed emulsifier system used in the formulation rather 
than the apparent intrinsic viscosity of the cream formulation. The components of the mixed 
emulsifier (Arlacel® 165) used in Dermovate® cream are essentially similar to the components of 
the mixed emulsifier (Gelot® 64) used in the manufacture of the generic batches. Therefore the 
behaviour of the mixed emulsifier in the cream formulation may have a dominant effect on the in 
vitro release rate of CP from semi-solid cream formulations, rather than the macro-viscosity of 
the semi-solid base.   
 
4.4. CONCLUSIONS 
 
The objective of these studies was to develop and assess a generic cream formulation for the 
delivery of clobetasol 17-propionate (CP) for use in the treatment of patients with inflammatory 
skin conditions, such as acute and chronic attacks of any type of eczema. 
 
Initial experiments were designed to facilitate the characterization of the innovator product, 
Dermovate® cream. Consequently, the innovator product was characterized in terms of 
clobetasol 17-propionate (CP) content, apparent intrinsic viscosity, pH and in vitro release rate of 
CP. The data generated from these studies were used as a benchmark for the development of 
extemporaneously manufactured generic CP cream batches. The CP content of Dermovate® 
cream was found to fall within the USP specifications, and the pH of the product was found to lie 
in the pH range of the human skin.  
 
Preliminary studies in the development of generic formulations were designed to facilitate the 
manufacture of a prototype generic formulation that showed no signs of physical instability, such 
as, for example, cracking, creaming, phase inversion and/or bleeding of the cream base from the 
container, immediately after the manufacture as well as twenty-four (24) hours after manufacture 
and storage at room temperature (22˚C).  
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Although a prototype formulation (Batch CP001) manufactured with Estol® 1474 as the primary 
emulsifier showed evidence of physical stability immediately after manufacture, the formulation 
was found to be physically unstable twenty-four (24) hours after manufacture and storage at 
room temperature (22˚C) and was therefore not considered for further investigation.  
  
Prototype formulations containing commercially available mixed emulsifiers, such as Ritapro® 
200 (Batch CP002), Emulcire® 61 WL (Batch CP003) and Gelot® 64 (Batch CP004) were found 
to be physically stable immediately after manufacture as well as twenty-four (24) hours after 
manufacture and storage at room temperature (22˚C) and were therefore considered for further 
evaluation. Once physically stable creams had been manufactured the in vitro release rate of CP 
from Batches CP002, CP003 and CP004 and Dermovate® cream was evaluated.  
 
The purpose of these studies was to identify a prototype batch with a similar in vitro release 
profile for CP that was similar to that for Dermovate® cream. It was found that Batch CP004 was 
the only batch with an in vitro release profile for CP that was similar to that of Dermovate® 
cream. The similarity of release profiles was assessed using a non-parametric statistical test 
recommended by the Food and Drug Administration (FDA).  
 
The successful manufacture of Batch CP004 necessitated the production of two additional 
batches of cream. Batches CP005 and CP006 were manufactured using Gelot® 64 as a mixed 
emulsifier with a composition exactly the same as that used to manufacture Batch CP004.  
Batches CP004, CP005 and CP006 were characterised in terms of CP content, apparent intrinsic 
viscosity, pH and in vitro release rate testing. The CP content of all three extemporaneously 
manufactured CP batches was within the specified USP limits and all the three batches had pH 
values within the pH range of healthy human skin.  
 
However, it was found that the apparent intrinsic viscosity of the innovator product was almost 
three (3) times greater than that of all three generic cream batches. The difference in intrinsic 
viscosity of Dermovate® cream was attributed to the physicochemical characteristics of the 
mixed emulsifiers used in the innovator product and possibly to manufacturing process variables, 
such as homogenization speed and mode of cooling.  
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Despite the difference in the apparent intrinsic viscosity of Dermovate® cream and the CP 
batches, the in vitro release rate of CP was found to be statistically similar to the innovator 
product for all three generic batches tested. It was concluded that the behaviour of the mixed 
emulsifier in both the commercially available cream and the extemporaneously manufactured 
creams, and not the apparent intrinsic viscosity of the formulations, has an impact on the in vitro 
release rate of CP from these formulations.  
 
Generic CP cream formulations have been successfully developed and characterized in vitro in 
terms of CP content, apparent intrinsic viscosity, pH and in vitro release rate testing. Although 
the viscosity of the generic CP cream formulations did not match the apparent viscosity of 
Dermovate® cream, the generic CP batches were equivalent to the innovator cream product in 
terms of other in vitro performance characteristics such as CP content, pH and in vitro release 
rate.  
 
The data generated from these studies formed the basis for manufacture of a larger batch of 
cream that was subjected to accelerated stability studies at 40°C/25% RH (Chapter 5).  
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CHAPTER FIVE 
 
 STABILITY OF CLOBETASOL 17-PROPIONATE CREAMS  
 
5.1. INTRODUCTION 
 
Every medicinal product on the market is required to have an expiry date allocated by the 
regulatory authorities in a particular country and the expiration date must be presented on the 
label of the container in which the product is stored [215, 216]. The expiration date can be 
defined as the time interval over which a pharmaceutical product remains within the 
specifications established for product strength, quality and purity [215-217]. The expiration date 
of a product may be determined by adding a product’s shelf-life period to the date of 
manufacture [216, 217]. The shelf-life of a product specifically refers to the time period during 
which the strength of the active pharmaceutical ingredient (API) in a product remains ≥ 90% of 
the original label claim and is therefore the period for which a product will be suitable for use by 
a patient  [215, 217]. 
 
In order to determine the shelf-life of a medical product, pharmaceutical manufacturers must 
conduct appropriate stability studies [216]. In addition to generating data on which to base 
proposals for a product’s shelf-life, stability studies may also reveal information that is vital for 
the selection of product packaging and storage conditions [217-219]. Stability studies may also 
provide evidence on how the quality of a drug product varies with time under the influence of a 
variety of different environmental factors, such as, for example, temperature, humidity and light 
[219-221]. Evaluation of the stability of a pharmaceutical product is therefore considered an 
integral part of formulation development studies [217, 218]. 
 
Most API molecules that are used in medicinal products are inherently unstable compounds 
[218]. This can be ascribed to the presence of reactive functional groups, which, in addition to 
providing reactive sites necessary to produce a therapeutic effect in vivo, may also increase the 
susceptibility of a drug molecule to chemical reactions outside the body, leading to degradation 
and subsequent loss of potency of a drug product [215]. Pharmaceutical products have been 
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reported to be susceptible to degradation via three (3) primary mechanisms: chemical, physical 
and biological. These degradation mechanisms may occur in isolation or in combination [215, 
222].  
 
Chemical degradation in pharmaceutical systems invariably results in chemical changes to the 
product. Such changes include for example the formation of degradation products, loss of API 
potency and/or loss of activity of excipients such as anti-microbial preservatives and/or anti-
oxidants [219]. These changes may occur as a result of intrinsic chemical reactions, such as 
hydrolysis, photolysis, oxidation, reduction and/or racemisation reactions [215, 222]. It has been 
suggested that intrinsic chemical reactions may be triggered by extrinsic factors and therefore the 
chemical stability of medicinal products may be regarded as the ability of a drug product to 
withstand the effects of moisture, light, humidity and heat [219].  
 
The physical degradation of pharmaceutical products may be caused by a range of external 
factors, such as, impact, vibration, abrasion and/or temperature fluctuations [222]. Physical 
degradation of a drug product may lead to changes in product appearance, consistency, 
uniformity, dissolution rate, colour, odour, moisture content and/or pH amongst others and such 
changes are usually dependent on the dosage form under investigation [219]. Biological and/or 
microbiological degradation in medicinal products may lead to the proliferation of micro-
organisms in non-sterile products and changes in the efficacy of preservatives [219] and may be 
caused by microbiological and/or non-microbiological organisms [222]. 
 
Whether a change in a delivery system is chemical, physical or microbiological such changes are 
likely to adversely affect any attribute of the quality of the product in terms of its fitness for use 
by a patient [215]. Therefore the stability of a pharmaceutical product may be defined as the 
ability of a formulation in a specific container to remain within the physical, chemical, 
microbiological and hence therapeutic, toxicological, protective and informational specifications 
for that product [215, 217, 221]. In other words, the stability of a pharmaceutical product is the 
extent to which a pharmaceutical product retains the same properties and characteristics that the 
product possessed at the time of manufacture, throughout the shelf-life of the product within 
specified limits [215, 217].  
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The factors that may adversely affect the stability of a pharmaceutical product include for 
example the [215, 217]: 
 
1) stability of the API, 
2) potential interaction between an API and inactive excipients, 
3) manufacturing process, 
4) dosage form, 
5) container/closure system, 
6) environmental conditions the product is exposed to during shipment, 
7) storage conditions, 
8) handling, and, 
9) length of time between manufacture and use. 
 
During the formulation development process and manufacturing procedure a formulation 
scientist may be able to control the external factors to which a dosage form or the components of 
the dosage form may be exposed and that may affect product stability, and by control of these 
parameters, minimize or prevent product instability [223]. However once a dosage form has left 
a manufacturing plant, the formulation scientist has little or no control if any over the variables 
that the dosage form in question may be exposed to during distribution, storage and use [223].  
 
It may be possible to minimize the potential hazards to which the dosage form may be exposed 
to during distribution, storage and use by selecting an appropriate package or packaging 
configuration for the product [223]. However of all the environmental attributes that may be 
involved in the degradation of an API in a dosage form, temperature is the most important factor 
and cannot be controlled by the selection of specific packaging [215], and it has been argued that 
the selection of a specific packaging configuration will not protect a pharmaceutical formulation 
form from the detrimental and adverse effects associated with the use of elevated temperatures 
[224]. The lack of protection from elevated temperatures afforded by packaging is problematic 
for pharmaceutical products destined for used in high temperature zones, such as for example 
Zones III or IV [218, 225].  
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In order to assess how a newly developed dosage form behaves under the influence of different 
environmental conditions and to minimize or avoid unforeseen adverse effects it is essential to 
assess the stability of the new pharmaceutical product in the desirable packaging configuration 
that is intended for use during marketing of the product. Stability studies are usually conducted 
under ambient and accelerated conditions [215-218, 221] and three different conditions for 
stability studies have been reported [217, 219, 221]. However only two types of stability studies 
viz., short-term and long-term have been widely reported [215-218, 221].  
 
Long-term stability studies are usually conducted under ambient storage conditions [215, 216, 
218, 221] and are defined as experiments for the evaluation of the physical, chemical, biological, 
biopharmaceutical and microbiological characteristics of a drug substance or product, during and 
beyond the expected shelf-life and the storage of samples at the recommended storage conditions 
[217, 219]. Stability data generated from long-term stability studies are invariably the primary 
stability data used to establish the shelf-life of a product and to confirm a projected shelf-life 
and/or the recommended storage conditions for a product [216, 217, 219].  
 
In contrast short-term or accelerated stability studies are experiments conducted under 
exaggerated storage conditions, such as, for example, high temperature and/or relative humidities 
[215-218, 221]. Accelerated stability studies are designed to increase the rate of a potential 
chemical and/or physical change of an API or medicinal product such that significant 
degradation, if it occurs, can be observed in a relatively short period of time [216, 219]. Data 
generated from short-tem stability studies may be used in conjunction with long-term stability 
studies to assess the longer term chemical effects at non-accelerated conditions and to evaluate 
the impact of short term deviations outside the appropriate storage conditions of a product, such 
as might occur during transportation, on product quality [217, 219, 226].  
 
The objective of these studies was to conduct stability studies at elevated temperatures on the 
clobetasol 17-propionate (CP) cream formulation developed and characterized as described and 
reported in Chapter 4. Although laboratory-scale stability data are not normally acceptable as 
primary stability data for use to establish product shelf-life and/or storage conditions, such data 
may be submitted to regulatory agencies to support primary stability data [218, 219].  
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It is however important to note that the purpose of these stability studies was not to generate 
primary stability data for use to estimate a shelf-life for the CP cream product but rather to 
determine whether or not the formulation development process was successful in producing a 
potentially stable CP cream product. The stability data generated for CP generic cream from 
these studies would then form the basis for further more comprehensive studies on the stability 
of the formulation.  
 
5.2. EXPERIMENTAL 
 
5.2.1. Overview 
 
The initial step in the generation of stability data requires that a stability protocol or a detailed 
stability testing plan is documented [218]. Since stability testing conditions may vary depending 
on the inherent stability of a drug compound, type of the dosage form and/or the proposed 
container-closure configuration to be used, the final stability protocol invariably relies on the 
type of drug substance or drug product being tested [218].  
 
The ultimate stability protocol will also depend on whether a medicinal product containing a 
specific API is already on the market [218]. As a consequence some guidelines on stability 
studies may require less stringent stability evaluations for drug substances and/or drug products 
that have been on the market for extended period of time [218]. In addition, the target market for 
a medicinal product must also be taken into account when establishing a stability protocol as 
room temperature conditions vary from location to location and will affect the storage condition 
requirements in addition to other test parameters [217, 218].  
 
The World Health Organization (WHO) [217], International Conference on Harmonisation 
(ICH) [221] and the Food and Drug Administration (FDA) [227] have published general 
guidelines pertaining to the assessment of stability of drug substances and/or drug products. The 
guidelines were used as a template to design a stability protocol for use in the assessment of 
stability of the CP topical cream formulation developed in these studies.  
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5.2.2. Stability study protocol 
 
5.2.2.1. Overview 
 
The stability protocol developed for use in these studies was designed to include the following 
information:  
 
1) selection of batches,  
2) number of batches,  
3) container closure system, 
4) sampling frequency, 
5) sampling plan, 
6) test storage conditions, 
7) test specifications,  
8) product specifications, 
9) test procedure, and  
10) statistical evaluation of the data. 
 
A stability test summary sheet for the CP cream formulation used in these studies is shown in 
Appendix 7. 
  
5.2.2.2. Selection of batches 
 
Specification requirements with respect to the selection of batches for stability testing have been 
reported [217, 221]. According to the WHO [217] and the ICH [221] it is largely irrelevant 
whether batches to be tested are of a pilot scale or large scale. However, the batches to be 
sampled and tested should be representative of the manufacturing procedure used to produce the 
product. Therefore the batches of CP cream that were subjected to stability testing were selected 
from amongst the best prototype batches viz., Batches CP004, CP005 and CP006 (Table 4.2), 
which were manufactured using the same procedure as described in Section 4.3.5. The size of 
each prototype batch that was produced was 500 g.  
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5.2.2.3. Number of batches 
 
Current international guidelines on stability evaluation of drug substances and/or drug products 
recommend the testing of a minimum of three (3) batches [217, 221, 227]. The use of three (3) 
batches may be a compromise between statistical and practical considerations [218, 227].  The 
testing of fewer batches may not allow for a reliable statistical estimate of batch-to-batch 
variability and the impact on product stability [218, 227]. However, practical considerations may 
prevent the collection of large amounts of data, since the generation of excessive data may cause 
stress on analytical and other facilities within a company [218, 227]. Testing of fewer batches 
such as, for example, one (1) batch may be allowed for stable and well-established products 
produced on a pilot scale [218]. As a consequence, one (1) batch of the three best CP cream 
products viz., Batch CP004 was used in these studies.  
 
5.2.2.4. Container-closure system  
 
According to the current guidelines [217, 221, 227] stability testing should be conducted using 
containers and closures that will be used for the marketing of the medicinal product. However, as 
part of the conditions for the accelerated stability testing of a dosage form, the ICH guidelines 
[221] consider the use of other packaging materials to be appropriate to generate supporting 
stability data for a product produced at a pilot scale level. As a consequence, the CP cream 
formulation was packed into 100 g glass ointment jars with tight-fitting closures. These 
containers were selected for use since it was easy to measure formulation parameters such as 
viscosity and pH directly from the ointment jar following storage of the samples for the requisite 
times (Section 5.2.2.8). 
 
5.2.2.5. Sampling frequency 
 
Accelerated stability studies may be undertaken for a minimum of six (6) months [217, 221, 
227]. During the six (6) month test period, the ICH suggests that samples should be removed at a 
minimum of three (3) time points including the initial and final time points, for example, at 0, 3, 
and 6 months [221]. The FDA [227] however sets the sampling frequency at a minimum of four 
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(4) time points, for example at 0, 2, 4 and 6, whereas the WHO [217] has set the sampling 
frequency at a minimum of five (5) time points such as, for example, at 0, 1, 2 and 3 and 6 
months (WHO). Since the objective of the current work was to determine whether the CP cream 
formulation is a potentially stable system, stability studies were conducted for a period of one (1) 
month and the sampling frequency in these studies was set at 1, 2, 3 and 4 weeks.  
 
5.2.2.6. Sampling plan 
 
Following completion of a sampling time plan, the total number of containers required for 
stability testing must be determined [218].  The primary requirement for determination of sample 
numbers is that the containers that are selected must represent the batch as a whole [218]. The 
formulation to be tested was packed into five (5) different 100 g glass ointment jars, resulting in 
the production of five (5) different test samples. The use of five (5) test samples was necessary to 
facilitate sampling at the different time points of 0, 1, 2, 3, and 4 weeks such that at the 
appropriate time, a jar could be removed without interfering with the remaining samples retained 
in the stability oven.  
 
5.2.2.7. Test storage conditions 
 
Haynes [228] gathered climatic data in various cities worldwide and has proposed a formula for 
the determination of the mean kinetic temperature (MKT) in these locations by taking into 
consideration variations in storage temperature. As a consequence different countries around the 
world have been distributed into four (4) different climatic zones, based on the prevailing annual 
climatic conditions in those regions [217-219]. The Republic of South Africa (RSA) falls into 
either Zones I or II [218, 225].  
 
For countries located in Zones I and II accelerated stability studies for pharmaceutical products 
should be conducted at 40 ± 2˚C and 75 ± 5% RH [217, 221, 227]. Due to lack of a controlled 
humidity stability chamber in our laboratory, stability studies on the CP cream formulation were 
conducted at 40 ± 2˚C and 25 ± 5% RH, which were the test storage conditions that could be 
achieved with the facilities available in our laboratory.  Whilst saturated salt chambers [229] may 
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be used to achieve the desired degree of humidity, the excessive salt required may affect the 
stability of the dosage form and containers and closures or cause corrosion and therefore these 
were not considered suitable for use. 
 
5.2.2.8. Test specifications 
 
The specifications for a stability test are designed to facilitate the selection of test parameters, 
analytical procedures and proposed acceptance criteria for a specific product [221]. Stability 
studies require that parameters of a product that may be susceptible to change during storage and 
that are more than likely to influence the quality, safety and/or efficacy of a product be tested 
[221].  
 
For topical formulations such as creams, attributes that should be investigated in stability studies 
may include the organoleptic properties and homogeneity of the dosage form, pH, viscosity, 
particle size distribution, strength, weight loss and API release rate [227, 230]. For the purpose 
of these studies, the CP cream formulation was evaluated in terms of its organoleptic attributes, 
CP content, consistency, pH and in vitro release rate of CP. The analytical procedures and 
acceptance criteria used in these studies are discussed in Sections 5.2.2.9 and 5.2.2.10, 
respectively, vide infra.  
 
5.2.2.9. Product specifications  
 
The test product specifications for the qualitative and quantitative parameters tested in these 
studies are listed in Table 5.1 and Table 5.2 respectively. The objective of these stability studies 
was to determine whether or not the organoleptic properties (Table 5.1) and the physico-
chemical parameters (Table 5.2) of the test formulation (Batch CP004) would remain within the 
specifications set prior to testing following exposure of the product to the stability test conditions 
used in these studies (Section 5.2.2.7). These specifications were determined for Batch CP004 
based on the data generated at the time of manufacture of that batch (Section 4.3.8). 
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Table 5.1. Specifications for qualitative parameters of the test cream formulation  
Product parameter Specification 
Appearance Shiny 
Colour White 
Odour Odourless 
Signs of physical instability None 
 
Table 5.2. Specifications for quantitative parameters of the test cream formulation  
Product parameter Specification 
CP content 90-115 %  
Intrinsic viscosity 13-18 KcP 
Intrinsic pH    4-6 
In vitro release rate (flux)   5-8 µg/cm2/hr1/2 
 
5.2.2.10. Methodology 
 
5.2.2.10.1. Test procedure 
 
Stability studies were conducted using a Model L.T.I.E. Labcon low temperature incubator 
(Labcon (Pty) Ltd, Krugerdorp, Gauteng, RSA). A week prior to use, the incubator was allowed 
to equilibrate to the temperature and relative humidity conditions set for these studies and these 
test conditions were monitored using a Thermo-Hygro pen (Beijing Gaupu Automation Control 
Co., Ltd, Beijing, China). Four (4) containers containing 100 g of cream were placed in the 
equilibrated incubator and at weeks 1, 2, 3 and 4 a 100 g sample was removed from the incubator 
and immediately analysed in terms of the following test parameters: 
 
a) organoleptic appeal, 
b) CP content, 
c) viscosity, 
d) pH, and 
e) CP release rate. 
 
The data generated in these tests were subjected to statistical analysis where appropriate. 
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5.2.2.10.2. Organoleptic appeal 
 
The appearance, odour and colour of the cream in each container was visually evaluated. 
Samples were also assessed for any signs of physical instability, such as for example, cracking 
and/or bleeding of the cream base from the container. 
 
5.2.2.10.3. CP content 
 
The CP content of the cream was evaluated using the sample preparation procedure described in 
Section 2.4.6.2 at each sampling time and a maximum of three (3) cream samples were used 
obtain an average value of CP.  CP content was determined using a validated HPLC method with 
UV detection at 240 nm (Chapter 2). These samples were assessed immediately after removing 
the cream sample container from the incubator. 
 
5.2.2.10.4. Intrinsic viscosity 
 
The apparent intrinsic viscosity of the creams was measured as described in Section 3.3.2.3.2 at 
each sampling time and a maximum of three (3) readings were taken to obtain an average 
apparent intrinsic viscosity value. Intrinsic viscosity readings were taken once, immediately after 
removing the cream sample from the incubator.  
 
5.2.2.10.5. pH-determination 
 
The apparent pH was determined as described in Section 4.3.1.4 at each sampling time and a 
maximum of three (3) readings were taken to obtain an average apparent pH value. The apparent 
pH readings were taken once, immediately after removing the cream sample from the incubator. 
 
5.2.2.10.6. In vitro release test 
 
The in vitro release rate of CP was assessed using the in vitro release test conditions described in 
Table 3.5, and were assessed following removal of the sample at each sampling time. A 
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maximum of six (6) Franz glass diffusion cells were used to determine the average in vitro 
release rate of CP (flux). In vitro release rate studies were conducted immediately after removing 
the cream sample from the incubator.    
 
5.2.2.11. Statistical evaluation  
 
In addition to describing how a stability study is to be designed and undertaken, the stability 
study protocol must also establish the statistical procedures to be used to analyse the stability 
data generated in the stability studies [227]. Stability data evaluation methods proposed in the 
current international guidelines [217, 221, 227] and in some published reports [218, 231-233] are 
intended to establish an expiration dating period during which the average strength of a batch of 
drug product may be expected to remain within the specifications for that product. The 
guidelines [217, 221, 227] and reports [231, 232] do not specify the statistical methods to be 
used to predict the stability of a drug product in terms of the physical attributes of a formulation 
such as viscosity, pH and in vitro release rates as were determined in these studies.  
 
The purpose of conducting these studies was to assess whether or not exposing the CP cream 
formulation to the test conditions reported in Section 5.2.2.7 would cause any relevant and/or 
significant changes to the organoleptic and physico-chemical properties of the cream. In terms of 
the qualitative tests, i.e. organoleptic properties, the formulation was considered to be stable if no 
changes were observed in terms of appearance, colour and odour of the product and if signs of 
physical instability, such as cracking and/or bleeding were absent during the test period. The 
organoleptic appeal was assessed qualitatively.  
 
The physico-chemical attributes of the formulation were evaluated quantitatively. The 
formulation was considered to be stable if there was no statistical relevant and/or significant 
change between the test results of the 100 g unit assessed immediately after manufacture (time 0 
weeks) and the 100 g units stored at accelerated  test conditions and analysed at 1, 2, 3 and 4 
weeks after storage. In order to assess whether or not these changes were statistically relevant 
and/or significant, the statistical procedure described by Timm et al., [97] as described in Section 
2.4.7.2 was used.  
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The responses used to calculate the confidence intervals as described by Timm et al., [97] were 
the CP content, apparent intrinsic viscosity, apparent pH and CP in vitro release rates. The 
percentage difference in response between the initial sample (at time 0 weeks) and stored 
samples (at times 1, 2, 3 and 4 weeks) were calculated and used to construct a 90% C.I.. The data 
are reported as confidence intervals depicting the percentage change from the initial reading for 
CP content in the formulation (n =3), intrinsic viscosity (n = 3) and apparent pH (n = 3) of the 
product and CP in vitro release rates from the formulation (n = 6). 
 
In addition, similarities or differences in the in vitro release rates of CP from each of the stability 
samples vs. the in vitro release rate of CP from the reference sample were evaluated using a non-
parametric test, which was described and reported in Section 3.2.11.   
 
5.2.3. Results and discussion 
 
5.2.3.1. Qualitative analysis 
 
There were no noticeable changes in the organoleptic properties of Batch CP004 in terms of 
appearance, colour and odour (Table 4.1) over the entire stability test period. In addition the 
formulation did not show any signs of physical instability such as phase separation or cracking 
and bleeding of the cream base from the container at any of the sampling times. Based on the 
organoleptic data observed in these studies the CP cream formulation may be considered to be 
potentially stable.  
 
5.2.3.2. Quantitative analysis 
 
The stability data for Batch CP004 evaluated in terms of CP content, intrinsic viscosity, intrinsic 
pH and in vitro release rate (flux) of CP from the cream formulation, generated over the entire 
stability test period are summarized in Table 5.3.  
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Table 5.3. Stability data generated for Batch CP004 after a four (4) week test period 
 Stability test parameters 
Sampling time 
(week) 
CP content (%) Intrinsic 
viscosity (KcP) 
Intrinsic pH Flux 
(µg/cm2/h1/2) 
0 111.7 ± 1.906 15.13 ± 0.7023 5.11 ± 0.00577 7.532 ± 0.8056 
1 110.4 ± 2.871 16.27 ± 1.115 5.15 ± 0.0265 7.800 ± 0.6016 
2 109.6 ± 2.474 17.17 ± 0.4163 5.21 ± 0.0568 7.480 ± 0.3761 
3 103.7 ± 4.418 17.70 ± 0.6080 5.17 ± 0.0550 7.626 ± 0.08207 
4 101.7 ± 4.073 17.23 ± 0.1528 5.25 ± 0.0608 6.727 ± 1.468 
 
5.2.3.2.1. CP content  
 
The data shown in Table 5.3 indicate a progressive decrease in the amount of CP in the 
formation as the time of exposure of the formulation to the stability test conditions increased. 
This may be due to degradation of the CP in the formulation and the longer the formulation 
remained exposed to the test conditions, the greater is the amount of CP that degrades. However, 
studies to establish whether or not the degradation of CP in the cream base occurred were not 
undertaken. Nevertheless, despite the progressive decrease in the amount of CP in Batch CP004 
after exposure to stability test conditions, the CP content remained within the specifications 
established for the formulation (Table 5.2) at all sampling times. 
 
The CP content data generated in these tests were subjected to a statistical analysis (Section 
2.4.7.2) and the results obtained from this test are shown in Figure 5.1. These results indicate that 
the percentage change from the initial amount of CP in the formulation after storage at 40 ± 2˚C 
and 25 ± 5% RH for 1, 2, 3, and 4 weeks is not statistically significant or relevant. Consequently, 
the CP cream can be considered as stable for the time period under investigation. 
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Figure 5.1. Effects of stability test conditions on CP content of the cream formulation after storage at 40 ± 
2˚C and 25 ± 5% RH for 1, 2, 3 and 4 weeks.  
 
5.2.3.3. Intrinsic viscosity  
 
The data shown in Table 5.3 showing the apparent intrinsic viscosity indicate that the apparent 
intrinsic viscosity of Batch CP004 remained within the established specifications (Table 4.2) 
over the stability test period.  
 
There seem to be a noticeable increase in the apparent intrinsic viscosity value of all the test 
samples when compared to the viscosity of the cream sample observed at time 0  weeks. The 
apparent intrinsic viscosity data generated in these tests were subjected to a statistical analysis 
(Section 2.4.7.2) to determine whether or not the increase was significant and/or relevant and the 
results obtained from this test are illustrated in Figure 5.2.  
 
These data reveal that the percentage change from the initial apparent intrinsic viscosity of the 
CP cream formulation after storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3, and 4 weeks is not 
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statistically significant or relevant. Based on these results, the CP cream formulation is 
considered stable for the 1 month test period under investigation. 
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Figure 5.2. Effects of stability test conditions on the apparent intrinsic viscosity of the CP cream 
formulation after storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3 and 4 weeks. 
 
5.2.3.4. Apparent intrinsic pH 
 
The data shown in Table 5.3 showing the apparent pH of the cream samples indicate that the 
apparent pH of the cream formulation remained within the established specifications (Table 4.2) 
over the entire test period. It appears that the apparent pH of the formulation increased slightly 
after exposure to the stability test conditions and this increase was proportional to the time of 
exposure.  
 
In order to determine whether or not the increase in the apparent intrinsic pH of the formulation 
was statistically significant and/or relevant, the apparent intrinsic pH data were subjected to a 
statistical analysis (Section 2.4.7.2) and the results generated from this test are illustrated in 
Figure 5.3.  
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These data reveal that the percentage change from the initial apparent pH of the CP cream 
formulation after storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3, and 4 weeks is not statistically 
significant or relevant. As a consequence, these results reveal that the pH of the product is still 
within the specified pH range for topical formulations [193, 194] and within the range set for this 
product (Table 5.2). The CP cream formulation can be considered stable in terms of maintaining 
the pH within the specified limits during the time period the formulation was tested.  
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Figure 5.3. Effects of stability test conditions on the apparent intrinsic pH of the cream formulation after 
storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3 and 4 weeks. 
. 
5.2.3.5. In vitro release rate testing 
 
The data shown in Table 5.3 for the in vitro release rate (flux) of CP from the cream reveal  that 
the in vitro release rate (flux value) of CP from the CP cream remains relatively constant but 
shows a slight decrease in flux for the 4 weeks sample that appears significant. Nevertheless, all 
in vitro release rates (flux values) calculated in these studies fall within the in vitro release rate 
specifications established for the cream formulation (Table 5.3). There appears to be a 
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correlation between this slight decrease in flux and the slight increase in the viscosity of the 
formulation following four weeks of storage. 
 
In order to determine whether or not changes between the in vitro release rates of CP release 
from cream samples are statistically significant and/or relevant, the in vitro release rate of CP 
data were subjected to a statistical analysis (Section 2.4.7.2) and the data generated are shown in 
Figure 5.4.  
 
These data indicate that the percentage change from the initial CP in vitro release rate of CP 
release from the cream formulation after storage at 40 ± 2˚C and 25 ± 5% RH for weeks 1, 2, 3, 
and 4 is not statistically significant or relevant. These results indicate that the cream formulation 
is stable over the period tested.  
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Figure 5.4. Effects of stability test conditions on the in vitro release rates of CP from the cream 
formulation after storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3 and 4 weeks 
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The data collected during in vitro release rate studies were also used to generate in vitro release 
rate profiles for CP and the data are plotted in Figure 5.5. These data are plotted as the 
cumulative amount of CP released per unit area (Q) vs. square root of time (t1/2). From these 
results, it is evident that there is no difference in the in vitro release rate profiles of CP from the 
cream samples tested over the entire test period.  
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Figure 5.5. In vitro release rate profiles for CP from CP cream samples at times 0, 1, 2, 3 and 4 weeks 
after storage  
 
In order to establish whether the apparent similarity in the in vitro release rate profiles for CP 
following storage of creams and the cream tested immediately after manufacture was real the 
data were tested using non-parametric statistical analysis (Section 3.2.11). 
 
 The lower limit (L.L.) and upper limit (U.L.) of a confidence interval (C.I.) calculated as 
described in Section 3.2.11 (Chapter 3) with the cream sample at week 0 (reference) and the 
cream sample at weeks 1, 2, 3 or 4 (test) are summarised in Table 5.4. If the in vitro release rate 
profile of CP release from the reference sample is to be considered equivalent to the in vitro 
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release rate profile for CP release from the test sample then the limits for the C.I. calculated from 
experimental data should lie within the 75%-133% limits [49].  
 
Table 5.4. The lower limit (L.L.) and upper limit (U.L.) of the confidence intervals (C.I.) calculated using 
cream sample at week 0 (reference) and cream samples at weeks 1, 2, 3 and 4 (test) 
  
 Confidence intervals (C.I.) 
 L.L. (%) U.L. (%) 
C.I. limits 75.00 133.0 
Week 0 vs. week 1 93.97 114.0 
Week 0 vs. week 2 89.43 110.9 
Week 0 vs. week 3 93.88 110.0 
Week 0 vs. week 4 86.02 108.1 
 
From the results summarised in Table 5.4 it is clear that there is no statistically significant 
difference in the in vitro rate of release of CP release from creams subjected to stability test 
conditions. These data are consistent with the results generated using the statistical test described 
by Timm et al., [97] (Figure 5.5), which reveal that the in vitro release rates of CP release from 
the tested cream samples at weeks 1, 2, 3 and 4 are equivalent to the in vitro release rate of CP 
release from the cream sample tested at week 0. Consequently Batch CP004 can be considered 
stable over the time period the formulation was tested 
 
5.3. CONCLUSIONS 
 
The stability of the CP cream formulation developed, assessed and reported in Chapter 4 has 
been evaluated using accelerated stability test conditions. The initial step taken in these studies 
was to develop a stability study protocol using currently published international guidelines for 
the stability testing of drug substances and drug products. Essentially, the stability protocol used 
in these studies was designed to facilitate the selection of batches, number of batches, container 
closure system, sampling frequency, sampling plan, test storage conditions, test specifications, 
test procedure and stability data evaluation procedure.  
 
One of the best prototype formulations, Batch CP004, was selected for use in stability testing 
studies. Based on the recommendations in the guideline documents a stability study on a single 
batch of the generic formulation was considered to be adequate for the purposes of these 
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investigations. The formulation was packed into four (4) 100 g glass ointment jars, to facilitate 
ease of sampling at the four (4) time points, 1, 2, 3, and 4 weeks.  
 
The stability study was conducted under accelerated conditions of 40 ± 2˚C and 25 ± 5% RH. 
Internal guidelines on stability studies specify that accelerated stability studies be conducted at 
40 ± 2˚C and 75 ± 5% RH. However, these conditions were slightly modified due to the 
availability of facilities in our laboratory. The main objective of these studies was to determine 
whether or not the modified accelerated stability conditions would have an effect on specific 
formulation attributes such as organoleptic appeal, CP content, apparent intrinsic viscosity, 
apparent pH and CP in vitro release rates.  
 
Sample were removed from the storage incubator at weeks 1, 2, 3 and 4 and immediately tested 
for organoleptic appeal, CP content, apparent intrinsic viscosity, apparent intrinsic pH and the 
CP in vitro release rates. 
 
Organoleptic data obtained from these studies were evaluated qualitatively, whereas quantitative 
data were generated for CP content, apparent intrinsic viscosity and pH and CP in vitro release 
rates. The data generated at each sample time were assessed using a statistical test procedure to 
determine whether a relevant and/or significant change occurred in the product following storage 
for up to four weeks as compared to that evaluated immediately after manufacture.  
 
The original appearance of the cream formulation did not change and the formulation did not 
show signs of physical instability, such as phase separation or cracking and bleeding of the 
cream base from the container at any of the sampling times. Quantitative analysis revealed that 
the percentage change from the initial product specifications such as CP content, apparent 
intrinsic viscosity and pH and CP in vitro release rates was in all cases not statistically significant 
or relevant.  
 
Based on the data generated in this pilot stability study, the CP cream formulation appears to be 
stable. However, it will be necessary to conduct additional studies of the cream formulation in 
conventional cream packaging and a stability chamber using the established accelerated stability 
 188
test conditions for longer periods to fully characterize the short-term and long-term stability of 
this formulation. Furthermore, it will be essential in future studies to conduct stability studies on 
the innovator product (Dermovate® cream) and compare the data generated from these studies to 
those obtained for the generic formulation. 
 
It is evident that the formulation development process was successful in producing a potentially 
stable CP cream product and these studies could form the basis for further studies on the 
formulation that has been developed. 
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CHAPTER SIX 
 
CONCLUSIONS 
 
Clobetasol 17-propionate (CP) has been labelled as a class I topical corticosteroid and is 
currently one of the most potent topical corticosteroids available on the market. CP is used for 
the short-term treatment of inflammatory and pruritic manifestations of moderate-to-severe 
glucocorticoid-responsive dermatoses. CP has physicochemical and pharmacological properties 
such as a relative high lipophilicity and local anti-inflammatory activity which make it an ideal 
candidate for incorporation into topical semi-solid formulations. The objective of this research 
project was to develop and characterize a CP topical cream formulation containing 0.05% w/w of 
the drug.  
 
Prior to initiating formulation development studies, it is vital that a suitable analytical method is 
developed and validated for the quantitation of drug and the characterization of dosage forms 
during the development and assessment process. A major difficulty often encountered in the 
analysis of semi-solid dosage forms is interference due to formulation adjuvants and 
preservatives that are usually present in what are relatively complex formulations. RP-HPLC is a 
commonly used, powerful and reliable analytical tool that can be used for the in vitro analysis of 
formulations of a complex nature, such as for example creams, gels and ointments.  
 
HPLC not only provides separation and quantitative data but also has the ability to eliminate 
almost all interference challenges. The initial phases of this project entailed the development and 
validation of a suitable RP-HPLC method that was suitable for the quantitative analysis of CP in 
cream formulations and CP release during in vitro release studies. Separation of CP and the 
internal standard (BV) was achieved on a Nova-Pak® C18 cartridge column (3.9 x 150 mm, 4µm) 
using a mobile phase consisting of acetonitrile-water (50:50) at a flow rate of 1.0ml/min with UV 
detection at 240 nm. The retention time of BV and CP were 5.6 and 8.2 min respectively and the 
total run time for analysis was 10 min. 
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The RP-HPLC analytical method was validated according to USP [23], FDA [98] and ICH [86] 
guidelines. The analytical method was found to be linear, precise, accurate, selective and 
sensitive and suitable for the intended purpose of CP quantitation. CP was found to be stable in 
the mobile phase following storage at 4˚C for a maximum of 14 days, and thus all calibration 
standards, which were made in the mobile phase, were stored at 4˚C and used within a period of 
14 days, after which fresh calibration standards were prepared.  
 
In vitro dissolution testing of solid oral dosage forms is a well-established technique used to 
guide the formulation development process, assess product quality and ensure batch-to-batch 
uniformity. However, as far as semi-solid formulations are concerned, only quality control tests, 
such as for example the determination of solubility, particle size and size distribution and 
crystalline form of an API, and evaluation of the intrinsic viscosity and homogeneity of a final 
product has been traditionally used to provide reasonable evidence of consistent product 
manufacture and performance. The main drawback with these quality control tests is that they 
provide little information about drug release characteristics of a product or the effects of 
processing and manufacturing variables on the performance of a finished product.  
 
In recent years, some international guidelines [49] have recommended the use of in vitro release 
test methods to determine if the diffusional rate of release of a drug from a formulation is the 
same following any post-approval formulation changes, as it was prior to the changes. Such tests 
can be used to detect the effects of changes in formulation composition on the rate of release of 
an API from a dosage form in which that API is suspended and/or dissolved and can therefore be 
used to ensure that the manufacture of semi-solid products is consistent. Therefore such tests 
may fulfil a similar role as dissolution testing does for tablets and capsules in evaluating topical 
semi-solid dosage forms.  
 
In contrast to dissolution testing, for which official test methods have been developed and 
reported for use in in vitro dissolution studies of solid oral dosage forms, there are currently no 
official guidelines or requirements for the performance evaluation of drug release from semi-
solid dosage forms. The onus is left to a formulation scientist to develop and validate specific in 
vitro release methods for the assessment of drug release from semi-solid products. Therefore, it 
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was essential to develop and validate an in vitro release test method for use in conjunction with 
traditional quality control tests to determine the quality and consistency of CP topical cream 
formulations that were to be manufactured during product development studies. The in vitro 
release method was also used to characterize formulations and evaluate batch-to-batch 
consistency, and in assessing the impact of storage at elevated temperatures on product 
performance.  
 
The in vitro release test method development studies entailed the selection of a suitable diffusion 
cell system, appropriate sampling times, receptor medium, temperature of the receptor medium 
and appropriate synthetic membranes. In addition the effects of sample application and sample 
occlusion or non-occlusion on in vitro release of CP from semi-solid dosage forms were also 
investigated. A modified Franz glass diffusion cell system was selected and used in these studies 
since it has the most potential for use as a standardized test system that may be adapted for use as 
a compendial method.  
 
The in vitro release of CP from 0.05% w/w cream formulations was tested using a receptor 
medium consisting of a binary mixture of water:propylene glycol (50:50) and a 0.025 µm 
nitrocellulose membrane. The temperature of the test system was set at 32° ± 0.5˚C to 
approximate the usual surface temperature of the skin and a 2 x 2 mm star head magnetic stirrer 
was used to agitate the receptor medium.  
 
About 300 mg of the semi-solid preparation that corresponded to an infinite dose was applied 
uniformly to the membrane and the formulation was occluded for the duration of testing, to 
prevent solvent evaporation and compositional changes to the formulation. Samples of the 
receptor medium were withdrawn at 2, 4, 8, 12, 24, 48 and 72 hours in order to generate a 
satisfactory CP release profile and to characterize the release of CP from semi-solid topical 
formulations. 
 
The in vitro release test method was validated using published protocols. Method validation 
studies involved assessing the ability of the test method to detect the effects of changes in 
 192
formulation characteristics on CP release rates. The effects of changes of strength, composition 
and intrinsic viscosity of topical formulations on in vitro release of CP were investigated.  
 
It was determined that the in vitro release method was able to detect the effects on CP release 
rates of changes in formulation in which CP is suspended and/or dissolved. The in vitro release 
test was used in conjunction with traditional quality control tests to determine the quality and 
consistency of CP topical formulations and the associated release characteristics of CP from the 
product during formulation development and assessment studies. 
 
In generic formulation development studies it is important to characterize the innovator product 
to generate data, which can be used as a benchmark for the development of the generic 
formulation. The initial experiments in these studies were designed to facilitate the 
characterization of the innovator formulation, Dermovate® cream. CP content, apparent intrinsic 
viscosity, apparent pH and in vitro release rates of CP from the formulation were determined and 
the data obtained from these studies were used as reference specifications for the development of 
a generic formulation.  
 
Preliminary studies were designed to facilitate the manufacture of a prototype generic 
formulation that showed no signs of physical instability, such as, for example, cracking, 
creaming, phase inversion and/or bleeding of the cream base from the container, immediately 
after the manufacture as well as twenty-four (24) hours after manufacture and storage at room 
temperature (22˚C). As a consequence, a prototype formulation, Batch CP001 was 
extemporaneously manufactured with Estol® 1474 as the primary emulsifier. Although Batch 
CP001 showed no signs of physical instability immediately after manufacture, the formulation 
had cracked twenty-four (24) hours after manufacture and storage at room temperature (22˚C) 
and was therefore not considered for further development.  
 
Three additional prototype formulations containing commercially available mixed emulgents, 
Ritapro® 200 (Batch CP002), Emulcire® 61 WL (Batch CP003) and Gelot® 64 (Batch CP004) 
were manufactured. All three formulations were found to be physically stable immediately after 
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manufacture as well as twenty-four (24) hours after manufacture and storage at room 
temperature (22˚C) and were therefore considered for further development.  
 
Following the manufacture of stable batches, the next phase of the formulation development 
studies was to investigate the in vitro release rate of CP release from Batches CP002, CP003 and 
CP004 and Dermovate® cream. These studies were conducted in order to identify a prototype 
batch with a similar in vitro release rate profile for CP similar to that of Dermovate® cream.  
 
The similarities or differences between the in vitro release rates of CP release from the prototype 
cream formulations and Dermovate® cream were statistically determined using a non-parametric 
test recommended by the FDA [49]. It was found that only the in vitro release rate of CP release 
from Batch CP004 was found to be equivalent to the in vitro release rate of CP release from the 
innovator formulation. Consequently, only Batch CP004 was developed and investigated further.   
 
Two additional batches, Batches CP005 and CP006, having similar a composition to Batch 
CP004, were manufactured using the same manufacturing procedure as that used to produce 
Batch CP004. The three formulations were then characterised for CP content, apparent intrinsic 
viscosity, pH and in vitro release rate and the data generated from these studies were compared 
to the data generated for the innovator product.  
 
The CP content of all generic formulations and the Dermovate® cream were comparable and fell 
within the USP limits for CP content in topical semi-solid formulations. In addition, the apparent 
pH values of Batches CP004, CP005 and CP006 were comparable to that of the innovator 
product and fell within the pH range of healthy human skin.  
 
The apparent intrinsic viscosity of Dermovate® cream was found to be almost three (3) times 
greater than that of generic cream batches and the difference in intrinsic viscosity of Dermovate® 
cream was attributed to the physicochemical characteristics of the mixed emulsifiers used in the 
innovator product and to manufacturing process variables, such as for example speed of 
homogenization speed and mode of cooling. 
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Despite the differences in apparent intrinsic viscosity the in vitro release rate of CP from Batches 
CP004, CP005 and CP006 was found to be statistically similar to the in vitro release rate of CP 
from the innovator product. It was concluded that the behaviour of the mixed emulsifier in both 
the commercially available cream and the extemporaneously manufactured creams, and not only 
the apparent intrinsic viscosity of the formulations, had e an impact on the in vitro release rate of 
CP from these formulations. 
 
Based on the comparative data generated for the generic cream and those for the innovator 
formulation, the formulation development process was considered to have been successful. 
Despite the fact that the apparent intrinsic viscosity of the generic formulations was significantly 
different to that of the Dermovate® cream, Batches CP004, CP005 and CP006 were found to be 
equivalent to the innovator cream product in terms of other in vitro performance characteristics 
such as CP content, pH and in vitro release rates. 
 
Following the development of batches of cream that were considered equivalent to the innovator 
formulation in terms of in vitro performance characteristics, three 500 g batches were produced 
for use in accelerated stability studies. The stability studies aimed to determine whether or not 
the formulation development process was successful in producing a stable CP cream product.  
 
Therefore the stability study was designed to facilitate the selection of batches, number of 
batches, container closure system, sampling frequency, sampling plan, test storage conditions, 
test specifications, product specifications, test procedure and stability data evaluation procedure. 
Batch CP004 was selected for testing and the formulation was packed into five (5) 100 g glass 
ointment jars, to facilitate ease of sampling at the five (5) time points, 0, 1, 2, 3, and 4 weeks, 
and a stability test was conducted under conditions of 40 ± 2˚C and 25 ± 5% RH in an incubator.  
 
Cream samples were tested for qualitative and quantitative attributes such as organoleptic appeal, 
CP content, apparent intrinsic viscosity, apparent pH and in vitro release rate. The product 
specifications for all parameters were set prior to initiating stability testing and qualitative data 
were generated by visual observation, whereas quantitative data were analysed and evaluated 
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using statistical testing. The cream samples were found to be physically stable over the entire test 
period and the samples did not change in appearance, colour or odour.  
 
Although, there appeared to be a progressive decrease in CP content of the cream as the time of 
cream exposure to the stability test conditions increased, the decrease was not statistically 
significant or relevant. The apparent intrinsic viscosity and pH values of the formulation 
increased slightly over the test period, but again these increases were found to be neither 
statistically significant nor relevant.  
 
The in vitro release rate of CP from the cream formulation appeared to remain constant, after 4 
weeks a decrease from the initial in vitro release rate of CP was observed. Nevertheless, 
statistical analyses indicated that the changes in in vitro release rates were not significant or 
relevant.   
 
The data generated during accelerated stability studies indicate that the CP cream formulation 
manufactured is potentially stable. However, it will be necessary to conduct additional studies on 
the cream formulation stored in conventional cream packaging and using a stability chamber 
with the ability to create established accelerated stability test conditions. Furthermore the product 
would have to be tested for longer periods to fully characterize the short-term and long-term 
stability of this formulation. In addition, stability studies would need to be conducted on the 
innovator product (Dermovate® cream) in order to provide comparative data for the assessment 
of the generic formulation.  
 
Future studies would entail an investigation of the effects of formulation and process variables 
on in vitro performance of the dosage forms. The apparent intrinsic viscosity of the formulations 
must be increased to match the viscosity of the innovator product. Intrinsic viscosity invariably 
affects drug release from a semi-solid formulation and although the viscosity does not appear to 
affect the in vitro release of CP from the semi-solid formulations developed in these studies, the 
viscosity may have a significant effect when testing the products in vivo.  
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The formulation appears stable at high temperatures following pilot-scale manufacture and 
therefore scale-up of the process is necessary and challenges associated with formulation scale-
up require investigation.  
 
In vivo studies could be conducted using the the human skin blanching assay [7] to determine 
whether the generic formulation developed in these studies is bioequivalent to the innovator 
product. In vitro release rate testing with rate limiting membranes, such as for example a silastic 
membrane or membranes derived from animal models, may assist in the development of a test 
model to establish an in vitro in vivo correlation (IVIVC) for CP release from topical 
formulations.  
 
 A stable cream formulation has been developed and assessed and the data generated reveal that 
the dosage form behaves similarly to Dermovate® during in vitro studies. The results obtained 
provide a suitable platform from which a bioequivalent CP semi-solid cream can be developed 
and commercialised.  
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APPENDIX ONE 
 
EXAMPLE OF THE CALCULATION OF A 95% CONFIDENCE INTERVAL FOR THE 
RATIO OF T/R RELEASE RATES 
 
 
A. Release rates (slopes) for reference system (R) and test system (T)   
Cell No.   Test        Reference   
1  5.4050    5.1894  
2  6.0153    4.3467  
3  6.1577    5.4699  
4  6.2852    5.9206  
5  5.3946    5.2937  
6   5.3641      4.3055   
B. Computation of 36 individual T/R ratios    
      (R) slopes       
(T)  5.1894 4.3467 5.4699 5.9206 5.2937 4.3055
5.4050   1.0415 1.2435 0.9881 0.9129 1.0210 1.2554 
6.0153  1.1592 1.3839 1.0997 1.0160 1.1363 1.3971 
6.1577  1.1866 1.4166 1.1257 1.0400 1.1632 1.4302 
6.2852  1.2112 1.4460 1.1491 1.0616 1.1873 1.4598 
5.3946  1.0395 1.2411 0.9862 0.9112 1.0191 1.2530 
5.3641   1.0337 1.2341 0.9807 0.9060 1.0133 1.2459 
C. Arrangement  T/R ratios from the lowest to 
highest (counting from left to right)       
0.9060 0.9112 0.9129 0.9807 0.9862 0.9881 1.0133 1.0160
1.0191 1.0210 1.0337 1.0395 1.0400 1.0415 1.0616 1.0997
1.1257 1.1363 1.1491 1.1592 1.1632 1.1866 1.1873 1.2112
1.2341 1.2411 1.2435 1.2459 1.2530 1.2554 1.3839 1.3971
1.4166 1.4302 1.4460 1.4598         
D. The eighth T/R ratio converted to % is 101.6% and the twenty-ninth T/R ratio 
converted to % is 125.3%, which lies between 75% and 133.3%. The test product is 
therefore equivalent to the reference product 
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APPENDIX TWO 
 
QUALITATIVE COMPOSITION OF DERMOVATE® CREAM 
 
Qualitative composition of Dermovate® cream [196] 
Excipients 
Clobetasol propionate 
Chrorocresol 
Cetostearyl alcohol 
Glyceryl monostearate 
Arlacel® 165 
Beeswax substitute 
Propylene glycol 
Sodium citrate 
Citric acid 
Purified water 
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APPENDIX THREE 
 
EXCIPIENTS USED IN CP CREAM FORMULATION DEVELOPMENT STUDIES 
 
Excipients  Trade name Manufacturer/Donor 
Clobetasol 17-propionate Clobetasol propionate Symbiotec Pharmalab P.V.T. Ltd (Pigdamber, Maharastra, India 
Propylene glycol propane-1,2-diol Merck Chemicals (pty) Ltd, Darmstadt, Germany 
Sodium citrate N/A Aspen Pharmacare, Port Elizabeth, Eastern Cape, SA 
Citric acid N/A Aspen Pharmacare, Port Elizabeth, Eastern Cape, SA 
Glyceryl monostearate Geleol®  Gattefosse SAS, Saint-Priest Cedex, France 
Cetostearyl alcohol N/A Aspen Pharmacare, Port Elizabeth, Eastern Cape, SA 
White beeswax BP N/A Croda Chemicals (SA) (Pty) Ltd, Johannesburg, Gauteng, SA 
Chlorocresol N/A Aspen Pharmacare, Port Elizabeth, Eastern Cape, SA 
Glyceryl stearate Estol® 1474 Uniqema (Pty) Ltd, Bryanstone, Gauteng, SA 
Stearyl alcohol and steareth-20 Ritapro® 200 Rita, Crystal Lake, IL, USA 
Cetyl alcohol, ceteth-20 and steareth-20 Emulcire® 61 WL Gattefosse SAS, Saint-Priest Cedex, France 
Glyceryl stearate and PEG-75 stearate Gelot® 64 Gattefosse SAS, Saint-Priest Cedex, France 
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APPENDIX FOUR 
 
QUALITATIVE AND QUANTITATIVE FORMULAE USED TO MANUFACTURE CP CREAM 
FORMULATIONS IN THESE STUDIES 
 
Material  Composition (% w/w) 
Clobetasol propionate 0.05000 
Propylene glycol 44.50 
Sodium citrate 0.05000 
Citric acid 0.05000 
Glyceryl monostearate A/S 5.000 
Cetostearyl alcohol 4.000 
White wax (beeswax bleeched) 0.6000 
Chlorocresol 0.0750 
Glyceryl monostearate SE 1.000 
Propylene glycol 7.000 
Propylene glycol 2.675 
Purified water 35.00 
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APPENDIX FIVE 
 
BATCH SUMMARY REPORTS 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
BATCH SUMMARY REPORT 
Formulator: Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP001    Batch Size:  200 g 
Manufacturing Date:  04-04-2006  Manual mixing time: 10 min    
      High speed homogenization time: 5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.1023 RM000150 
Propylene glycol         44.50 89.04 RM000181 
Sodium citrate  0.05000 0.1019 RM000183 
Citric acid  0.05000 0.1026 RM000185 
Geleol® pastilles  5.000 10.05 RM000182 
Cetostearyl alcohol  4.000 8.053 RM000184 
White beeswax BP  0.6000 1.020 RM000142 
Chlorocresol  0.07500 0.1508 RM000186 
Estol® 1474    1.000 2.005 RM000160 
Propylene glycol  7.000 14.10 RM000181 
Propylene glycol  2.675 5.350 RM000181 
Purified water         35.00 70.07 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate:  Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer:  Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated: 
 
 
 
 
 
In vitro release rate      Comments / Observations 
Not evaluated 
 Mean SD 
CP content Not evaluated Not evaluated
Viscosity Not evaluated Not evaluated
pH Not evaluated Not evaluated
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream cracked 24 hours after 
manufacture 
• Physico-chemical attributes of the 
cream  were not evaluated 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
BATCH SUMMARY REPORT 
Formulator:  Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP002    Batch Size: 200 g 
Manufacturing Date:  11-05-2006  Manual mixing time: 10 min    
      High speed homogenization time:  5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.1033 RM000150 
Propylene glycol         44.50 89.10 RM000181 
Sodium citrate  0.05000 0.1055 RM000183 
Citric acid  0.05000 0.1008 RM000185 
Geleol® pastilles  5.000 10.07 RM000182 
Cetostearyl alcohol  4.000 8.071 RM000184 
White beeswax BP  0.6000 1.218 RM000142 
Chlorocresol  0.07500 0.1527 RM000186 
Ritapro® 200    1.000 2.019 RM000140 
Propylene glycol  7.000 14.01 RM000181 
Propylene glycol  2.675 5.450 RM000181 
Purified water         35.00 70.03 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate:  Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer:  Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated: 
 
 
 
 
 
In vitro release rate      Comments / Observations 
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Dermovate® cream Batch CP002
 Mean SD 
CP content (% ) 104.6 3.722 
Viscosity (KcP) 23.07 0.9741 
pH 5.20 0.0152 
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream remained physically 
stable 24 hours after manufacture 
• Physico-chemical attributes of the 
cream were evaluated 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
BATCH SUMMARY REPORT 
Formulator:  Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP003    Batch Size:  200 g 
Manufacturing Date:  21-06-2006  Manual mixing time: 10 min    
      High speed homogenization time:  5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.1018 RM000150 
Propylene glycol         44.50 89.00 RM000181 
Sodium citrate  0.05000 0.1019 RM000183 
Citric acid  0.05000 0.1026 RM000185 
Geleol® pastilles  5.000 10.05 RM000182 
Cetostearyl alcohol  4.000 8.053 RM000184 
White beeswax BP  0.6000 1.220 RM000142 
Chlorocresol  0.07500 0.1528 RM000186 
Emulcire® 61 WL    1.000 2.005 RM000178 
Propylene glycol  7.000 14.00 RM000181 
Propylene glycol  2.675 5.350 RM000181 
Purified water         35.00 70.00 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate:  Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer:  Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated: 
 
 
 
 
 
In vitro release rate      Comments / Observations 
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Dermovate® cream Batch CP003
 Mean SD 
CP content 113.1 2.605 
Viscosity   11.43 0.05774 
pH     5.15 0.0264 
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream remained physically 
stable 24 hours after manufacture 
• Physico-chemical attributes of the 
cream were evaluated 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
BATCH SUMMARY REPORT 
Formulator:  Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP004    Batch Size:  500 g 
Manufacturing Date:  10-10-2006  Manual mixing time:  10 min    
      High speed homogenization time:  5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.2538 RM000150 
Propylene glycol         44.50 222.8 RM000181 
Sodium citrate  0.05000 0.2596 RM000183 
Citric acid  0.05000 0.2548 RM000185 
Geleol® pastilles  5.000 25.01 RM000182 
Cetostearyl alcohol  4.000 20.13 RM000184 
White beeswax BP  0.6000 3.01 RM000142 
Chlorocresol  0.07500 0.3759 RM000142 
Gelot® 64    1.000 5.100 RM000177 
Propylene glycol  7.000 35.44 RM000181 
Propylene glycol  2.675 13.68 RM000181 
Purified water         35.00 175.0 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate:  Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer:  Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated: 
 
 
 
 
 
In vitro release rate      Comments / Observations 
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 Mean SD 
CP content 109.8 1.114 
Viscosity   15.50 4.359 
pH     5.15 0.0264 
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream remained physically 
stable 24 hours after manufacture 
• Physico-chemical attributes of the 
cream were evaluated 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
BATCH SUMMARY REPORT 
Formulator: Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP005    Batch Size:  500 g 
Manufacturing Date:  14-10-2006  Manual mixing time: 10 min    
      High speed homogenization time: 5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.2524 RM000150 
Propylene glycol         44.50 222.8 RM000181 
Sodium citrate  0.05000 0.2539 RM000183 
Citric acid  0.05000 0.2533 RM000185 
Geleol® pastilles  5.000 25.02 RM000182 
Cetostearyl alcohol  4.000 20.07 RM000184 
White beeswax BP  0.6000 3.02 RM000142 
Chlorocresol  0.07500 0.3778 RM000142 
Gelot® 64    1.000 5.030 RM000177 
Propylene glycol  7.000 35.03 RM000181 
Propylene glycol  2.675 13.46 RM000181 
Purified water         35.00 175.2 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate:  Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer:  Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated: 
 
 
 
 
 
In vitro release rate      Comments / Observations 
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 Mean SD 
CP content 109.8 2.474 
Viscosity   12.37 0.03214 
pH     5.11 0.05770 
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream remained physically 
stable 24 hours after manufacture 
• Physico-chemical attributes of the 
cream were evaluated 
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BATCH SUMMARY  
Formulator:  Kasongo Wa Kasongo 
Product:  Clobetasol 17-propionate cream 
Batch ID:  CP006    Batch Size:  500 g 
Manufacturing Date:  24-10-2004  Manual mixing time:  10 min    
      High speed homogenization time:  5 min 
Formula 
Material % (w/w) Amount added (g) Rhodes # 
CP  0.05000 0.2498 RM000150 
Propylene glycol         44.50 222.55 RM000181 
Sodium citrate  0.05000 0.2490 RM000183 
Citric acid  0.05000 0.2523 RM000185 
Geleol® pastilles  5.000 25.01 RM000182 
Cetostearyl alcohol  4.000 20.09 RM000184 
White beeswax BP  0.6000 3.000 RM000142 
Chlorocresol  0.07500 0.3765 RM000142 
Gelot® 64    1.000 5.060 RM000177 
Propylene glycol  7.000 35.10 RM000181 
Propylene glycol  2.675 13.47 RM000181 
Purified water         35.00 175.40 N/A 
   
Production equipment used: 
Water bath:  Model NB-34980 Colora Ultra-Thermostat water bath  
Hotplate: Model RCH IKA-Combimag hotplate magnetic stirrer  
Homogenizer: Model 6-105 AF Virtis homogenizer  
 
Parameters evaluated : 
 
 
 
 
 
In vitro release rate      Comments / Observations 
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 Mean SD 
CP content (%) 113.1 2.605 
Viscosity (KcP)   11.43 0.05774 
pH     5.15 0.0264 
• Shiny, white, odourless cream was 
produced 
• The cream was physically stable 
immediately after manufacture 
• The cream remained physically 
stable 24 hours after manufacture 
• Physico-chemical attributes of the 
cream were evaluated 
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 APPENDIX SIX 
 
BATCH PRODUCTION RECORDS  
 
Note that only one (1) batch production record for the CP cream formulations viz., production 
record for Batch CP001 is included here. The batch production records for the other five (5) 
batches, viz., Batches CP002, CP003, CP004, CP005 and CP006 are available on request. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  1 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
MANUFACTURING APPROVALS 
 
Batch record issued by__________________________  Date______________________ 
 
Master record issued by__________________________ Date______________________ 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  2 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
MASTER FORMULA AND BATCH FORMULA 
Item Material Quantity 
(% w/w) 
Rhodes # Amount/ 
Batch 
(g) 
Amount 
dispensed 
(g) 
Dispensed 
by 
Checked
by 
1 CP 0.05000 RM000150 0.1000 0.1023   
2 Propylene glycol 44.50 RM000181 89.00 89.04   
3 Sodium citrate 0.05000 RM000183 0.100 0.1029   
4 Citric acid 0.05000 RM000185 0.100 0.1026   
5 Geleol® pastilles 5.000 RM000182 10.00 10.05   
6 Cetostearyl alcohol 4.000 RM000184 8.000 8.053   
7 White beeswax BP 0.6000 RM000142 1.200 1.020   
8 Chlorocresol 0.07500 RM000186 0.1500 0.1508   
9 Estol® 1474 1.000 RM000160 2.000 2.005   
10 Propylene glycol 7.000 RM000181 14.00 14.10   
11 Propylene glycol 2.675 RM000181 5.350 5.350   
12 Purified water 35.00 N/A 70.00 70.07   
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  3 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
 
EQUIPMENT VERIFICATION 
Description Type Verified by Confirmed by 
Weighing scale Model AE-163 Mettler    
Hot plate Model RCH IKA-Combimag   
Water bath Model NB-34980 Colora Ultra-Thermostat   
Sonicator Model 8845-30 ultrasonic bath   
Homogenizer Model 6-105 AF Virtis   
Homoginizer Model-HO valve type   
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  4 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
 MANUFACTURING PROCEDURE 
Step Procedure Time Done by Checked by 
1 Weigh all the materials    
2 Heat water (item 12) to 90˚C in a beaker. Bring 
down the temperature to 60˚C. Dissolve sodium 
citrate (item 3) and citric acid (item 4) to a clear 
solution. Mix the resultant solution with propylene 
glycol (item 2). Maintain the temperature of the 
resultant aqueous phase (step 4) at 60˚C.   
   
3 Melt Geleol® pastilles (item 5) and Estol® 1474 
(item 9) together with cetostearyl alcohol (item 6), 
white beeswax BP (item 7) and chlorocresol (item 
8) while stirring in a beaker previously heated to 
75˚C using a hotplate. Cool the resultant oil phase 
to 60°C in a water bath and maintain the 
temperature at 60°C.  
   
4 Mix CP (item 1) in propylene glycol (item 10) and 
sonicate for approximately twenty-five (25) 
minutes or until a clear solution is obtained. Heat 
the resultant drug phase to 50˚C and maintained at 
50˚C. 
   
5 Transfer the aqueous phase (step 2) to the oil phase 
(step 3) at 60˚C. Stir the mixture manually with a 
glass stirring rod for ten (10) minutes at 60˚C. 
Homogenize the mixture at 15,000 rpm for five (5) 
minutes at 60˚C.  
   
6 Place the beaker containing the mixture (step 5) in 
a water bath at 20˚C and cool down the temperature 
of the resultant dispersed phase to 50˚C while 
stirring manually  
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  5 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
 MANUFACTURING PROCEDURE 
Step Procedure Time Done by Checked by 
7 Add the drug phase (step 4) to the dispersed phase 
(step 7). Rinse the beaker previously containing the 
drug phase with propylene glycol (item 11) and add 
to the dispersed phase. Mix manually for ten (10) 
minutes at 50˚C. Homogenize the resultant cream 
at 15,000 rpm for five (5) minutes at 50˚C. 
   
8 Cool the resultant cream (step 7) to 30˚C with 
continual manual stirring and with the 
manufacturing beaker placed in a water bath at 
20˚C.  
   
9 Pass the cooled formulation (step 8) through a 
valve type of homogenizer, to generate a smooth 
cream of improved consistency.  
   
10 Pack the resultant cream (step 9) into 100 g 
ointment jars and store the cream at room 
temperature (22˚C) until required for further 
analysis. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
BATCH PRODUCTION RECORD 
 
Product name:  Clobetasol 17-propionate cream    Page:  6 of 6 
Batch ID:  CP001        Batch size:  200 g 
 
SIGNATURE AND INITIAL REFERENCE 
Full Name (Print) Signature Initials Date 
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APPENDIX SEVEN 
 
STABILITY TEST SUMMARY SHEET 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, SOUTH AFRICA 
 
STABILITY TEST SUMMARY SHEET 
 
ACCELERATED STABILITY STUDIES 
Product name: Clobetasol 17-propionate cream 
Manufacturer: Kasongo Wa Kasongo 
Address: Rhodes University, Faculty of Pharmacy, Division of Pharmaceutics, Grahamstown, South 
    Africa 
Active ingredient: Clobetasol 17-propionate 
Dosage form: Cream  
 
Batch ID Date of manufacture 
CP004 10-10-2006 
 
Batch size Type of batch 
500 g Experimental 
 
Samples tested (per batch): Four (4) samples 
Test period: Four (4) weeks 
 
Storage/test conditions 
Temperature (˚C) Humidity (% RH) 
40.0 25.0 
 
RESULTS 
Chemical findings:  
• The percentage change from the initial amount of CP in the cream formulation after storage at 40 ± 
2˚C and 25 ± 5% RH for 1, 2, 3, and 4 weeks was not statistically significant or relevant. 
• The percentage change from the initial apparent pH of the cream formulation after storage at 40 ± 2˚C 
and 25 ± 5% RH for 1, 2, 3, and 4 weeks is not statistically significant or relevant 
Physical findings 
• No noticeable change in the organoleptic properties of the cream formulation in terms of appearance, 
colour and odour over the entire stability test period. No signs of physical instability such as phase 
separation or cracking and bleeding of the cream base from the container at any of the sampling 
times. 
• The percentage change from the initial apparent intrinsic viscosity of the CP cream formulation after 
storage at 40 ± 2˚C and 25 ± 5% RH for 1, 2, 3, and 4 weeks is not statistically significant or relevant. 
• The percentage change from the initial CP in vitro release rate of CP release from the cream 
formulation after storage at 40 ± 2˚C and 25 ± 5% RH for weeks 1, 2, 3, and 4 was not statistically 
significant or relevant 
Conclusions: The CP cream formulation (Batch CP004) was stable for the 1 month test period under 
investigation. 
Responsible Officer: Date: 
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